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The type III secretion system (T3SS) is required by many pathogenic Gram-
negative bacteria for the initiation and maintenance of infections within eukaryotic host 
cells. T3SS harboring bacteria include the causative agents of food poisoning/typhoid 
fever (Salmonella Typhimurium/Typhi), dysentery (Shigella flexneri/dysenteriae), 
nosocomial pneumonia (Pseudomonas aeruginosa), bubonic plague (Yersinia pestis), 
melioidosis (Burkholderia pseudomallei), and trachoma (Chlamydia trachomatis). 
Together, these bacteria are estimated to result in millions of deaths worldwide each year. 
Therefore, it is of great interest to elucidate the mechanisms of T3SS-mediated virulence 
utilized by pathogenic Gram-negative bacteria. Salmonella is the focus of this dissertation 
because it is an excellent model organism for T3SS research due to the ease of genetic 
manipulation and the availability of biological assays.  
The T3SS is utilized to inject bacterial virulence factors (also known as effectors) 
into the host cell cytoplasm, where they manipulate host cell signaling pathways to 
promote bacterial engulfment, maintenance of infection, and evasion of the host immune 
system. T3SS effectors are translocated across both bacterial and host cell membranes by 
the structural component of the T3SS, the needle apparatus. The needle apparatus 
contains a bacterial membrane embedded base structure, an extracellular needle with a 
25Å wide channel, a tip complex that regulates secretion and serves as an environmental 
sensor, and translocon proteins that assemble a pore in the host cell membrane. How the 
needle, tip and translocon proteins interact with each other to assemble a functional T3SS 
needle apparatus and coordinate the secretion of T3SS effectors is poorly understood. 
Because the needle, tip and translocon proteins are essential for the pathogenesis of T3SS 
	 iv	
harboring bacteria, are exposed to the extracellular environment during infection, and are 
conserved in structure and function, they are attractive targets for the development of 
novel virulence based anti-bacterial therapeutics. Hence, the importance of elucidating 
the structure, function and molecular interactions of the T3SS needle, tip and translocon 
proteins.  
This dissertation is focused on two major themes. The first theme is the 
elucidation of essential protein-protein interactions of the Salmonella T3SS needle 
apparatus through a combination of solution nuclear magnetic resonance (NMR) and 
fluorescence spectroscopy. To this end, I used amide (15N) and isoleucine, leucine and 
valine methyl (ILV 13C-methyl) probes in NMR titrations to map the interaction of T3SS 
proteins. I additionally labeled T3SS proteins with fluorescent probes to perform 
fluorescence polarization (FP) and Förster resonance energy transfer (FRET) protein-
protein binding assays to complement the NMR studies. Using these methods, the 
interaction between the Salmonella SP-1 T3SS needle protein PrgI and the tip protein 
SipD, as well as between SipD and the major translocon protein SipB, are described in 
detail and validated using bacterial invasion assays. The results of NMR and FP/FRET 
experiments allowed for the proposal of a model for the needle/tip/translocon protein-
protein interaction interface where the proximal end of SipD (the bottom of the coiled-
coil) is used for interaction with PrgI, while the distal end of SipD (the top of the coiled-
coil and the mixed α/β domain) is the surface used for interaction with SipB. The second 
theme is focused on the T3SS needle apparatus as an attractive target for the development 
of inhibitors. A review of the current T3SS inhibitor literature is described. In addition, I 
identified small molecules binders of the tip and translocon proteins from a surface 
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plasmon resonance (SPR) screen and subsequently validated and mapped the protein-
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Chapter 1. Introduction  
 
“Biological systems, through evolution, have achieved levels of intricacy and subtlety 
that dwarf the complexity of the 20th century’s most sophisticated engineering feats.” 
- Department of Energy’s “Genomes to Life” 
1.1. Introduction to the Type III Secretion System (T3SS)  
 
The development and popularization of novel genetic and molecular biology tools 
in the 1970s, especially recombinant DNA techniques and sequencing, resulted in a 
wealth of scientific discoveries, one being the elucidation and characterization of protein 
secretion systems. The secretion of proteins across cellular membranes is now recognized 
as a fundamental requirement for the survival of many organisms, including plants1, 
animals2, Gram-positive bacteria3 and Gram-negative bacteria4. Secreted proteins 
perform a vast array of functions, including biogenesis of extracellular constituents, 
nutrient acquisition from the environment, intercellular communication, and regulation of 
motility5. The general secretory pathway (i.e. sec-dependent protein secretion) and twin-
arginine translocation pathway are sufficient for transport of proteins by Gram-positive 
bacteria due to their single membrane composition3; 6. However, Gram-negative bacteria 
have evolved additional specialized secretory systems to secrete proteins across both 
inner and outer membranes5. Gram-negative bacteria encode at least six distinct secretion 
machineries (types I through VI), which are classified based on their structure, function 
and substrate specificities7. Importantly, because secretion systems are fundamental to the 
virulence of pathogenic bacteria, secretion system have recently become targets for the 
development of novel antibacterial therapeutics8. One such virulence machinery utilized 
by many Gram-negative bacteria is the type III secretion system (also denoted in the 
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literature as type 3 secretion system or type three secretion system; abbreviated herein as 
T3SS). Because the majority of pathogenic Gram-negative bacteria that are linked to 
significant public health threats and infectious disease in humans harbor one or more 
T3SSs, it is arguably one of the most well characterized bacterial secretion systems to 
date. Although a bulk of the initial T3SS discoveries were made in the late 1980s and 
early 1990s, it wasn’t until two 1993 reviews on Gram-negative bacterial secretion 
systems that the term ‘type III secretion system’ was popularized4; 9. 
During the 1980s and 1990s, the laboratories of Guy Cornelis and Hans Wolf-
Watz were simultaneously attempting to determine the mechanism of Ca2+ dependency 
and the mechanism of virulence for Yersinia pestis, the causative agent of bubonic 
plague. Several virulent Yersinia species were found to harbor a ~70 kb plasmid (whose 
name varies between species) that expressed virulence determinants and Ca2+ response 
regulators10; 11. The virulence-associated proteins, or effectors, that were secreted were 
called Yops for Yersinia outer proteins12; 13 and were secreted independently of the 
classical sec secretion pathway signals13; 14. In Yersinia pestis, the newly identified 
plasmid encoded protein secretion machinery, which had not yet been visualized, was 
called the Ysc, or Yersinia secretion component, secretion apparatus. Likewise, Jorge 
Galán and Roy Curtiss were characterizing the molecular determinants of virulence in 
Salmonella Typhimurium. A key unknown that they wanted to address was the molecular 
mechanism that allowed Salmonella to invade intestinal epithelial cells. Previous results 
had shown that invasion was correlated with a gene locus called inv for invasion in 
Yersinia15 (independent of the plasmid associated virulence Ysc mentioned above). 
Therefore, Galán and Curtiss isolated the chromosomal genetic locus, which they also 
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called inv, that conferred to the ability of Salmonella to invade epithelial cells16. The 
distribution of the inv genes was evaluated in other Salmonella serovars and found to be 
present in most virulent serovars17. Interestingly, these results were quite different 
observations from the plasmid encoded Yersinia T3SS results in that the Salmonella 
T3SS genes were laid out into operons (called Salmonella pathogenicity islands or SPI) 
on the bacterial chromosome instead of on a plasmid. History would later show that 
Yersinia contains two distinct T3SS apparatuses, one encoded by a plasmid (Ysc) and one 
encoded by the chromosome (Ysa, SPI-like). The next few years, Galán and colleagues 
continued to characterize genetic and biochemical aspects of the T3SS. It wasn’t until 
1998 that the supramolecular structure of the T3SS was visualized by electron 
microscopy18. Galán and coworkers described the apparatus as resembling a syringe or 
needle with a basal structure that was anchored into the bacterial cell surface18. This 
discovery led to others later referring to the T3SS as a bacterial nanoinjector or 
injectisome.19; 20 Since, the T3SS apparatus has been visualized in other bacteria, 
including Yersinia20, enteropathogenic E. coli21, Shigella21 and Pseudomonas22 (Fig. 1-1).  
During this time, experiments that would also elucidate the presence of the T3SS in 
Gram-negative bacterial pathogens of plants and insects were identified. In 1986, 
hypersensitive response genes, hrp, that are required for bacteria to trigger a plant 
defense response were identified in Pseudomonas syringae23. Later, hrp genes would be 
shown to be essential in the secretion of bacterial proteins into plant cells in a T3SS-like 
manner24; 25. In rare cases the hrp T3SS has also been documented to be essential for 










Fig. 1-1 – Visualization of T3SS Needle Complexes by Electron Microscopy 
(A) S. Typhimurium needle complexes purified using a CsCl density gradient (Adapted 
by permission from the American Association from the Advancement of Science from 
Figure 2A by Kubori et al.18) (B) Y. enterocolitica needle complex on the bacterial 
membrane negatively stained with 2% uranyl acetate (Adapted by permission from 
Macmillan Publishers Ltd from Figure 2A by Cornelis20) (C) EPEC E. coli needle 
complexes purified using a CsCl density gradient (Adapted by permission from Figure 








Initially, the diversity of Gram-negative bacterial pathogens and the vast array of 
distinct diseases they cause led to the thinking that their molecular virulence mechanism 
must be distinct as well. Furthermore, many T3SS harboring bacteria can infect a wide 
range of organisms, including mammals, plants, fungi and insects27. However, over the 
years it has become clear that T3SS apparatus is conserved, especially the basal 
components, while each bacterium has evolved a unique flavor of host infection niche 
adapted T3SS effector proteins28. The prevalence of the T3SS is partially explained by 
the observation that T3SS genes can be transferred between bacteria through horizontal 
acquisition29. The major function of the T3SS is to deliver bacterial effectors into the 
cytoplasm of target eukaryotic cells. The end goal of the T3SS is to manipulate host 
cellular signaling pathways for the benefit of bacteria, such as promoting engulfment of 
the bacteria, evasion of the host innate immune system, and the establishment of a 
systematic infection. To this end, the T3SS is highly regulated, both at the transcriptional 
and post-transcriptional level30. Although the T3SS is usually defined as being host cell 
contact dependent for the induction of translocation, secretion can be artificially induced 
(for example by Congo Red in Shigella, calcium depletion in Yersinia, changes in 
osmolarity in Salmonella)31 and extracellular leakage of effector proteins has been 
observed32. The T3SS is hypothesized to share a common evolutionary ancestor with the 
well-studied homologous flagellar secretion system (confusingly, also the called type III 
secretion system)33; 34. Therefore, the T3SS that translocates effector proteins into 
eukaryotic cells, which is a distinct protein apparatus from the flagellar T3SS, is 
sometimes referred to as the non-flagellar type III secretion system (NF-T3SS). However, 
in this dissertation I will refer to the NF-T3SS system simply as the T3SS and make note 
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whenever the flagellar T3SS system is of interest. The type III secretion system has been 
classified into a few different families based on phylogenetic analysis between eight 
homologous core proteins present in both the flagellar and non-flagellar T3SS34 (Table 1-
1). Distinguishable T3SS families include the following: i) SPI-1 (homology to Inv-Mxi-
Spa), ii) SPI-2 (homology to Ssa-Esc), iii) Ysc (homology to Psc), iv) Chlamy, v) Rhizo, 
and vi) Hrp1 (homology to Hcr1) and Hrp2 (homology to Hrc2). Desulfovibrionales and 
myxococcales have also been identified as potentially unique T3SS families34. 
Interestingly, some bacteria harbor two or more distinct T3SSs that are used for specific 
stages of infection. For example, Salmonella enterica utilizes the SPI-1 apparatus for 
initial invasion of the intestinal epithelium, but additionally utilizes the SPI-2 apparatus, 
which has its own set of effectors, to facilitate bacterial replication in Salmonella-
containing vacuoles and establish a systematic infection35. The observation that T3SSs 
are ubiquitous in nature and utilized in both pathogenic and symbiotic bacteria-host 
interactions suggests a need to understand T3SS structure and function. Some of the 
scientific goals in this T3SS field include the following: i) solving atomic structures of 
T3SS apparatus components, chaperones and effectors, ii) elucidating protein-protein 
interactions involved in the assembly of the T3SS, iii) building an atomic model of the 
entire T3SS apparatus, iv) determining structures of the T3SS effectors, v) determining 
genetic regulation of secretion, and vi) determining how effectors influence the host cell. 
Structural characterization and protein-protein interaction information will aid the 
development of new therapeutics targeting the T3SS. For these reasons, this dissertation 
is written with an emphasis on biochemical and biophysical characterization of essential 
T3SS protein-protein interactions. 
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T3SS Family Type Bacterium Disease 
 Chromosomal Burkholderia mallei Glanders 
 Chromosomal Burkholderia pseudomallei Melioidosis 
SPI-1 
(Inv-Mxi-Spa) Chromosomal Chromobacterium violaceum Septicemia 
 Chromosomal Enteroinvasive E. coli, EIEC Gastroenteritis 
 Chromosomal Salmonella enterica Salmonellosis 
 Plasmid Shigella flexneri Shigellosis 
 Chromosomal Sodalis glossinidius Tsetse fly symbiont 
 Chromosomal Yersinia enterocolitica Gastroenteritis 
 Chromosomal Citrobacter rodentium Mouse pathogen 
 Chromosomal Chromobacterium violaceum Septicemia 
 Chromosomal Edwardsiella tarda Gastroenteritis 
 Chromosomal 
Enterohaemorrhagic E. coli, 
EHEC Uremia and hemolysis 
SPI-2 
(Ssa-Esc) Chromosomal 
Enteropathogenic E. coli, 
EPEC Gastroenteritis 
 Chromosomal Salmonella enterica Salmonellosis 
 Chromosomal Sodalis glossinidius Tsetse fly infection 
 Chromosomal Yersinia pestis Bubonic plague 
 Chromosomal Yersinia pseudotuberculosis Far Eastern scarlatina-like fever 
 Plasmid Aeromonas salmonicida Fish pathogen 
 Chromosomal Bordetella pertussis Pertussis (whooping cough) 
 Chromosomal Photorhabdus asymbiotica Skin infection 
Ysc (Psc) Chromosomal Pseudomonas aeruginosa Nosocomial infections/pneumonia 
 Chromosomal Vibrio parahaemolyticus Gastroenteritis 
 Plasmid Yersinia enterocolitica Gastroenteritis 
 Plasmid Yersinia pestis Bubonic plague 
 Plasmid Yersinia pseudotuberculosis Far Eastern scarlatina-like fever 
Chlamy Chromosomal Chlamydia trachomatis Trachoma, genital infections 
 Chromosomal Chlamydophila pneumoniae Pneumonia 
Rhizo Chromosomal Mesorhizobium loti Plant symbiont 
 Plasmid Rhizobium sp. Plant infection 
 Chromosomal Erwinia amylovora Plant infection 
Hrp1 (Hcr1) Chromosomal Pseudomonas syringae Plant infection 
 Chromosomal Vibrio parahaemolyticus Gastroenteritis 
 Chromosomal Burkholderia mallei Glanders 
 Chromosomal Burkholderia pseudomallei Melioidosis 
Hrp2 (Hrc2) 
 Plasmid Ralstonia solanacearum Plant infection 
 Chromosomal Xanthomonas campestris Plant infection 
 
Table 1-1 – Classification of T3SS Families 
A list of the seven different T3SS families and examples in different bacteria. An 
exhaustive list of T3SS containing genomes can be found in dataset S2 from Abby et al.34 
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1.2. The Salmonella Typhimurium T3SS  
1.2.1. Overview of Salmonella as a Pathogen 
This dissertation is focused on the T3SS proteins from the bacterium Salmonella. 
These are a few reasons for this. First, there exists a large body of knowledge on the 
Salmonella T3SS in the literature to serve as a framework for the studies performed here. 
Second, biological invasion assays are well established and Salmonella is easily 
genetically manipulated, unlike other systems, such as Chlamydia. Third, Salmonella 
T3SS proteins are soluble and stable, which allows for ease of recombinant protein 
expression and characterization by techniques that may require long experiment times, 
such as solution NMR spectroscopy. Fourth, Salmonella infections are extremely 
common in both the US and worldwide. Therefore, a cheap drug therapy or preventative 
treatment for Salmonella would significantly reduce the public health burden of Gram-
negative bacteria, especially in children or immunocompromised individuals. 
Salmonella are non-spore forming motile rod-shaped Gram-negative bacterium 
belonging to the gammaproteobacteria class and the enterobacteriaceae family. They 
range in size from 2 to 5 µm in length and 0.7 to 1.5 µm in diameter. The genus of 
Salmonella contains two species, S. bongori and S. enterica. Disease associated 
infections by S. bongori are very rare in humans because their natural reservoir is 
primarily cold-blooded animals, such as reptiles36. While S. enterica contains two 
competent type III secretion systems, called SPI-1 and SPI-2, S. bongori only contains 
the SPI-1 system36; 37. S. enterica is divided into 6 subspecies: arizonae, diarizonae, 
enterica, houtenae, indica and salamae. The subspecies are further divided into >2500 
serovars. Human disease is primarily linked to infection by Salmonella enterica subsp. 
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enterica. The natural reservoir for other subspecies is primarily cold-blooded animals. 
However, although rare, human disease has also been reported due to infections by other 
Salmonella enterica subspecies38. The most well studied serovars of Salmonella enterica 
subsp. enterica are Choleraesuis, Enteriditis, Paratyphi, Typhi and Typhimurium. 
Serovars are distinguished by their surface antigens, such as the flagellar ‘H’ antigen, the 
oligosaccharide ‘O’ antigen and the polysaccharide ‘Vi’ antigen. Although the full name 
of a serovar might be, for example, Salmonella enterica subsp. enterica serovar 
Typhimurium, it is often simply referred to as Salmonella Typhimurium, which is the 
nomenclature that will be used herein. Diseases caused by the Salmonella enterica subsp. 
enterica serovars are dependent on the serovar and the host, but primarily include 
gastroenteritis, bacteremia (septicemia) and enteric fever (typhoid fever). Gastroenteritis 
and bacteremia are often linked to Choleraesuis, Enteriditis and Typhimurium, while 
enteric fever is linked to Typhi and Paratyphi39. Non-typhoidal Salmonella infections in 
healthy individuals are often resolved without treatment in less than two weeks by the 
host natural immune system40. In contrast, infections in children below the age of five, 
elderly and immunocompromised individuals are often severe and treated with 
antibiotics, such as ciprofloxacin or	ceftriaxone40. A vaccine against typhoid fever is 
currently available, though limited in treatment, and vaccines against non-typhoidal 
Salmonella are currently under development41. The global burden of non-typhoidal 
Samonella has been estimated to be 94 million illnesses and 155,000 deaths yearly42, 
while the global burden of typhoidal Salmonella has been estimated to be 22 million 
illnesses and 220,000 deaths yearly43.   
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Salmonella are zoonotic pathogens, which means they are naturally transmissible 
from non-human hosts to humans. Transmission typically occurs by an oral-fecal route 
through contaminated food or water sources, or by physical interaction with infected 
organisms. After transmission, Salmonella activates an acid-tolerance response 
mechanism to survive the acidic environment of the host stomach44. The bacterium then 
moves to the small intestines, through the intestinal mucus layer and encounters intestinal 
epithelial cells, where it primarily infects apical M cells in Peyer’s patches using the SPI-
1 T3SS44. During infection, injected T3SS effectors induce host cell membrane ruffling 
by modulating the host cell cytoskeletal system leading to the engulfment of bacteria into 
large membrane vesicles and resulting in the formation of the Salmonella-containing 
vacuole (SCV)44. The bacterium may also migrate to the basolateral space, for example 
by disrupting host cell tight junctions, where they are taken up by phagocytes and 
disseminate into the blood stream. Other target cells include B cell, T cells, gut epithelial 
cells, neutrophils, macrophages, monocytes, granulocytes and dendritic cells39.  
 
1.2.2. Genetic Organization of the S. Typhimurium T3SS  
The T3SS is an essential virulence determinant in Salmonella and is located 
within two Salmonella pathogenicity islands, SPI-1 and SPI-2. SPI-1 and SPI-2 each 
encode a distinct T3SS apparatus. SPI-1 is a 40 kb segment located at centisome 63 on 
the Salmonella chromosome and contains multiple operons for proteins that assemble the 
SPI-1 structural apparatus (org, prg, sip, spa and inv), chaperones (sicA, invB, sicP), 
effectors (avrA, sptP) and transcriptional regulators (sprB, hilADC) (Fig. 1-2). The 
primary function of the SPI-1 T3SS is to promote initial invasion of intestinal epithelial 
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cells and modulate the host immune system. SPI-2 is a 40 kb segment located at 
centisome 30 on the Salmonella chromosome and contains the genes for proteins that 
assemble the SPI-2 apparatus (Fig. 1-2). The primary function of the SPI-2 T3SS is to 
promote intercellular bacterial survival within SCVs, macrophages death and the 
establishment of a systematic infection. In addition to the SPI-1 and SPI-2, there are other 
virulence determinants in Salmonella. S. Typhimurium contains at least 10 additional 
pathogenicity islands: SPI-3, SPI-4, SPI-5, SPI-6, SPI-9, SPI-11, SPI-12, SPI-13, SPI-14 
and SPI-16. SPI-3 encodes a magnesium uptake system and the adhesion MisL45. SPI-4 
encodes the T1SS and the non-fimbrial adhesin SiiE45. SPI-5 encodes T3SS effectors, 
such as SopB and PipB45. SPI-6 encodes the T6SS45. SPI-9 encodes components of the 
T1SS and biofilm formation45. SPI-11 encodes proteins important for bacterial survival in 
host macrophages, such as PagC, PagD and MsgA45. SPI-12 encodes T3SS effectors, 
such as SspH245. The function of the other SPIs have yet to be extensively characterized. 
 
 
Fig. 1-2 – Organization of T3SS Genes 
The genetic organization of (A) SPI-1 and (B) SPI-2 from Salmonella Typhimurium. 
Genes are color-coded based on their known or hypothesized function. Gene sizes are not 
drawn to scale. This figure was adapted from a reference by Fàbrega et al.44 There are 
additional T3SS genes that are encoded by other SPIs.  
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1.3. Structural Components of the T3SS Apparatus 
The T3SS apparatus is a 3.5 MDa nanomachine comprised of more than a dozen 
structural proteins. The primary constituents of the apparatus are the following: i) a 
bacterial inner and outer membrane spanning structure called the base, ii) a needle-like 
structure that protrudes into the extracellular space, iii) a tip complex at the distal end of 
the needle, and iv) translocon proteins that assemble a pore in the host cell membrane 
(Fig. 1-3). The term ‘needle complex’ is often used in reference to the base and the 
needle, while the term ‘needle apparatus’ is often used in reference to the complete T3SS 
apparatus, which includes the base, the needle, the tip and the translocon46. The 
supramolecular structure of the SPI-1 T3SS needle complex was first visualized by 
electron microscopy (EM) in Salmonella Typhimurium18 following its isolation using a 
CsCl density gradient. Non-SPI-1 apparatuses have also been visualized, such as S. 
Typhimurium SPI-2 apparatus47, Y. pestis Ysc apparatus20, C. trachomatis apparatus48; 49, 
Rhizobium sp. apparatus50 and the P. syringae Hrp apparatus51. Unfortunately, the tip 
complex is often lost or falls off the needle during purification of needle complexes, 
especially in preparations of Salmonella needles46. Hence, the needle complex being 
defined as the base plus the needle. However, the appearance of the tip complex is likely 
dependent on the purification method or bacterial species, because visualization of the 
T3SS needle complexes has sometimes resulted in density corresponding to the tip, such 
as with Y. enterocolitica52. The number of needle complexes per cell ranges from as low 
as 10 to as many as 10053; 54.  
The dimensions of the needle complex are on average 25 nm wide and 80 nm 
long (30 nm base plus a 50 nm needle)18. The needle channel is 2.5 nm in diameter, 
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which is large enough to accommodate two well-packed α-helices. Therefore, most T3SS 
substrates require unfolding for efficient secretion55. Structural elucidation of many 
protein components of the needle apparatus has been achieved by X-ray crystallography, 
NMR spectroscopy, circular dichroism, EM, structure prediction or a combination of 
techniques (Table 1-3). Cryoelectron tomography coupled with molecular docking of 
atomic structures has begun to form a partial atomic model of the needle apparatus (Fig. 
1-3). The following sections will describe in detail what is known about the structure and 
function for each T3SS component with an emphasis on the Salmonella Typhimurium 
SPI-1 T3SS system. Primary amino acid sequences of T3SS proteins vary in sequence 
homology. Salmonella and Shigella translocon and tip proteins share ~30 to 40% 
sequence homology, whereas the needle proteins share ~60% sequence homology. 
Protein structures are often fairly homologous as well: Salmonella SipD and Shigella 
IpaD have a root mean square-deviation (RMSD) of 1.8Å. Similarly, Yersinia and 
Pseudomonas translocon and tip proteins share 40% sequence homology, whereas the 
needle proteins share ~60% sequence homology. The primary sequence homology 
between the Salmonella/Shigella and Yersinia/Pseudomonas systems is ~15 to 30% for 
the needle, tip and translocon proteins. Salmonella SipD and Yersinia LcrV have an 
RMSD of 2.5Å. Constituents of the base apparatus have slightly higher primary sequence 
homology. Salmonella PrgK/PrgH/InvG and Shigella MxiJ/MxiG/MxiD have ~40 to 
50% sequence homology. Yersinia YscJ/YscD/YscC and Pseudomonas PscJ/PscD/PscC 








Fig. 1-3 – Organization of the Salmonella T3SS SPI-1 Apparatus  
(A) Cryoelectron tomography of an in situ injectisome from S. flexneri by Hu et al56. 
EMDB accession code is 2667. The map was processed with UCSF Chimera57.  Known 
or suspected localization of each T3SS apparatus constituent is labeled. (B) Known 
structures of T3SS apparatus components (see: Table 1-3) are shown as spherical models. 
This figure is meant to show the overall organization/localization of T3SS components 
and known structures, as well as the current gap in knowledge. PDB accession codes are 
1KDL (YopD amphipathic helix, SipC homolog), 3TUL (SipB N-terminal domain), 
3NZZ (SipD), 2LPZ (PrgI needle), 3J1V (InvG), 3J6D (PrgH/PrgK), 3C01(SpaS), 4A5P 
(MixA, InvA homolog), 4YX7 (SpaO-OrgB fusion), 3AJW (flagellar FliJ, InvI 









Role S. Typhimurium  
(SPI-1) 
S. Typhimurium  
(SPI-2) 
S. flexneri  
(SPI-1) 
Y. pestis  
(Ysc) 
Y. pestis  
(Ysa/SPI-2) 
Translocon SipB/SipC SseC/SseD IpaB/IpaC YopB/YopD YspB/YspC 
Tip SipD SseB IpaD LcrV YspD 
Needle PrgI SsaG MxiH YscF ? 
OM ring InvG SsaC MxiD YscC YsaC 
Inner rod PrgJ SsaI MxiI YscI YsaI 
IM ring PrgK/PrgH SsaJ/SsaD MxiJ/MxiG YscJ/YscD YsaJ/YsaD 
Export apparatus SpaP SsaR Spa24 YscR YsaR 
 SpaQ SsaS Spa9 YscS YsaS 
 SpaR SsaT Spa29 YscT YsaT 
 SpaS SsaU Spa40 YscU YsaU 
 InvA SsaV MxiA YscV [LcrD] YsaV 
ATPase InvC SsaN Spa47 YscN YsaN 
Gatekeeper InvE SsaL MxiC YopN YsaW 
Sorting platform OrgA ? MxiK YscK ? 
Sorting platform OrgB SsaK MxiN YscL ? 
Sorting platform SpaO SsaQ Spa33 YscQ YsaQ 
Regulator/Ruler InvJ SsaP Spa32 YscP ? 
Pilotin InvH ? MxiM YscW YsaP 
 
Role Enteropathogenic 
E. coli (Esc/SPI-2) 
B. pseudomallei  
(SPI-1) 
P. aeruginosa  
(Ysc) 
Chlamydia 
Translocon EspD/EspB BipB/BipC PopB/PopD CopB/CopD 
Tip EspA BipD PcrV CT584 
Needle EscF BsaL PscF CdsF 
OM ring EscC BsaO PscC CdsC 
Inner rod EscI BsaK PscI ? 
IM ring EscJ/EscD BsaJ/BsaM PscJ/PscD CdsJ/CdsD 
Export apparatus EscR BsaW PscR CdsR 
 EscS BsaX PscS CdsS 
 EscT BsaY PscT CdsT 
 EscU BsaZ PscU CdsU 
 EscV BsaQ PscV [PcrD] CdsV 
ATPase EscN BsaS PscN CdsN 
Gatekeeper SepL BsaP PopN CopN 
Sorting platform EscK OrgA PscK CT560 
Sorting platform EscL OrgB PscL CdsL 
Sorting platform EscQ BsaV PscQ CdsQ 
Regulator/Ruler EscP BsaU PscP ? 
Pilotin ? ? ExsB ? 
Table 1-2: List of T3SS Apparatus Homologs  
Compiled from a vast number of references32; 34; 46; 58; 59; 60; 61.  




Role Protein Organism EMBD/PDB ID Type 
Translocon SipB82-226 (N-term.) 
IpaB74-224 (N-term.) 
IpaB16-72 + IpgC 
YopD278-300 (amphipathic α-helix) 
YopD56-65 + SycD 
PopB51-59 + PcrH 
PopD47-56 + PcrH 



























SipD39-343 + Deoxycholate 
IpaD15-332 
IpaD (tetramer) 
IpaD39-322 + Deoxycholate 
LcrV28-322 









































YscF50-87 + YscE/YscG 

















































































































































In situ injectisome 
In situ injectisome 
In situ injectisome 














Table 1-3: Structural Proteins of the T3SS Needle Apparatus 
Note: for the corresponding literature reference please visit the PDB entry. 
Adapted from a review by Burkhinshaw et al.62 
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1.3.1. The Base 
The T3SS base anchors the needle complex into the bacterial membranes. The 
base transverses the inner membrane (IM) through the periplasm and peptidoglycan layer 
to the outer membrane (OM). The base is composed of inner membrane rings, the neck 
and outer membrane rings. The Salmonella SPI-1 base contains a three-fold symmetry, 
where the 15-mer outer ring/neck connects to the 24-mer inner ring63. Interestingly, 
differences have been reported in the Shigella SPI-1 base, which is reported to have 
twelve-fold symmetry where the 12-mer outer ring/neck connects to a 24-mer inner 
ring64.  
The inner membrane ring (IR) consists of two stacked oligomeric ring structures 
comprised of the proteins PrgK (28.2 kDa) and PrgH (44.4 kDa) in the S. Typhimurium 
SPI-1 T3SS base65. The two concentric rings are 27 nm wide (PrgH ring) and 18 nm wide 
(PrgK)65. IR1 (PrgK + PrgH) is localized in the bacterial periplasm/IM, while IR2 (PrgH) 
is localized in the bacterial cytoplasm below the IM. PrgK contains a lipidated N-terminal 
domain that is anchored into the bacterial IM and a C-terminal transmembrane domain18. 
The atomic structure of the PrgK monomer was solved independently for its two globular 
domains: PrgK19-76 (N-terminal domain) by solution NMR spectroscopy and PrgK98-200 
(C-terminal domain) by X-ray crystallography66. PrgH contains a cytoplasmic N-terminal 
domain and a C-terminal transmembrane/periplasmic domain. Crystal structures of 
PrgH11-119 (cytoplasmic domain) and PrgH170-392 (periplasmic domain) have been 
reported63. The cytoplasmic domain of PrgH and its Shigella homolog MixG contain a 
forkhead-associated domain that is commonly reported to bind phosphothreonine and is 
hypothesized to mediate protein-protein interactions of the base63; 67; 68. Nanogold 
	 18	
labeling of needle complexes has shown that PrgH and PrgK are topologically inverted 
with respect to each other65. Together, the atomic structures of the PrgK and PrgH 
monomers docked into EM maps of in situ needle complexes has led to an atomic model 
of the SPI-1 inner ring63; 66 (Fig. 1-4).  
The outer membrane rings and the neck are comprised of InvG (61.7 kDa), which 
is a member of the secretin family of outer membrane proteins65; 69. The N-terminus of 
InvG forms the neck of the base and extends downwards making contacts with the inner 
membrane ring (PrgH/PrgK), while the C-terminus extends upwards to form the outer 
membrane ring and neck63. The assembly and stability of InvG are aided by the 
lipoproten pilotin InvH (16.4 kDa)69. The structure of the Shigella pilotin MxiM (InvH 
homolog) has been solved70. In addition, the periplasmic domain of InvG22-178 has been 
solved by X-crystallography and allowed for an atomic model of the periplasmic ring of 
InvG that interacts with the inner membrane rings63 (Fig. 1-4). The diameter of the 12-
mer InvG is 15 nm71. Elucidation of the structure of the C-terminal region of InvG in the 
future will allow for an atomic model of the neck and outer membrane ring.  
The mechanism of ring formation by PrgH, PrgK and InvG has been a topic of 
discussion for sometime. It has been suggested that electrostatic forces at the interface of 
a conserved protein domain with an αββαβ configuration called the ring-building motif 
drive the oligomerization63; 72. However, this domain was not required for ring formation 
of the Shigella protein MixA (InvA homolog)73. It has also been suggested, at least with 
PrgK, that oligomerization is driven by domain-swapped interaction facilitated by a 
linker region66. For now there is no single mechanism of ring formation proposed and the 
mechanism of ring formation may be unique for each protein.  
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Enclosed in the neck of the base and linked to the needle is the ‘inner rod’ formed 
by the protein PrgJ (10.9 kDa). Direct binding has been observed by	yeast two-hybrid 
mating analysis and GST pull-down assays between the inner rod YscI (PrgJ homolog) 
and the needle YscF (PrgI homolog) of Y. pestis74. The hypothesized role of the inner rod 
is to aid the regulator protein InvJ (36.4 kDa) in substrate switching and regulating needle 
length75; 76; 77; 78. Although the atomic structure of PrgJ is currently unknown, circular 
dichroism and solution NMR studies indicate that it is most likely a partially folded α-
helical protein (at least in monomer form) that is partially similar to the needle protein 
PrgI79. Currently, no structural information exists concerning the regulator protein InvJ or 
its homologs.  
 
 
Fig. 1-4 – Organization of the Salmonella T3SS SPI-1 Base  
(A) Cryoelectron tomography of an in situ injectisome from S. Typhimurium by Radics et 
al.80 EMDB accession code is 2481. The map was processed with UCSF Chimera57 and 
fitted with PyMol structures of the ring monomers. PDB accession codes are 3J6D (PrgK 
N-terminal domain), 4G1I (PrgH periplasmic C-terminal domain), 4G2S (PrgH 
cytoplasmic N-terminal domain) and 4G08 (InvG N-terminal domain). Adapted from 
Figure 1 in a reference by Galán et al.46 (B) Modeled structures of InvG periplasmic ring 




1.3.2. The Needle 
The T3SS needle protrudes from the distal end of the base at the bacterial surface 
into the extracellular space. The role of the needle is to serve as a conduit for the 
translocation of bacterial effector proteins into the host cell. The needle is assembled 
from the polymerization of ~100 copies of PrgI (8.8 kDa) arranged in a helical manner81. 
The needle contains a channel that is 2.5 nm in diameter, which is large enough to 
accommodate two well-packed α-helices. Therefore, most T3SS substrates must be 
unfolded to travel through the needle channel. EM studies show the wild-type S. 
Typhimurium SPI-1 T3SS needle displays a phenotype of Gaussian distribution of sizes 
between 30-70 nm (length) and 10-13 nm (width)77; 78. Interestingly, the length of the 
T3SS flagellar hook is regulated in a similar manner to the NF-T3SS needle82. The length 
of the NF-T3SS needle is hypothesized to be important in regulating efficiency of 
translocation, likely dependent on the ability to penetrate the host cell in the presence of 
elongated bacterial cell surface molecules, such as lipopolysaccharide and adhesins82; 83. 
Initially, structural elucidation of recombinant forms of the needle monomers was 
not possible due to their tendency to spontaneously polymerize in solution84. However, it 
was found that deletion of five residues from the C-terminus (CΔ5) decreased the ability 
of the needle monomer to polymerize85, which allowed for structure determination of the 
needle monomers of Salmonella PrgI86, Shigella MxiH85, and Burkholderia BsaL87. 
Unfortunately, the CΔ5 mutation also decreased the ability of bacteria to invade intestinal 
epithelial cells in vitro88. Therefore, a soluble and functional PrgI V65A,V67A mutant 
was designed and its structure was determined88. In general, the structure of the needle 
monomers are conserved and consist of an α-helical hairpin, where two helices are linked 
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by a short sequence, often containing a PXXP motif, where P is proline and X is any 
amino acid (Fig. 1-5). The N-terminus and C-terminus that flank the hairpin are flexible 
and disordered. Atomic structures of the needle monomers from Pseudomonas PscF89 and 
Yersinia YscF90 have also been solved. However, these needle monomer structures were 
solved in complex with their cognate chaperones, which have been hypothesized to 
prevent premature needle polymerization prior to secretion91. Chaperones have also been 
identified for other T3SS needle proteins. For example, EscE and EscG are chaperones to 
the E. coli needle filament protein EscF92. To date no chaperones have been reported for 
PrgI, MxiH or BsaL.  
Elucidation of the structure of the polymerized needle began with cryo-EM/X-ray 
diffraction studies coupled with docking of atomic structures of the needle monomers. At 
first, these experiments generated low-resolution models of the Salmonella T3SS needle 
at 18Å93 and Shigella needle at 16Å85. Currently, atomic models of the Salmonella needle 
at a precision of 0.5Å94 and Shigella needle at a precision of 0.4Å95 are available (Fig. 1-
6). These high-resolution models were achieved through a combination of solid-state 
NMR spectroscopy, EM and Rosetta modeling. Results show that the structure of the 
polymerized Salmonella needle94 and Shigella needle95, like the structure of the needle 
monomers, are extremely conserved. The needle is 8 nm wide with a 2.5 nm diameter 
channel lumen. Needle subunits are oriented in a right-handed 11-start helical manner 
with ~5.7 subunits per turn and a helical pitch of ~2.4 nm. Subunits stabilized by both 
intersubunit and intrasubunit contacts. The N-terminus is surface exposed, the PXXP 
motif containing linker is oriented upwards distal from the base and the C-terminus is 
facing towards the needle channel lumen. Residues that face towards the lumen are 
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highly conserved and polar. In contrast, residues facing the surface are weakly or non-
conserved hydrophilic residues. The extreme C-terminal residue (Arg80 in PrgI and 
Arg83 in MxiH) places a positive charge into the channel. The electrostatic potential of 
the needle channel is hypothesized to aid in substrate progression through the channel96. 
The needle proteins are also hypothesized to have additional functions. For 
example, they have been identified as ligands that elicit a host cell immune response 
through Toll-like receptor dependent cytokine release and inflammasome activation97; 98. 
The phenomenon of needle protein dependent host cellular signaling and cytokine release 
has been suggested to occur through an unknown mechanism involving the non-
conserved N-terminus of T3SS needle proteins99. The needle is additionally hypothesized 
to serve as a potential mechanism where contact with the host cell is relayed down to the 
T3SS base by conformational changes in the needle100. In these models, the needle is not 
as rigid as previously thought, and instead is a semi-flexible filament. However, further 
experiments are needed to validate these hypotheses.  
Regulation of the needle length is related to substrate switching. Because the 
needle protein is considered an early effector protein (PrgI itself is secreted to polymerize 
the needle), at some point the T3SS machinery undergoes a substrate switch from the 
needle protein to the tip/translocon and this process is connected to regulating the needle 
length. The regulator protein is known to play an essential role in substrate switching. In 
the absence of InvJ, the inner rod PrgJ cannot form, but abnormally long needles can 
assemble75. One hypothesis is InvJ measures length by being in an extended 
conformation in T3SS channel lumen. When the terminus of the protein reaches the end 
of the export apparatus/sorting platform it leads to substrate switching by an unknown 
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mechanism. This theory is partially supported by the observation that varying the length 
of Yersinia YscP (InvJ homolog) results in a different average distribution of needle 
lengths (for example, longer YscP led to longer needles)101. This ‘molecular ruler’ model 
is further supported by structural and functional studies of the Pseudomonas proteins 
PscP and PscU102. In addition, an alternative model has been proposed where InvJ aids in 
the formation of the socket of the base that allows for efficient inner rod formation and 
proper anchoring to the base. In this model, once PrgJ is properly assembled substrate 
switching occurs by an unknown mechanism. This ‘timer model’ is supported by the 
observation that mutations in PrgJ also lead to abnormally long needles, but substrate 
switching occurs and allows for a functional needle complex, unlike InvJ deletions75. 
More experimental evidence is required to determine which model of needle length 


















Fig. 1-5 – Needle Monomer Structures   
Atomic structures of needle monomers are shown. Proteins are oriented with the N-
terminus to the left and C-terminus to the right with α-helix 1 and 2 colored in cyan. The 
termini are removed because they are highly flexible and/or disordered. The linker region 
is colored in grey and shows specific sequence for the PXXP motif for each protein. PDB 








Fig. 1-6 – Atomic Models of Polymerized T3SS SPI-1 Needles  
Atomic models of the polymerized Salmonella94 and Shigella95 needles are shown. 
Needles are oriented with the N-terminus (colored in grey) as surface exposed, while the 
C-terminus faces the lumen. PDB accession codes are 2LPZ (Salmonella PrgI needle) 




1.3.3. The Tip Complex 
At the distal end of the needle is the tip complex, comprised by the non-
filamentous oligomerization of the protein SipD (36.5 kDa) in the Salmonella SPI-1 
T3SS103. In other systems, such as the EspA (20.5 kDa) containing E. coli system104, the 
tip is an extended helical filament similar to the needle. The role of the tip complex is to 
sense contact with host cells105; 106, regulate effector protein secretion105; 107 and act as a 
platform for the insertion of the translocon into the host membrane108; 109.  
Tip monomers with known structures include S. Typhimurium SipD110, S. flexneri 
IpaD111, B. pseudomallei BipD111, Y. pestis LcrV112, E. coli EspA113 and C. trachomatis 
CT584114 (Fig. 1-7). SipD, IpaD and BipD contain a similar ‘dumb-bell’-like 
configuration. Each protein contains an N-terminal α-helical hairpin, a central coiled-coil 
and a mixed α/β domain (Fig. 1-7). LcrV (also called the V-antigen) contains the central 
coiled-coil domain and mixed α/β domain, but contains a globular N-terminal domain in 
place of the N-terminal α-helical hairpin112 (Fig. 1-7). CT584 and EspA have even more 
divergent structures (Fig. 1-7). CT584 contains an N-terminal four α-helix bundle, a 
three-stranded anti-parallel β-sheet and a C-terminal kinked α-helical hairpin114. The 
structure of monomeric EspA (in complex with its chaperone CesA) is an extended two 
α-helix bundle; similar to the central coiled-coil domains of other T3SS tips113. Each 
domain has been shown to have specific function. For SipD/IpaD/BipD, the N-terminal 
domain functions as a self-chaperone that prevents oligomerization within the bacterial 
cytoplasm and regulates interaction with other T3SS proteins111. The structure of the tip 
N-terminal hairpin domain is similar of the needle monomer structure and the needle is 
hypothesized to replace the tip N-terminal domain in the needle/tip complex during 
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effector translocation115; 116. In contrast, in the bacterial cytoplasm LcrV and EspA are in 
complexes with their cognate chaperones, LcrG117; 118 and CesA, respectively119. The 
central coiled-coil of tip proteins have been shown to be essential for interactions with the 
needle protein115, as well as promoting self-oligomerization111.  
Multiple models of the tip complex (oligomerized tip monomers) have been 
proposed. EM, cross-linking and docking of the crystal structure of IpaD (SipD homolog) 
led to a model of the Shigella flexneri SPI-1 T3SS tip complex120. The model proposed 
by Cheung and co-workers suggests four or five copies of IpaD form the tip complex, 
which has a 1 nm pore (slightly smaller than the 2.5 nm needle channel)121. This may 
represent a ‘closed’ translocation deficient conformation. The C-terminus of IpaD faces 
the channel lumen and the mixed α/β doman is surface exposed (Fig. 1-8). It should be 
mentioned that their model lacks docking of the N-terminal domain of IpaD, although 
they argue there is EM density to fit the domain121. Interestingly, some their tip 
complexes contained IpaB (the major translocon protein), though a significant proportion 
did not121. One hypothesis is that IpaB is unstable in the tip complex in the absence of 
necessary stabilizing factors, such as host membrane lipids. Whether IpaB is a true 
constituent of the tip complex remains to be shown. In agreement, low resolution EM of 
Y. pestis shows a pentameric LcrV tip complex122. The E. coli SPI-2 T3SS system is 
unique and contains a filamentous tip structure that is divergent from the more flat 
globular tip complex models of Shigella and Yersinia21. EspA has a similar coiled-coil α-
helical structure to the flagellin protein FliC and is hypothesized to assemble into a 
helical filamentous structure, though no model for the E. coli tip filament is currently 
available113.  
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Bilt salts are present in high concentrations in the host intestines and have been 
shown to interact with some tip proteins. Examples of such bile salts are deoxycholate, 
taurodeoxycholate, and chenodeoxycholate. Interestingly, the binding of bile salts to 
Salmonella SipD and Shigella IpaD have opposite effects: invasiveness is increased in 
Shigella123; 124; 125, but repressed in Salmonella126. X-ray structures have been reported 
with deoxycholate interacting with SipD110; 116 or IpaD127. Furthermore, solution NMR 
titrations between deoxycholate and SipD128 or IpaD129 have been reported. Results from 
NMR show that deoxycholate binds SipD under the mixed α/β domain using a surface at 
the bottom of the coiled-coiled128. Although exact interacting residues are different, 
deoxycholate also binds at the bottom of the coiled-coil of SipD by crystallography110 
and with a SipD-PrgI fusion protein116. In contrast, NMR shows deoxycholate binds IpaD 
between N-terminal hairpin and the coiled-coiled129, while crystallography shows under 
the mixed α/β domain at the bottom of the coiled-coiled127. Together, these data are 
inconclusive, but may suggest a difference in binding mode of deoxycholate with tip 
proteins that could potentially explain the difference invasiveness of Salmonella and 
Shigella in the presence of bile salts. Binding of bile salts to the tip protein is 
hypothesized to induce a conformational change that relays a signal back down to the 










Fig. 1-7 – Tip Monomer Structures   
Atomic structures of tip complex monomers are shown. Proteins are oriented with their 
N-terminal domain to the left. The N-terminus and C-terminus are labeled. PDB 
accession codes are 3NZZ (SipD), 2J0O (IpaD), 2J9T (BipD), 4JBU (LcrV), 4MLK 
(CT584) and 1XOU (EspA). SipD, IpaD and BipD are self-chaperoning proteins and 
have conserved structure that includes an N-terminal α-helical hairpin, a central coiled-
coil and a mixed α/β domain. LcrV, CT584 and EspA have non-conserved structures. The 
chaperones for LcrV (LcrG) and EspA (CesA) are not shown. The chaperoning nature of 
CT584 is yet to be defined fully, but it is suggested to have some chaperoning 
capabilities130. Not shown is the structure of the tip protein from Chromobacterium 










Fig. 1-8 – Atomic Model of the Shigella flexneri T3SS SPI-1 Tip Complex   
A model of the Shigella tip complex is shown120. (A) Four subunits of IpaD are present 
with the C-terminus facing towards the channel lumen and the mixed α/β domain surface 
exposed. (B) The authors suggest the other subunit  (the ‘open space’, easily visible on 
complex visible from the top on the right of the image) could be either IpaD or IpaB 













1.3.4. The Translocon 
The tip complex is present on the bacterial surface at the distal end of the needle 
prior to contact with host cells103; 131; 132. Contact with the host cell is a trigger that 
promotes complete assembly of the T3SS apparatus by promoting the secretion and 
assembly of the translocon133. The translocon is a host cell membrane embedded pore 
created by bacterial T3SS proteins that serves as the final stage of passage for the 
delivery of effector proteins. The translocon is often said to be required for effector 
translocation, but dispensable for effector secretion. In this context, secretion is defined 
as protein transfer from the bacterial cytoplasm into the extracellular space, while 
translocation is defined as protein transfer from the bacterial cytoplasm into the host cell 
cytoplasm. 
In the S. Typhimurium SPI-1 T3SS, the translocon is formed by two hydrophobic 
proteins, SipB (62.4 kDa) and SipC (44 kDa). Because of their difference in molecular 
weight and number of transmembrane regions, sometimes SipB is referred to as ‘major’ 
translocon component, whereas SipC is called the ‘minor’ translocon component. SipB 
contains an N-terminal coiled-coil region, two transmembrane regions and C-terminal 
amphipathic region134. The N-terminal region interacts with a chaperone, SicA, and has 
been shown to be responsible for self-oligomerization134. The SipB N-terminal domain is 
also implicated in being responsible for the interaction with the tip protein SipD135. The 
transmembrane and C-terminal regions are essential for interaction with host membranes 
components and SipC134; 136. The membrane topology of SipB suggests the N-terminal 
domain protrudes into the extracellular space137. SipC contains an N-terminal region, one 
transmembrane region and a C-terminal region138. The C-terminal region of SipC has 
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been show to be important with binding of SipB139. Some reports in the literature 
consider the hydrophilic tip protein (SipD) as part of the translocon, although it has not 
been shown to insert into membranes133. 
The atomic structures of the full-length translocon proteins have so far been 
difficult to solve due to poor stability or solubility issues in solution. However, partial 
structures of short major translocon peptides have been solved in complex with their 
cognate chaperones, such as IpaB16-72 with IpgC and PopB51-59 with PcrH.140; 141 In 
addition, crystal structures of a protease resistant soluble N-terminal domain of 
Salmonella SipB and Shigella IpaB have been solved142. The structure of the N-terminal 
domain of SipB revealed an extended trimeric coled-coil formed by three anti-parallel 
helices142 (Fig. 1-9). Recently, a partial structure of Aeromonas AopB from residues 45 to 
263 in complex with its cognate chaperone AcrH was solved by crystallography (Fig 1-
9). This structure was unique in that it contained AopB transmembrane regions, which 
allowed for a working model of membrane insertion143.  
Much less is known structurally about the minor translocon proteins. Short minor 
translocon peptides have been solved with their cognate chaperones, such as YopD56-65 
with SycD and PopD47-56 with PcrH144; 145. The C-terminal amphipathic α-helix of 
YopD278-300 has also been solved by solution NMR146 (Fig. 1-9). Even less is known 
about the assembled translocon complex. Atomic force microscopy of E. coli translocon 
in red blood cells suggests a complex of 6 to 8 total subunits with an outer diameter of 60 
nm and a height of 20 nm147. The inner diameter of the pore has been estimated to be 
between 2 and 3.5 nm147; 148. These estimates correlate relatively well with the measured 
diameters of the needle (2.5 nm) and tip complex (1 nm) channels described in the above 
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sections. In Pseudomonas, single-molecule fluorescence photobleaching experiments 
suggests that the translocon proteins assemble a hexadecameric membrane complex with 
eight copies of PopB and eight copies of PopD.149 Translocon proteins also have non-
structural roles, such as serving as effector proteins. For example, SipC bundles F-actin in 
the host cytoplasm to promote invasion150; 151; 152 and SipB induces macrophage 





Fig. 1-9 – Partial Structures of T3SS Translocon Proteins 
Partial structures of T3SS translocon components are shown. The N-terminal domain of 
the major translocon from Salmonella, Shigella and Aeromonas are shown in red with the 
N-terminus facing left. The AopB structure was solved in the presence of the chaperone 
AcrH (not shown here). The amphipathic helix from the minor translocon of Yersinia is 
shown on the right in green. PDB accession codes are 3TUL (SipB), 3U0C (IpaB), 





1.3.5. Assembly of the T3SS Apparatus 
The assembly of the T3SS apparatus occurs in a hierarchal fashion155; 156. In the 
Salmonella SPI-1 T3SS, the stages of assembly are the following: i) assembly of the 
export apparatus, sorting platform and basal body, ii) assembly of the inner rod and 
needle, and iii) assembly of the tip and translocon156. T3SS apparatus assembly is 
initiated at the bacterial inner membrane by the export apparatus proteins SpaP, SpaR, 
SpaQ and SpaS156. The assembled export apparatus serves as a nucleation point for the 
formation of the inner membrane rings formed by PrgH and PrgK156. Next, the secretin 
InvG assembles the membrane outer rings with the help of the pilotin InvH65. This model 
is supported by several observations. First, the export apparatus can assemble in the 
absence of the rest of the needle complex156. Second, the inner membrane rings can 
assemble in the absence of the outer membrane secretin InvG65. Finally, E. coli EscC 
(InvG homolog) requires the inner membrane rings for efficient assembly157. The sorting 
platform (OrgA/OrgB/SpaO) has been suggested to exist as a pre-assembled complex 
prior to incorporation into the T3SS apparatus158. Incorporation of the ATPase InvC 
requires an assembled sorting platform56. Interestingly, the Yersinia Ysc apparatus is 
hypothesized to assemble by a reverse mechanism, where the outer membrane rings 
assemble first followed by the inner membrane rings, the export apparatus and sorting 
platform155. The final steps of assembly are not yet well established. However, it is 
thought that the inner rod PrgJ assembles, with the help InvJ, to serve as the inner 
channel of the base and serve as a platform for needle assembly159. The needle is 
polymerized by the addition of subunits at the growing distal end of the needle and is 
controlled by substrate switching. Protein refolding and conformational changes in the 
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needle monomer may be needed for efficient needle assembly88. The assembly of the 
translocon requires the tip protein109. 
 
 1.4. Functional Components of the T3SS  
1.4.1. The Export Apparatus, Sorting Platform and Associated Proteins 
The Salmonella SPI-1 T3SS export apparatus is comprised of the inner membrane 
proteins SpaP, SpaQ, SpaR, SpaS and InvA156. The assembled complex of these proteins 
is suggested to serve as the export channel for the entrance of T3SS substrates and as a 
docking platform for essential cytoplasmic components, such as the ATPase and inner 
rings156. Little is known about the structure and function of SpaP, SpaQ and SpaR. SpaS 
(40 kDa) is known as the T3SS autoprotease. SpaS contains an N-terminal domain that is 
associated with the inner membrane ring and a C-terminal domain that undergoes 
autoprotease cleavage to regulate substrate switching160; 161. SpaS cleavage occurs 
between Asp and Pro of a NPTH motif162. Shigella Spa40 cleavage (SpaS homolog) has 
been shown to be essential for interaction with other export apparatus proteins162. The C-
terminal domain structure of SpaS and its E. coli homolog EscU have been solved163. In 
addition, structures of Shigella Spa40164, Yersinia YscU165 and Chlamydia CdsU have 
been solved. InvA (76 kDa) is the largest member of the export apparatus and is 
hypothesized to form the export apparatus pore. InvA contains an N-terminal integral 
membrane domain linked to a C-terminal cytoplasmic domain. Structures of the 
monomeric C-terminal domain of InvA have been solved166; 167. In addition, crystal 
structure of the C-terminal cytoplasmic domain of the Shigella homolog MxiA revealed a 
nonameric ring with 15 nm width, 5 nm pore and 5.5 nm height73.  
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Below the export apparatus is the cytoplasmic hexameric ATPase InvC, which 
forms a complex the sorting platform proteins SpaO, InvI, OrgA and OrgB168. The role of 
the ATPase is to promote chaperone release from their cognate T3SS effector proteins, as 
well to promote effector unfolding, in an ATP hydrolysis dependent manner55. The 
ATPase is hypothesized to be dispensable for T3SS secretion and instead is suggested to 
enhance secretion efficiency169. Known structures of NF-T3SS ATPases include E. coli 
hexameric EscN170 and the Salmonella SPI-2 hexameric ATPase SsaN171.  The roles of 
the other export apparatus proteins are not as well defined. InvI has been suggested to 
form the central stalk γ subunit of the ATPase172; 173. OrgB is suggested to form the 
peripheral stalk, while the function of OrgA is currently undefined172. SpaO is 
hypothesized to be the homolog to the flagellar C-ring. The structure of two C-terminal 
domains of SpaO have been recently solved by solution NMR, as well a complex 
between those SpaO domains and a peptide of OrgB174. Many electron microscopy 
studies of in vitro and in situ T3SS injectisomes failed to visualize densities of the export 
apparatus and sorting platform175. In contrast, Shigella mini-cells containing T3SS 
apparatuses allowed for visualization of the export apparatus/sorting platform densities56. 
Docking of atomic structures of sorting platform components allowed for the most 
complex model of the T3SS injectisome to date56. 
 
1.4.2. T3SS Chaperones 
Many T3SS apparatus constituents and effectors, but not all, have cognate 
chaperones. In the context of the T3SS, chaperone proteins play many unique roles. First, 
they can deliver T3SS effectors to the ATPase/sorting platform at the cytoplasmic 
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interface with the base, after which they are released back into the cytoplasm55. Second, 
they can minimize interactions with other proteins in the bacterial cytoplasm, prevent 
premature oligomerization and inhibit degradation of T3SS effectors176. Unlike many 
eukaryotic chaperone proteins, T3SS chaperones do not usually directly contribute to 
protein folding or refolding.  
Chaperones are categorized into different classes based on their structure and 
function177. The structures of many chaperones have been solved, some in complex with 
their cognate effector protein (Table 1-4). The definition of the chaperone classes varies 
in the literature, but three to five classes have been recognized. Class I chaperones are 
small (in the range of 15 kDa) acidic (pI of 4 to 5) cytoplasmic proteins that contain an α-
β-β-β-α-β-β-α fold178. The class is further divided in chaperones that interact with either 
one effector (class Ia) or multiple effectors (class Ib). Class II chaperones interact with 
the translocon proteins. Class III chaperones are sometimes considered as chaperones that 
bind to needle proteins62; 178, but have also been defined as specifically binding to 
flagellar proteins177. Other groups have referred to needle protein-binding chaperones as 
class V chaperones90. Class II and III/V chaperones contain many tetratricopeptide folds 
that are comprised of anti-parallel helices178. There are other chaperones that are so 
structurally distinct from other classes that they warrant their own class, such as the E. 








Organism Class PDB ID 
InvB SipA Salmonella IB 2FM8 
SicP SptP Salmonella IA 1JYO 
SigE n/a Salmonella IA 1K3S 
IpgC IpaB peptide Shigella II 3GZ2 
Spa15 n/a Shigella IB 1RY9 
CesT n/a Escherichia IB 1K3E 
CesAB EspA Escherichia IV 1XOU 
SycD [LcrH] YopD peptide Yersinia II 4AM9 
SycE YopE Yersinia IA 1L2W 
SycH YopH Yersinia IB 4GF3 
SycH YscM2 Yersinia IB 1TTW 
SycN-YscB YopN Yersinia IA 1XKP 
SycT n/a Yersinia IA 2BSJ 
YscE-YscG YscF Yersinia V 2P58 





PscE-PscG PscF Pseudomonas V 2UWJ 
SpcS ExoT Pseudomonas IA 4JMF 
SpcU ExoU Pseudomonas IA 3TU3 
AscE-AscG n/a Aeromonas V 3PH0 
Scc3 CopN Chlamydia II 4NRH 







Effector T3SS Biochemical 
Activity  
Host Target(s) Host Pathway(s) 
Influenced 
PDB ID 
GtgE SPI-2 Cysteine protease Rab29, Rab32, Rab38 SCV maintenance 4MI7 
PipB2 SPI-1/2 ? Kinesin-1 SIF extension, 
SCV maintenance 
2LEZ 












SipB SPI-1 ? Caspase-1 Macrophage apoptosis 3TUL 





SlrP SPI-1/2 E3 ubiquitin 
ligase 
ERdj3, Trx Apoptosis 4PUF 








SopB SPI-1 Inositol 
phosphatase 






SopE SPI-1 GEF Cdc42, Rab5, Rac1 Actin remodeling 1GZS 
SopE2 SPI-1 GEF Cdc42, Rac1 Actin remodeling 1R9K 
SptP SPI-1 Tyrosine 
phosphatase 







G-actin SCV maintenance, 
Actin remodeling 
2GWM 
SpvC SPI-1/2 Phosphothreonine 
lyase 
ERK2, MAPK1, p38 
JNK 





Filamin A, IQGAP1, 
TRIP6 
Macrophages migration, 
Dendritic cells migration 
4G29 
SrfJ SPI-2 Glycoside 
Hydrolase 
? ? 2WNW 
SspH1 SPI-1/2 E3 ubiquitin 
ligase 
PKN1 MAPK inactivation 4NKH 
SspH2 SPI-2 E3 ubiquitin 
ligase 
Filamin A, Profilin-1, 
UbcH5, 14-3-3, AIP, 
BAG2,  BUB3, SGT1 




Table 1-5: Atomic Structures of Salmonella Typhimurium T3SS Effectors 
A list of known Salmonella effector structures and their hypothesized functions and host 
cell targets. GEF - Guanine nucleotide-exchange factors. SIF – Salmonella-induced 
filaments. SCV – Salmonella-containing vacuole. Adapted from multiple references179; 






1.4.3. Salmonella Typhimurium T3SS Effectors 
The main purpose of the T3SS is the translocation of effectors from the bacterial 
cytoplasm into the host cell. The effector proteins are the ‘work horse’ of the bacterium 
in the context of virulence, allowing for the initial invasion of host cells, as well as their 
prolonged maintenance and survival within the host. Targeting of T3SS effectors to the 
apparatus often depends on a structurally disordered N-terminal peptide signal sequence 
within the first 20 amino acids, but is also dependent on targeting via their cognate 
cytoplasmic chaperone184. Effectors are often specialized in each bacterium for their 
specific host environment infection niche. Furthermore, in bacteria that contain more than 
one T3SS system (such as the Salmonella SPI-1 and SPI-2 system), each T3SS may 
contain its own set of effectors with unique functions that regulate a certain stage of 
infection. The focus in this section is on S. Typhimurium effectors. Reviews of T3SS 
effector proteins in other bacterial systems can be obtained elsewhere180; 185; 186. 
Effectors often fall into the following classes: i) host cytoskeleton regulators, ii) 
cell junction regulators, iii) Salmonella-containing vacuole regulators, iv) cell migration 
and cell death regulators, v) host transcriptional regulators, and vi) host immune response 
regulators. The currently known structures of T3SS effectors are summarized in Table 1-
5. For an in depth review of the function of SPI-1 and SPI-2 Salmonella effectors refer to 
a reference by Ramos-Morales179. Briefly, host actin cytoskeleton is rearranged and 
remodeling by the activation of host cell Rho GTPases by SopE and SopB and by direct 
binding by SipA and SipC.183 SipA, SopB and SopE contribute to the disruption of tight 
junctions by disrupting ZO-1 and occludin183. Biogenesis of the SCV is achieved with the 
help of SopB and SptP and maturation/maintenance of the SCV is dependent on SifA, 
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SseF and SseG, PipB2, SseJ and others183. SopA leads to transepithelial migration of 
neutrophils183. Epithelial cell death is promoted by AvrA, SopB, SpvB and SlrP. 
Macrophage cell death is promoted by SipB, SopB and PrgJ183. Transcriptional regulation 
of host cell genes and regulation of the host immune system occurs via an array of 
effectors, which includes SopB, SopE, SopE2, SipA, PipB, AvrA, SpvC, GogB and 
SseL179. In some cases, for example Pseudomonas ExoS and Yersinia YopE, a negative 
feedback mechanism for effector translocation control has been proposed where the 
effectors themselves are a signal for transcription and secretion187; 188. 
 
1.5. Future Directions of T3SS Research 
Bacterial T3SSs have been engineered as drug delivery platforms useful in 
biotherapeutic therapy. For example, the T3SS from Salmonella Typhimurium has been 
engineered in non-replicating nanoparticles derived from bacterial mini-cells and can 
deliver an antigen to eukaryotic cells both in vitro and in vivo189. Similar T3SS drug 
delivery platforms have been engineered in attenuated Pseudomonas190 and Yersinia191. 
The application of this drug/antigen delivery scheme could treat diseases including viral 
infection192, bacterial infections193, cancer194 and malaria195. Future research will further 
develop and evaluate bacterial T3SS based drug/antigen delivery systems.   
Currently, T3SS proteins are under evaluation as potential vaccine candidates. 
The T3SS tip and needle are thought to be excellent candidate due to their surface 
presentation and contact with host cells during and prior to translocation196. Many T3SS 
proteins that have been shown to be immunogenic antigens, including Salmonella SipD, 
PrgI and SseB197; 198, Shigella IpaD, IpaB and MxiH198; 199, Yersinia LcrV200, 
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Burkholderia BipD, BsaL and BopE198; 201, Pseudomonas PcrV202 and Chlamydia T3SS 
effector Tarp203. Further formulation and pre-clinical studies, including animal models, 
are needed to develop these T3SS proteins into potent vaccines. There are also a number 
of small molecules that have been discovered as T3SS inhibitors. These are reviewed in 
depth in Chapter 9. Together, vaccines and small molecules are potential avenues for the 
treatment and prevention of many diseases caused by T3SS harboring bacteria.  
The amount of progress, as well as the wealth and speed of discoveries, made 
since the first visualization of the T3SS apparatus in 1998 (only 17 years ago) is a 
testament to the development of novel technologies and methods to solve new problems. 
However, much remains to be elucidated. There are many protein densities in current 
high-resolution cryo-EM maps that have not yet been accounted for (Fig. 1-3). 
Identification and localization of these unresolved T3SS components will allow for 
proper docking into those densities. Structures of many proteins are currently not known, 
including the full-length translocon proteins and components of the T3SS SPI-1 base. 
Structure elucidation of full-length proteins will likely require reconstitution in a 
membrane environment, such as liposomes or nanodiscs. Structures of many of the 
components of the SPI-2 apparatus remain to be solved. The ultimate goal is to develop a 
complete atomic model of the entire SPI-1 and SPI-2 needle apparatus.  
The mechanism of secretion and activation of secretion are both poorly 
understood. For example, how are substrates are recognized, unfolded at the T3SS base 
and fed into the export apparatus channel is unclear. A recently published cryo-EM of a 
substrate trapped T3SS has begun to resolve some questions204. Activation of secretion is 
hypothesized to require substrate switching, whose mechanism is not fully understood. 
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Furthermore, how contact with host cell membrane and extracellular molecules, such as 
bile salts, can relay a signal down to the T3SS base is unknown. Many T3SS effectors 
have been identified with unknown structures and functions that have yet to be defined. 
The fuel that powers the T3SS remains poorly understood. One possibility is energy 
derived from ATP hydrolysis by the ATPase during substrate unfolding may provide 
some energy for secretion46. Another mechanism has been hypothesized where proton 
motive force allows for rotation of the T3SS apparatus that aids in substrate travel 
through the channel205. These questions and more will drive T3SS research for many 
years to come.  
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Chapter 2. Assignment of ILV Methyl Resonances of SipDΔ38 
 
[Some of the data in this chapter has been published with the following citation: McShan 
AC, Kaur K, Chatterjee S, Knight KM, De Guzman RN. NMR Identification of the 
Binding Surfaces Involved in the Salmonella and Shigella Type III Secretion Tip-
Translocon Protein-Protein Interactions. Proteins. 2016] 
 
2.1. Introduction 
SipD is the hydrophilic tip protein from the Salmonella Typhimurium SPI-1 T3SS 
(see section 1.3.3. for review). SipD is known to interact with T3SS apparatus 
components, including the needle protein PrgI1; 2 and the major translocon protein SipB3. 
SipD is also known to interact with biological molecules, such as bile salts4, to help 
regulate secretion of T3SS effectors. Furthermore, because SipD is present at the distal 
end of the needle and exposed to the extracellular environment prior to and during 
infection, it is an essential interaction hub and represents an excellent candidate for drug 
discovery5. SipD contains 343 amino acids and has a molecular weight of 37.1 kDa. The 
atomic structure of SipD has been solved by X-ray crystallography6; 7. Unfortunately, it 
does not crystallize in complex with other T3SS proteins, such as PrgI and SipB, likely 
due to weak protein-protein interactions or presence of disordered regions. These 
observations prompted the characterization of the interaction between SipD with PrgI or 
SipB by NMR spectroscopy, due to the sensitivity of NMR to characterize protein 
interactions from nM to mM affinity8 and availability for amino acid reside specific 
information. Backbone and side-chain amide resonances of SipD39-343 C244S (herein 
called SipDΔ38) were assigned to 93% previously4. The N-terminal residues 1-38 were not 
included in the NMR construct of SipDΔ38 because those residues were structurally 
disordered and interfered with obtaining good quality 2D 1H-15N TROSY NMR data. 
Nevertheless, in the 2D 1H-15N TROSY spectrum many SipDΔ38 resonances were 
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overlapped due to the complexity of the spectra of a large protein (>300 NMR peaks), 
which made analysis of any interactions tedious and unreliable for overlapping residues. 
For this reason, we proposed to isotopically label SipDΔ38 in such a manner that resulted 
in a less complex NMR spectrum, but still allowed for significant coverage of potential 
interaction surfaces. To this end, I chose isoleucine, leucine and valine (ILV) side-chain 
methyls. ILV 13C-methyl labeling is a method that was developed and popularized by 
Lewis Kay and co-workers9. In this method, α-ketoacids, such as α-ketobutyrate and α-
ketoisovalerate, serve as biosynthetic precursors for isotopically labeled Ile and Leu/Val 
side-chain methyl carbons, respectively10 (Fig. 2-1).  ILV methyl probes are useful 
because of the following: i) they allow for good correlations and favorable relaxation 
properties for high molecular weight proteins11, ii) are generally more sensitive than 
amide resonances because the signal averaging from three protons12, iii) are good probes 
to study protein dynamics13, and iv) reduce complexity of the system compared to amide 
labeling by reducing the number of peaks observed. Here, ILV 13C-methyl labeled 
SipDΔ38 was expressed and purified. Subsequently, the 2D 1H-13C HSQC NMR spectrum 
of ILV methyl labeled SipDΔ38 was acquired and the corresponding resonances were 
assigned by a combination of site-directed mutagenesis and 3D NMR. 
 
2.2. Materials and Methods  
2.2.1. Expression and Purification of Perdeuterated SipDΔ38 
Salmonella Typhimurium strain SL1344 T3SS SPI-1 tip protein SipDΔ38 was 
previously subcloned6 into a modified pET-21a expression vector containing an N-
terminal His6 tag followed by a tobacco etch virus (TEV) protease cleavage site and β1 
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streptococcal protein G (GB1) as a solubility tag14. Isotopically labeled 15N/ILV 13C-
methyl SipDΔ38 (perdeuterated) was expressed in E. coli BL21(DE3) DNAY cells in 1 
liter of 1✕ M9 minimal media with antibiotics in D2O at 37°C containing 1 g/L 15NH4Cl 
(Sigma-Aldrich, St. Louis, MO) and 2 g/L deuterated d7-D-glucose (Cambridge Isotope 
Laboratories, Inc.). At an OD600 of 0.4 the growth medium was supplemented with 60 mg 
of 2-ketobutyric acid-4-13C (#571342 Sigma; which labels the isoleucine 13Cδ1 methyl 
group) and 100 mg of 2-keto-3-(methyl-13C)-butyric-4-13C acid (#571334 Sigma; which 
labels the leucine 13Cδ and the valine 13Cγ methyl groups) dissolved in 1 mL sterile 
water. This protocol was adapted from a previous ILV 13C-methyl labeling protocol10. 
Recombinant protein expression was induced with 1 mM isopropyl-β-D-
thiogalactopyrandoside (IPTG) at an OD600
 
of 0.8 and cell growth was continued 
overnight at 15°C. Bacterial cells were harvested by centrifugation at 4000 rpm for 10 
minutes, resuspended with 30 mL binding buffer (500 mM NaCl, 20 mM Tris-HCl, 5 
mM imidazole, pH 8.0, 1 mM phenylmethanesulfonyl fluoride) and sonicated on ice. 
Sonication was performed using a Branson Digital Sonifier for 5 minutes and 20 seconds 
at amplitude 32% with 2 second on pulses and 6 second off pulses. The cell lysate was 
centrifuged for 10 minutes at 13000 rpm. Next, 700 µL of 5% (v/v) polyethyleneimine 
was added to the supernatant, which was centrifuged again to remove further cellular 
debris. The supernatant was loaded onto a 10 mL Ni2+-affinity chromatography column 
(Gold Biotechnology), the column was washed with 150 mL binding buffer (500 mM 
NaCl, 20 mM Tris-HCl, 5 mM imidazole, pH 8.0) and bound protein was eluted with 40 
mL elution buffer (500 mM NaCl, 20 mM Tris-HCl, 250 mM imidazole, pH 8.0). Eluted 
proteins was then incubated in 250 µL of 0.04 mM recombinant TEV protease in TEV 
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protease buffer (50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 1 mM DTT, 20 mM NaCl) at 
20°C overnight and then purified by Ni2+-affinity chromatography to separate protein 
from the affinity tag. All purified proteins were dialyzed into NMR buffer (see below) 
and concentrated using Amicon Ultra 3K (Millipore) filtration columns. Protein 




Fig. 2-1 – ILV Side-Chain Methyl Isotope Labeling Strategy 
(A) 2-ketobutyric acid is a precursor for the labeling of isoleucine methyl carbon δ1 (red 
dotted circle). One methyl carbon atom is labeled. Therefore one NMR peak is observed 
for each Ile in a 2D 1H-13C HSQC experiment. (B) 2-keto-3-methylbutyric acid (α-
ketoisovalerate) is a precursor for the labeling of valine methyl carbons γ1 and γ2 and 
leucine methyl carbons δ1 and δ2 (green and red dotted circles). Two methyl carbon 
atoms are labeled on each amino acid. Therefore two NMR peaks are observed for each 




2.2.2. 1H-13C HSQC of Perdeuterated SipDΔ38 
Data was collected using a Bruker Avance 800 MHz spectrometer equipped with 
a cryogenic triple resonance probe and were processed using NMRPipe15 and analyzed 
using NMRView16. As a reference for the 3D HMQC-NOESY, a high quality 2D 1H-13C 
HSQC spectra (pulse sequence hsqcetgp) was acquired using 0.9 mM perdeuterated 
15N/ILV 13C-methyl labeled SipDΔ38 dissolved in NMR buffer (20 mM NaCl, 10 mM 
sodium phosphate, pH 7.4) then lyophilized and resuspended in 100% (v/v) D2O at 30°C. 
Acquisition parameters were 8 scans with 1024 complex points (1H) and 256 complex 
points (13C) with sweep width 10.01 ppm for 1H centered at 4.69 ppm and 20 ppm for 13C 
centered at 19 ppm.  
 
2.2.3. 3D 13C-1H-13C HMQC-NOESY-HMQC of Perdeuterated SipDΔ38 
For 3D NMR data acquisition, 0.9 mM perdeuterated 15N/ILV 13C-methyl labeled 
SipDΔ38 was dissolved in NMR buffer then lyophilized and resuspended in 100% (v/v) 
D2O. The 3D 1H-13C HMQC-NOESY experiment was acquired using 8 scans with 2048 
complex points (1H), 80 complex points (13C) and 100 complex points (NOE 13C) with a 
mixing time (D8) of 300 milliseconds and relaxation delay (D1) of 2 seconds. Sweep 
widths were 10.01 ppm for 1H centered at 4.69 ppm and 20.0 ppm for 13C centered at 
19.0 ppm.  
 
2.2.4. Assignment Strategy and Data Analysis 
ILV methyls were assigned using a methodology reported by Xiao and co-
workers17. First, isoleucine-to-leucine point mutants of SipDΔ38 were created using 
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Quikchange kit (Stratagene) and confirmed by DNA sequencing. Ile-to-Leu mutants 
provided Ile methyl assignments as an anchor of stereospecific Leu/Val methyl resonance 
assignments from through-space 1H-1H nuclear Overhauser effects (NOEs) observed in 
the 3D HMQC-NOESY experiment in combination with distance information from the 
previously determined X-ray crystal structure of SipDΔ38 (PDB ID 3NZZ). NMR data 




2.3.1. SipDΔ38 Purification and Ile Methyl Assignments 
Analysis of the position of ILV residues on the crystal structure of SipDΔ38 
showed that ILVs covered most surfaces of the protein, suggesting that ILV methyls were 
a suitable probe for interaction studies involving SipD (Fig. 2-2). Notably, one surface 
remained relatively free of ILVs: the side of helix α8 facing the surface of the SipD (Fig. 
2-2). SipDΔ38 contains 12 isoleucines, 33 leucines and 18 valines. Therefore, the 2D 1H-
13C HSQC spectrum of ILV 13C-methyl labeled SipDΔ38 was expected to show 114 NMR 
peaks (12 Ile + 2x33 Leu + 2x18 Val).  
To serve as an anchor point for assignment of Leu/Val methyl resonances in the 
2D 1H-13C HSQC SipDΔ38 spectrum, 12 Ile-to-Leu point mutations of SipDΔ38 were 
created. Point mutants were constructed using site-directed mutagenesis and confirmed 
with DNA sequencing. Each SipDΔ38 Ile-to-Leu point mutant was expressed and purified. 
A representative example of the purification of perdeuterated SipDΔ38 is shown in Fig. 2-
3. Two-dimensional 1H-13C HSQC NMR datasets were acquired for each SipDΔ38 point 
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mutant. In those experiments, one Ile methyl peak was expected to disappear from the Ile 
methyl region of the HSQC spectrum (the average chemical shift of ile δ1 carbon is 13.5 
ppm and δ1 proton is 0.67 ppm)18, hence its corresponding assignment. Four examples of 
the Ile-to-Leu mutagenesis assignment strategy can be seen in Fig. 2-4. In this manner the 






Fig. 2-2 – Position of ILV Residues on SipDΔ38 
The position of Ile (red), Leu (green) and Val (magenta) residues on SipDΔ38 is shown. 
ILVs cover most of the protein, except for an extended region of helix α8. PDB ID for 










Fig. 2-3 – SDS-PAGE Gel of SipDΔ38 Purification 
Nickel column affinity purification of perdeuterated 15N/ILV 13C-methyl labeled SipDΔ38 
is shown. (A) An SDS-PAGE gel of the Ni2+ column purification before cleavage with 
TEV protease. Lane 3 contains His-GB1- SipDΔ38 (42.3 kDa). (B) An SDS-PAGE gel of 
the Ni2+ column purification after cleavage with TEV protease. Lane 6 and 7 contain 














Fig. 2-4 – Examples of SipDΔ38 Assignment Strategy Using Ile-to-Leu Point Mutants 
The 2D 1H-13C HSQC spectra of four different SipDΔ38 Ile-to-Leu point mutants allowed 
for unambiguous assignment of I46 δ1, I170 δ1, I208 δ1 and I268 δ1. In all cases, there 
was a clear example of peak disappearance, allowing for Ile methyl assignment (indicated 








2.3.2. SipDΔ38 Leu and Val Methyl Assignments by 3D NMR 
The 2D 1H-13C HSQC spectra of 15N/ILV 13C-methyl labeled SipDΔ38 showed 114 
of 114 predicted methyl resonances. Eventually, 100% assignment of ILV methyl 
resonances of SipDΔ38 was achieved through the combination of site-directed 
mutagenesis (Fig. 2-4), through-space 1H-1H nuclear Overhauser effects (NOEs) 
observed using a 3D HMQC-NOESY dataset of perdeuterated 15N/ILV 13C-methyl 
labeled SipDΔ38 and distance information provided from the crystal structure of SipDΔ38. 
In a typical assignment strategy, the strip for an assigned Ile methyl (by site-directed 
mutagenesis) would be analyzed in NMRView (an example with Ile 208 Cδ is shown in 
Fig. 2-5). Next, the strip for each corresponding Leu/Val NOE that the Ile observed 
would be identified. If that Leu/Val residue had an NOE with the Ile, it should also have 
a back NOE with the Ile (blue line at the top of Fig. 2-5A goes through all residues, 
showing each residue has an NOE with Ile 208). Next, the crystal structure of SipDΔ38 
would be utilized to measure the distance of the closest residues (< 10Å) to the specific 
Ile (shown in Fig. 2-5B). The distance to the Ile residue should correlate with the strength 
of the NOE observed. This method allowed for an assignment of a large number of 
Leu/Val residues. After that, the remaining Leu/Val residues were assigned using a 
similar method using confident Leu/Val assignments as the reference. The final 
stereospecific assignment of each SipDΔ38 ILV methyl resonance is found in Fig. 2-6. 
These assignments were later largely confirmed in Chapter 3 when comparing 
overlapping ILV methyl resonances with SipDΔ132, which lacked residues 39-131 (Fig. 3-
4). The ILV methyl resonances assigned to the 39-131 region did not show up in the 







Fig. 2-5 – Representative Example of SipDΔ38 Leu/Val Assignment From 3D Data 
(A) Strips taken from 3D 13C-1H-13C HMQC-NOESY-HMQC NMR experiment of 
SipDΔ38. Red asterisks indicate the diagonal peak of each residue. Peaks not marked with 
an asterisk are NOE cross peaks. Blue line is shown to indicate residues that have an 
NOE with other residues of the same spin system. (B) Distance information from the 
crystal structure of SipDΔ38 was utilized (Ile in red, Leu in blue and Val in pink). An 
expanded view of the region shown as strips in A is shown with distance measurements 
that correlated to the strength of NOEs with Ile 208 (Ile δ1 in red, Val γ2 in light pink, 




Fig. 2-6 – Complete Assignment of ILV Methyl Resonances of SipDΔ38 
The 2D 1H-13C HSQC spectrum of SipDΔ38 with stereospecific resonance assignments of 
ILV side-chain methyl residues (δ1 for Ile, δ1 or δ2 or Leu and γ1 and γ2 for Val). An 







Here, the ILV 13C-methyl NMR peaks of SipDΔ38 were assigned. Assignment of 
ILV 13C-methyl resonances allow for completely new sets of NMR experiments to be 
performed that could complement typical 15N labeling. The favorable relaxation 
properties of ILV methyls should allow for interaction studies where amide peaks would 
be broadened out. Indeed, later chapters of this dissertation will show that SipDΔ38 ILV 
methyl assignments aided in elucidating interactions between SipDΔ38 with the needle 
(Chapter 4), the translocon (Chapter 7) and small molecules (Chapter 10).  
Importantly, 100% of ILV methyls of SipDΔ38 could be assigned (Fig. 2-6). 
However, there were two resonances in the Leu/Val ppm range of the 2D 1H-13C HSQC 
SipDΔ38 spectrum that could not be assigned because they did not have an NOE with any 
other resonance (data not shown). It is likely that that each Leu/Val resonance should at 
least see an NOE with its stereo partner. Furthermore, because all ILV residues were 
accounted for in the assignment, these peaks are likely experimental noise or 
experimental artifacts.  
In conclusion, a strategy utilizing isoleucine to leucine point mutation, 3D 
HMQC-NOESY-HMQC experiments and distance measurements with the SipDΔ38 
crystal structure was a successful method for the assignment of ILV methyl resonances. 
 
2.5. Accession Codes 
NMR assignment of SipDΔ38 ILV 13C-methyl resonances have been deposited into the 

































































Chapter 3. NMR Characterization of SipDΔ132 
3.1. Introduction  
The N-terminal α-helical domain of the Salmonella tip protein SipD resembles the 
α-helical hairpin structure of the needle protein PrgI1. Furthermore, the N-terminal α-
helical domain of SipD has been shown to function as a self-chaperone and is 
hypothesized to become displaced by PrgI during interaction at the distal end of the 
needle2. For these reasons, a construct of SipD that lacked the N-terminal domain, 
residues 39-131, was subcloned (herein called SipDΔ132). SipDΔ132 crystallized, but failed 
to form co-crystals with PrgI (data not shown). Because backbone and side-chain amide3 
and ILV methyl resonances (Fig. 2-6) of SipDΔ38 were previously assigned, SipDΔ132 was 
characterized by NMR spectroscopy for use in protein titration experiments to test 
whether SipDΔ132 would bind tighter to PrgI than SipDΔ38. It was hypothesized that 
because SipD contains distinct protein domains, the overall chemical environment of 
most residues would not change significantly following deletion of its N-terminal 
domain. If this were the case, comparison the 2D 1H-15N TROSY and 2D 1H-13C HSQC 
spectra of SipDΔ38 should allow for the assignment of SipDΔ132. Here, SipDΔ132 is 
compared to SipDΔ38 by circular dichroism (CD) and solution NMR spectroscopy. Amide 
and ILV methyl assignments are successfully transferred from SipDΔ38 to SipDΔ132. 
 
3.2. Materials and Methods  
3.2.1. Expression and Purification of SipDΔ132 
SipDΔ38 was purified as mentioned in Chapter 2. Salmonella Typhimurium strain 
SL1344 T3SS SPI-1 tip protein SipD 133-343 C244S (SipDΔ132) was subcloned into a 
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modified pET-21a expression vector containing an N-terminal His6 tag followed by a 
TEV protease cleavage site and GB1 as a solubility tag. Isotopically labeled 15N/ILV 13C-
methyl SipDΔ132 was expressed and purified in E. coli BL21(DE3) DNAY cells as 
described for SipDΔ38 in Chapter 2. Purified proteins were dialyzed into NMR buffer and 
concentrated using Amicon Ultra 3K (Millipore) filtration columns. Protein 
concentrations were measured by the absorbance at A280. 
 
3.2.2. Circular Dichroism of SipDΔ38 and SipDΔ132 
Far-UV CD experiments were acquired using a JASCO J-815 Spectropolarimeter. 
CD spectra of SipDΔ38 and SipDΔ132 were acquired using 0.05 mg/mL protein in 2 mL 
sterile water in a quartz cuvette. A water blank was acquired and subtracted from each 
CD spectra of SipD. To assess the protein secondary structure, CD spectra were acquired 
from 190 to 260 nm in triplicate at 20°C with a scan rate of 50 nm/minute. To assess 
protein stability and folding, thermal denaturation experiments were performed by 
measuring ellipticity at 222 nm over a temperature range of 20°C to 90°C with a ramp 
rate of 2°C/minute. The experimental CD values of ellipticity (mdeg) were converted to 
molar ellipticity (θ = deg cm2/dmol). The melting temperature (Tm) was calculated using 
JASCO J-815 software. 
 
3.2.3. 1H-15N TROSY of SipDΔ38 and SipDΔ132 and Transfer of Assignments 
NMR data was collected using a Bruker Avance 800 MHz spectrometer equipped 
with a cryogenic triple resonance probe and were processed using NMRPipe4 and 
analyzed using NMRView5. For 2D 1H-15N TROSY experiments, data was acquired on 
0.3 mM 15N/ILV 13C-methyl labeled SipDΔ38 or SipDΔ132 in NMR buffer (20 mM NaCl, 
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10 mM sodium phosphate, pH 7.4 and 10% D2O) at 30°C. The Bruker pulse sequence 
trosyetf3gpsi was compared to the pulse sequence trosy3gpphsi19.2. After comparison, 
trosy3gpphsi19.2 was chosen as the primary 2D 1H-15N TROSY experiment because it 
was much more sensitive. Typical acquisition parameters were 16 scans with 2048 
complex points (1H) and 128 complex points (15N) with sweep width 10.01 ppm for 1H 
centered at 4.69 ppm and 17.9 ppm for 15N centered at 119 ppm. Backbone and side-
chain amide assignments were transferred from SipDΔ38 using assignment by Wang and 
co-workers3. 
 
3.2.4. 1H-13C HSQC of SipDΔ38 and SipDΔ132 and Transfer of Assignments 
For 2D 1H-13C HSQC experiments, data was acquired on 0.3 mM 15N/ILV 13C-
methyl labeled SipDΔ38 or SipDΔ132 dissolved in NMR buffer at 30°C. Acquisition 
parameters were 8 scans with 1024 complex points (1H) and 256 complex points (13C) 
with sweep width 10.01 ppm for 1H centered at 4.69 ppm and 20 ppm for 13C centered at 
19 ppm. Ile-to-leu point mutants of SipDΔ132 were created by site-directed mutagenesis 
using a QuikChange kit (Stratagene) and confirmed by DNA sequencing. SipDΔ132 
mutants were expressed and purified as described in section 3.2.2 and NMR data was 
acquired as described in section 3.2.3. Leu/Val 13C-methyl carbon assignments were 
transferred from the ILV methyl assignments of SipDΔ38 as described in Chapter 2. 
 
3.3. Results 
3.3.1. Circular Dichroism of SipDΔ38 and SipDΔ132 
CD was used to determine whether SipDΔ38 and SipDΔ132 contained similar 
secondary structure characteristics. Typical of α-helical proteins, both SipD constructs 
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showed minima at 208 nm and 222 nm (Fig. 3-1A). The θ222/208 ratio was 0.96 for 
SipDΔ38 and 0.97 for SipDΔ132. Both SipD constructs contained θ222/208 ratios close to 1, 
which indicates the presence of a coiled-coil6, as expected from the crystal structure of 
SipD7; 8. In addition, the two SipD constructs showed slightly different thermal 
denaturation profiles. SipDΔ38 contained two melting temperatures (Tm) at 61°C and 
75°C, while SipDΔ132 contained a single Tm at 75°C (Fig. 3-1B). The absence of the 61°C 
Tm in the SipDΔ132 melting curve likely corresponds to the removal of the N-terminal α-
helical domain. Together, the CD experiments suggested that SipDΔ38 and SipDΔ132 
contain similar secondary structure characteristics and that the removal of the N-terminal 
domain did not drastically alter the overall folding of SipD.   
 
3.3.2. 1H-15N TROSY of SipDΔ38 and SipDΔ132 and Transfer of Assignments 
Previous 2D 1H-15N TROSY experiments required long acquisition times for low 
protein concentration (>8 hrs for 0.3 mM protein). Therefore, the previously used 
TROSY pulse sequence (trosyetf3gpsi) was compared to a potentially more sensitive 
TROSY pulse sequence (trosy3gpphsi19.2). Both experiments were acquired on 0.3 mM 
SipDΔ38 and took 3 hours. Better signal resolution was achieved with the pulse sequence 
trosy3gpphsi19.2 when the same experimental parameters were used (Fig. 3-2A). A 
likely explanation is that the trosyf3gpphsi19.2 pulse sequence contains WATERGATE 







Fig. 3-1 – Circular Dichroism of SipDΔ38 and SipDΔ132 
(A) Far-UV CD spectra from 190 nm to 260 nm of SipDΔ38 (black) and SipDΔ132 (red). 
Peak minima at 208 nm and 222 nm are typical of α-helical proteins. (B) Terminal 
denaturation profile monitoring the ellipticity at 222 nm of SipDΔ38 (black) and SipDΔ132 
(red) from 20°C to 90°C. SipDΔ38 shows two Tms at 61°C and 75°C, while SipDΔ132 




Fig. 3-2 – Testing Trosyetf3gpsi vs. Trosy3gpphsi19.2 with SipDΔ38 
Comparison of 2D 1H-15N TROSY spectra of 0.3 mM SipDΔ38 using two different Bruker 
pulse sequences under the same experimental conditions. (A) trosyf3gpphsi19.2 is more 
sensitive and NMR peaks are more well-resolved than the data acquired using (B) the 








Fig. 3-3 – Comparison of Trosyf3gpphsi19.2 and Trosyetf3gpsi Bruker Pulse 
Programs 
Cartoon representation of the pulse sequences of (A) trosyf3gpphsi19.2 and (B) 
trosyetf3gpsi. Figure adapted from the Pulse Program Catalogue for TOPSPIN v1.3. 






Two-dimensional 1H-15N TROSY datasets were acquired on 15N labeled SipDΔ38 
and SipDΔ132. In support of my initial hypothesis that deletion of the N-terminal residues 
of SipD (residues 38-131) would not greatly alter its overall structure, many NMR peaks 
overlapped between the two spectra (Fig. 3-4). Because the chemical shift values of most 
residues were similar between the constructs, the backbone and side-chain amide 
assignments from SipDΔ38 could be unambiguously transferred to SipDΔ132 (Fig. 3-5). In 
fact, transfer of assignments allowed for coverage of 82% of backbone and side-chain 
amide resonances of SipDΔ132. In comparison, 93% of amide resonances of SipDΔ38 were 
previously assigned by Wang and co-workers3.  
 
3.3.3. 1H-13C HSQC of SipDΔ38 and SipDΔ132 and Transfer of Assignments 
In a similar method used for the assignment of ILV methyls of SipDΔ38 in Chapter 
2, Ile-to-Leu point mutants of SipDΔ132 were created. Four examples of isoleucine 
assignment using Ile-to-Leu mutants are shown in Fig. 3-6. These experiments allowed 
for unambiguous methyl assignment for the 7 isoluecine methyls present in SipDΔ132. 
Two-dimensional 1H-15N HSQC datasets were acquired on ILV 13C-methyl labeled 
SipDΔ38 and SipDΔ132. As with the amide resonances (Fig. 3-4), many ILV 13C-methyl 
NMR peaks had similar chemical shift values, confirming the hypothesis that removal of 
the N-terminal domain of SipD did not greatly alter the structure of SipD (Fig. 3-7). 
Because of peak overlap, the ILV methyl assignments from SipDΔ38 could be transferred 
to SipDΔ132 (Fig. 3-8). Transfer of assignments allowed for coverage of 76% of ILV 
methyl resonances of SipDΔ132. In comparison, 100% of ILV methyl resonances of 








Fig. 3-4– Comparison of the Amide Resonances of SipDΔ38 and SipDΔ132 
Overlay of the 2D 1H-15N TROSY spectra of SipDΔ38 (black) and SipDΔ132 (red). Many 
NMR peaks show the similar chemical shift values. In other cases, peaks disappeared. 
These disappearing peaks primarily belong to assignments of SipD residues from 39 to 
131. In some cases, new peaks appeared. These new peaks are likely due to a major 
change in chemical shift values for residues along the SipD coiled-coil surface that was 








Fig. 3-5 – Backbone and Side-Chain Amide Assignments of SipDΔ132 
(A) 2D 1H-15N TROSY spectrum of SipDΔ132 with amide assignments transferred from 
SipDΔ38. Because of peak overlap with SipDΔ38, 82% of amide resonances in SipDΔ132 
could be assigned. Each peak is labeled with its corresponding SipD residue number with 
tryptophan side-chains denoted as ‘sc’. (B) An expanded view of the central region with 









Fig. 3-6 – Ile-to-Leu Point Mutation Allows for Assignment of SipDΔ132 Ile Methyls 
The 2D 1H-13C HSQC spectra of four isoleucine-to-leucine point mutants of SipDΔ132. In 
each case, one Ile methyl peak clearly disappears, allowing for unambiguous assignment. 











Fig. 3-7 – Comparison of ILV Methyl Resonances of SipDΔ38 and SipDΔ132 
Overlay of two 2D 1H-13C HSQC spectra of SipDΔ38 (black) and SipDΔ132 (red). Many 
ILV methyl peaks have chemical shift values that are similar. In other cases, peaks 
disappeared. These disappearing peaks primarily belong to assignments of SipD residues 
from 39 to 131. In some cases, new peaks appeared. These new peaks are likely due to a 
major change in chemical shift values for residues along the SipD coiled-coil surface that 







Fig. 3-8 – ILV Methyl Assignments of SipDΔ132 
The 2D 1H-13C HSQC spectrum of SipDΔ132 with corresponding ILV 13C-methyl 
assignments. Because of the majority of peaks contained similar chemical values with 
ILV methyl resonances of SipDΔ38, 76% of ILV methyl resonances in SipDΔ132 could be 
assigned. Each peak is labeled with its corresponding SipD stereospecific residue number 
(δ1 for Ile, δ1 and δ2 for Leu, γ1 and γ2 for Val).  
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3.4. Discussion  
Here, a SipD construct lacking its N-terminal α-helical hairpin domain (SipDΔ132) 
was compared to a construct containing its N-terminal domain (SipDΔ38). I hypothesized 
that the removal of the N-terminal of SipDΔ38 would not greatly alter the overall structure 
of SipD. If this were indeed the case, assignment transfer of NMR peaks from SipDΔ38 to 
SipDΔ132 should be possible because the overall chemical environment and chemical shift 
values of the SipD NMR peaks would be similar. CD experiments showed that SipDΔ38 
and SipDΔ132 contained similar secondary structure with similar θ222/208 ratios (Fig. 3-1A). 
Thermal denaturation experiments showed that SipDΔ38 contained two melting 
temperatures at 61°C and 75°C, while SipDΔ132 contained a single melting temperature at 
75°C (Fig. 3-1B). The absence of the 61°C Tm in the SipDΔ132 thermal denaturation 
profile is likely due to the removal of the N-terminal α-helical domain. Comparison of 
two 2D 1H-15N TROSY pulse sequences, trosyf3gpphsi19.2 and trosyetf3gpsi, showed 
that trosyf3gpphsi19.2 is a much more sensitive pulse sequence for TROSY data 
acquisition with SipD (Fig. 3-2). This trosyf3gpphsi19.2 pulse sequence reduced data 
acquisition times three-fold and resulted in NMR peaks with much less line broadening 
than trosyetf3gpsi. Pulse sequence trosyetf3gpsi is a phase-sensitive ge-2D 1H-15N 
TROSY using echo-antiecho, while trosyf3gpphsi19.2 is a phase-sensitive ge-2D 1H-15N 
TROSY using WATERGATE and improved sensitivity by altering the Gz gradient (Fig. 
3-3). An overlay of the 2D 1H-15N TROSY (Fig. 3-4) and 2D 1H-13C HSQC (Fig. 3-7) 
spectra showed that the chemical environment of many SipD residues was not changed 
by the removal of the N-terminal domain. Some new peaks appeared that are likely the 
residues along the coiled-coil of SipD that were previously in contact with the N-terminal 
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α-helical domain. In the case of those residues, the removal of the N-terminal domain 
altered their chemical environment, corresponding in a large change in chemical shift. 
However, this was only a small proportion of SipD residues (<10%). In summary, the 
transfer of 82% of amide (Fig. 3-5) and 76% of ILV methyl (Fig. 3-8) resonances to 
SipDΔ132 from SipDΔ38 was achieved. Amide and ILV methyl assignments of SipDΔ132 

































Chapter 4. NMR Characterization of the Protein-Protein Interaction of 
the Tip SipD and Needle PrgI of Salmonella 
4.1. Introduction  
Based on the structure similarity between the α-helical hairpin structure of the 
Salmonella T3SS needle protein PrgI and the N-terminal α-helical domain of the tip 
protein SipD, it has been hypothesized that PrgI could displace the N-terminal domain of 
SipD upon assembly of the tip/needle complex1. To test whether removal of the N-
terminal domain (residues 39 to 131) of SipD affected its binding affinity with PrgI, 
solution NMR spectroscopy was used to examine the interaction between a soluble and 
functional PrgI V65A, V67A mutant2 (herein called PrgI*) and a SipD construct 
containing the N-terminal domain (SipDΔ38) or lacking the N-terminal domain (SipDΔ132). 
Previous NMR data was collecting using PrgICΔ5, a C-terminal deletion mutant that 
prevented self-oligomerization and allowed for concentration to mM amounts for NMR3. 
Unfortunately the PrgICΔ5 mutant is not functional in invasion assays. Therefore, PrgI* 
was used because it was a functional mutant in invasion assays and gave good quality 
NMR data2. Here, NMR spectroscopy is used to show that PrgI* interacts with SipDΔ132 
with greater affinity when compared to SipDΔ38.  
 
4.2. Materials and Methods  
4.2.1. Protein Expression and Purification 
Isotopically 15N/ILV 13C-methyl labeled SipDΔ38 and SipDΔ132 were expressed 
and purified as described in Chapter 2. Salmonella Typhimurium strain SL1344 T3SS 
SPI-1 needle protein PrgI*2 was subcloned into a modified pET-21a expression vector 
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containing an N-terminal His6 tag followed by a TEV protease cleavage site and GB1 as 
a solubility tag. Isotopically 15N/ILV 13C-methyl labeled PrgI* was expressed in E. coli 
BL21(DE3) DNAY cells in 1 liter of 1✕ M9 minimal media with 30 µg/mL kanamycin 
and 100 µg/mL carbenicillin at 37°C containing 1 g/L 15NH4Cl (Sigma-Aldrich, St. 
Louis, MO) and 2 g/L D-glucose. At an OD600 of 0.4, the growth medium was 
supplemented with 60 mg/L of 2-ketobutyric acid-4-13C-sodium salt hydrate (#571342 
Sigma) and 100 mg/L of 2-keto-3-(methyl-13C)-butyric-4-13C acid sodium salt (#571334 
Sigma). Recombinant protein expression was induced with 1 mM IPTG at an OD600
 
of 
0.6 and cell growth was continued overnight at 15°C.  
Bacterial cells were harvested by centrifugation at 4000 rpm for 10 mins, 
resuspended with binding buffer (500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole, pH 
8.0, 1 mM phenylmethanesulfonyl fluoride) at 4°C and sonicated while keeping lysate 
ice-cold. Cells were sonicated using a Branson Digital Sonifier for 5 minutes and 20 
seconds at amplitude 32% with 2 second on pulses and 6 second off pulses. The cell 
lysate was centrifuged for 10 minutes at 13,000 rpm. Next, 700 µL of 5% 
polyethyleneimine was added to the supernatant, which was centrifuged again to remove 
further cellular debris. The supernatant was loaded onto a 10 mL Ni2+-affinity 
chromatography column (Gold Biotechnology), the column was washed with 150 mL 
binding buffer (500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole, pH 8.0) and bound 
protein was eluted with 40 mL elution buffer (500 mM NaCl, 20 mM Tris-HCl, 250 mM 
imidazole, pH 8.0). The column elutions were incubated overnight at room temperature 
with 250 µL of 0.04 mM recombinant TEV protease in TEV protease buffer (50 mM 
Tris-HCl, pH 8.0, 0.5 mM EDTA, 1 mM DTT, 20 mM NaCl). The digest was then 
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purified by Ni2+-affinity chromatography using binding and elution buffer as mentioned 
above to separate protein from the affinity tag. All purified proteins were dialyzed into 
NMR buffer and concentrated using Amicon Ultra 3K (Millipore) filtration columns. 
Protein concentrations were determined by the absorbance at A280. 
 
4.2.2. 1H-15N TROSY of SipD and 1H-15N HSQC of PrgI* 
NMR data was collected using a Bruker Avance 800 MHz spectrometer equipped 
with a cryogenic triple resonance probe and were processed using NMRPipe4 and 
analyzed using NMRView5. Two-dimensional 1H-15N TROSY spectra were acquired at 
30°C using 0.2 mM of 15N/ILV 13C-methyl labeled SipDΔ38 or SipDΔ132 in NMR buffer 
(50 mM NaCl, 10 mM sodium phosphate, pH 7.4 and 10% D2O). For PrgI*, 2D 1H-15N 
HSQC spectra were acquired at 30°C using 0.2 mM of 15N/ILV 13C-methyl labeled PrgI* 
in NMR buffer. Typical acquisition parameters were 16 scans with 2048 complex points 
(1H) and 128 complex points (15N) with sweep width 10.01 ppm for 1H centered at 4.69 
ppm and 17.9 ppm for 15N centered at 119 ppm.  
 
4.2.3. 1H-13C HSQC of SipD and PrgI* 
Two-dimensional 1H-13C HSQC spectra were acquired at 30°C using 0.2 mM 
15N/ILV 13C-methyl labeled SipDΔ38, SipDΔ132 or PrgI* in NMR buffer. Acquisition 
parameters were 8 scans with 1024 complex points (1H) and 256 complex points (13C) 




4.2.4. NMR Titrations Between PrgI* and SipDΔ38 or SipDΔ132  
For NMR titration experiments, 0.2 mM of 15N/ILV 13C-methyl labeled SipDΔ38 
was titrated with unlabeled PrgI* at a 1:4 mole ratio. In addition, 0.2 mM 15N/ILV 13C-
methyl labeled SipDΔ132 was titrated with unlabeled PrgI* at increasing SipD:PrgI mole 
ratios, up to 1:4. SipD:PrgI* ratios above 1:4 were not used because PrgI* began to 
polymerize above 1 mM. Similarly, 0.2 mM of 15N/ILV 13C-methyl labeled PrgI* was 
titrated with unlabeled SipDΔ132 at increasing PrgI:SipD molar ratios, up to 1:4.  
Amide and ILV methyl assignments of SipDΔ38 and SipDΔ132 used were described 
in Chapter 2 and Chapter 3. Assignment of the amide peaks of PrgI* were transferred 
from the previous assignment of the PrgI* 2D 1H-15N HSQC spectrum by Poyraz and co-
workers2. Peak intensity analysis of the SipD:PrgI* 1:2 mole ratio over the mole 1:0 ratio 
was performed. Affected residues were mapped onto the crystal structure of SipD (PDB 
ID 3NZZ) or PrgI (PDB ID 2KV7).  
 
4.3. Results  
4.3.1. Titration of SipDΔ38 and SipDΔ132 with PrgI* 
NMR titration experiments were performed to test the hypothesis that PrgI* 
would interact with greater affinity to a SipD construct lacking an N-terminal domain 
(SipDΔ132) than a SipD construct containing an N-terminal domain (SipDΔ38). Isotopically 
15N/ILV 13C-methyl labeled SipDΔ38 was titrated with unlabeled PrgI* and the titration 
was monitored by acquiring 2D 1H-15N TROSY and 2D 1H-13C HSQC datasets. Titration 
of SipDΔ38 with PrgI* at a SipDΔ38:PrgI* mole ratio of 1:4 showed little or no change in 
SipD NMR peak position or peak intensity, suggesting a lack of interaction between 
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PrgI* with amides of SipDΔ38 (Fig. 4-1). Similarly, a lack of interaction was observed 
between SipDΔ38 and PrgI* in 2D 1H-13C HSQC experiments (Fig. 4-2), suggesting PrgI* 
also did not affect ILV methyl peaks of SipDΔ38. Together, these experiments showed a 
lack of interaction between SipDΔ38 and PrgI* as monitored by solution NMR.  
In contrast, when 15N/ILV 13C-methyl labeled SipDΔ132 truncated construct was 
titrated with increasing concentrations of PrgI*, chemical shift perturbations of specific 
SipDΔ132 amide peaks were observed in a concentration dependent manner (Fig. 4-3A). 
Peak changes were primarily due to decreased peak intensity due to broadening, such as 
D190, E228 and S331 (Fig. 4-3B), indicating the interaction was in the intermediate 
exchange NMR time-scale6. Similarly, the interaction between SipDΔ132 and PrgI* in ILV 
titrations was observed (Fig. 4-4A), showing PrgI* also affected the ILV methyl peaks of 
SipDΔ132 (Fig. 4-4B). Interestingly, new peaks appeared in the 2D 1H-13C HSQC spectra 
of SipDΔ132 upon titration with PrgI* (Fig. 4-4A & Fig. 4-5, arrows). An attempt was 
made to assign the new SipD peaks using ZZ-exchange experiments, but was 
unsuccessful. Peak intensity analysis of the 15N titration of SipDΔ132 and PrgI* at a 1:2 
mole ratio showed a cluster of affected residues, including W135, D147 and V323, at the 
bottom of the SipDΔ132 coiled-coil (Fig. 4-6A). However, some residues were also 
affected at the distal end of SipDΔ132, such as D269 (Fig. 4-6A). Similarly, peak intensity 
analysis of the ILV titration of SipDΔ132:PrgI* showed a cluster of affected residues, 
including I145, L326 and L334, at the bottom of the SipDΔ132 coiled-coil, but some 
residues were also affected at the distal end of SipDΔ132 (Fig. 4-6B). Together, NMR 
titrations showed that, unlike SipDΔ38, SipDΔ132 interacted with PrgI* and a cluster of 




Fig. 4-1 – 15N Titration of SipDΔ38 with PrgI*  
(A) Overlay of two 2D 1H-15N TROSY spectra of 15N/ILV 13C-methyl labeled SipDΔ38 
without PrgI* (1:0, black) or in the presence of PrgI* (1:4, magenta). No significant 
changes in peak chemical shift position or peak intensity were observed. (B) An 




Fig. 4-2 – ILV Titration of SipDΔ38 with PrgI*  
(A) Overlay of two 2D 1H-13C HSQC spectra of 15N/ILV 13C-methyl labeled SipDΔ38 
without PrgI* (1:0, black) or in the presence of PrgI* (1:4, magenta). No changes in peak 
chemical shift position or peak intensity were observed. (B) An expanded view of four 







Fig. 4-3 – 15N Titration of SipDΔ132 with PrgI*  
(A) Overlay of four 2D 1H-15N TROSY spectra of 15N/ILV 13C-methyl labeled SipDΔ132 
titrated with PrgI* at increasing SipDΔ132:PrgI* mole ratios (black 1:0; blue 1:0.5; green 
1:2; magenta 1:4). Changes in peak intensity were observed, indicating interaction 
between the two proteins. (B) An expanded view of eight selected SipD amide peaks 






Fig. 4-4 –ILV Titration of SipDΔ132 with PrgI*  
(A) Overlay of four 2D 1H-13C HSQC spectra of 15N/ILV 13C-methyl SipDΔ132 titrated 
with PrgI* at increasing SipDΔ132:PrgI* mole ratios (black 1:0; blue 1:0.5; green 1:2; 
magenta 1:4). Changes in peak intensity were observed, indicating interaction between 
the two proteins. New peaks observed upon titration with PrgI* are indicated with 













Fig. 4-5 – New Peaks from ILV Titration of SipDΔ132 with PrgI*  
An expanded region taken from the 2D 1H-13C HSQC spectrum in Fig. 4-4 showing the 
appearance of new SipDΔ132 ILV methyl peaks upon titration with PrgI*. SipDΔ132:PrgI* 











Fig. 4-6 – Peak Intensity Analysis of 15N and ILV Titrations of SipDΔ132 with PrgI*  
(A) Peak intensity analysis of the 15N titration of SipDΔ132 with PrgI* at a mole ratio of 
1:2 compared to 1:0. (B) Peak intensity analysis of the ILV titration of SipDΔ132 with 
PrgI* at a mole ratio of 1:2 compared to 1:0. In (A) and (B) affected residues are mapped 








4.3.2. Titration of PrgI* with SipDΔ132 
To identify which PrgI* residues were affected upon titration with SipDΔ132, 
15N/ILV 13C-methyl labeled PrgI* was titrated with unlabeled SipDΔ132 and monitored by 
acquiring 2D 1H-15N HSQC and 2D 1H-13C HSQC datasets. Titration of 15N/ILV PrgI* 
with increasing concentrations of SipDΔ132 up to a PrgI*: SipDΔ132 mole ratio of 1:4 
resulted in chemical shift perturbations of specific PrgI* amide peaks in a concentration 
dependent manner (Fig. 4-7A). Peak changes were a combination of decreased peak 
intensities due to broadening, as well as changes in chemical shift position (Fig. 4-7B), 
indicating that some residues were in intermediate exchange NMR time-scale, whereas 
other residues were in the fast exchange NMR time-scale6. Peak intensity analysis of the 
PrgI*: SipDΔ132 interaction at a 1:2 mole ratio showed a cluster of affected residues, 
including W5, L9, L76, Q24 and Y57, at the middle of the α-helical hairpin and near the 
N- and C-termini of the PrgI* (Fig. 4-7C). Chemical shift deviation analysis was not 
performed because only a few PrgI* peaks were in the fast exchange NMR time-scale 
and most of the residues that underwent fast exchange were also in intermediate 
exchange, such as S6 and the W5 side-chain (Fig. 4-7B). In addition, interaction between 
SipDΔ132 and PrgI* in 2D 1H-13C HSQC experiments was observed (Fig. 4-8), showing 
SipDΔ132 also affected ILV methyl resonances of PrgI*. Unfortunately, PrgI* ILV methyl 
titration analysis was not performed because its ILV methyl have not been assigned. 
Together, amide and ILV experiments confirmed an interaction between SipDΔ132 and 
PrgI* with cluster of affected residues at the middle of the α-helical hairpin and at the N- 












Fig. 4-7 – 15N Titration of PrgI* with SipDΔ132 
(A) Overlay of four 2D 1H-15N HSQC spectra of 15N/ILV 13C-methyl labeled PrgI* 
titrated with SipDΔ132 at increasing PrgI*:SipDΔ132 mole ratios (black 1:0; blue 1:0.5; 
green 1:2; magenta 1:4). Changes in peak intensity and chemical shift position were 
observed, indicating an interaction between the two proteins. (B) An expanded view of 
eight selected PrgI* amide peaks from the 15N titration is shown. (C) Peak intensity 
analysis of the PrgI*:SipDΔ132 interaction at a mole ratio of 1:2 compared to 1:0. Affected 









Fig. 4-8 – ILV Titration of PrgI* with SipDΔ132 
(A) Overlay of four 2D 1H-13C HSQC spectra of 15N/ILV 13C-methyl labeled PrgI* 
titrated with SipDΔ132 at increasing PrgI*:SipDΔ132 molar ratios (black 1:0; blue 1:0.5; 
green 1:2; magenta 1:4). Changes in peak intensity and chemical shift position were 
observed, indicating an interaction between the two proteins. An expanded view of two 
selected PrgI* residues, called peak A and peak B due to lack of assignments, is shown. 
ILV methyl resonances of PrgI* have not been assigned. Therefore, analysis of the 
interaction was not performed.  
 
	 102	
4.4. Discussion  
NMR titrations were performed to test the hypothesis that a SipD construct 
lacking its N-terminal domain (SipDΔ132) would interact with PrgI* with greater affinity 
than a SipD construct containing its N-terminal domain (SipDΔ38). Both amide and ILV 
titrations of 15N/ILV labeled SipDΔ38 with PrgI* showed a lack of interaction as observed 
by solution NMR (Fig. 4-1 & Fig. 4-2). In contrast, at the same molar ratio, an 
interaction was observed between 15N/ILV SipDΔ132 and PrgI* (Fig. 4-3 & Fig. 4-4). 
Analysis of the 15N and ILV methyl titrations of 15N/ILV SipDΔ132 with PrgI* at 1:2 
molar ratio showed a cluster of affected residues at the bottom of the SipD coiled-coil, 
suggesting a likely interaction site with PrgI* (Fig. 4-6A & Fig. 4-6B). Interestingly, a 
few SipDΔ132 residues at its distal region were also affected upon titration of PrgI* (Fig. 
4-6A and Fig. 4-6B). However, these could be due to a conformational change of 
SipDΔ132 upon binding by PrgI*. This explanation is plausible because residues at the 
distal end of SipDΔ38 were not affected upon titration with PrgI* in the presence of the 
SipD N-terminal domain (Fig. 4-1 & Fig. 4-2). Importantly, experiments monitoring 
amide and ILV peaks of SipD are in agreement. Together, these data support the 
hypothesis that the removal of the N-terminal α-helical hairpin of SipD allows for a 
stronger interaction with PrgI*.  
Likewise, NMR titrations were also performed between 15N/ILV PrgI* and 
SipDΔ132. Results of 15N titrations indicated that the affected PrgI* residues clustered at 
middle of the α-helical hairpin and at the N- and C-termini of PrgI*, suggesting a likely 
interaction site with SipDΔ132 (Fig. 4-7C). ILV titrations also show interaction between 
PrgI* and SipDΔ132 (Fig. 4-8). However, the ILV methyl peaks of PrgI* have not been 
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assigned so titration analysis was not performed. The 2D 1H-13C HSQC of PrgI* showed 
the expected 29 ILV methyl peaks (3 isoleucines, 8 leucines and 5 valines, with each 
isoleucine showing only one peak and each valine and leucine showing two peaks each). 
Therefore, in the future assignment of PrgI* ILV methyl resonances is possible because 
of the good quality NMR data. 
The interaction between PrgI* and SipDΔ132 as detected by solution NMR is weak 
(in the µM range) because NMR titration experiments showed residues in intermediate 
and/or fast exchange NMR time-scale. However, new peaks did appear in the ILV 
titrations of 15N/ILV SipDΔ132 with PrgI* (Fig. 4-5B, arrows), but not in the ILV 
titrations of 15N/ILV PrgI* with SipDΔ132 (Fig. 4-8). Interestingly, none of the original 
SipDΔ132 ILV methyl peaks disappeared (Fig. 4-4), as one might expect if the new peaks 
were due to a true slow exchange phenomenon. There was an attempt made to identify 
and assign the new SipDΔ132 peaks using NMR experiments (by EXSY/ZZ-exchange) to 
no avail. Although the assignment of the new peaks is unknown, it is possible that the 
new peaks are due to a conformational change in the ILV methyls of SipDΔ132 in the 
presence of PrgI*. Although the amide resonance of SipDΔ132 did not show any signs of 
huge conformational change upon titration with PrgI* (Fig. 4-3A), the ILV methyl 




























Chapter 5. Characterization of the SipD and PrgI Interaction by 
Fluorescence Spectroscopy 
 
[Some of the data in this chapter has been published with the following citation:	
Rathinavelan T, Lara-Tejero M, Lefebre M, Chatterjee S, McShan AC, Guo DC, Tang C, 
Galan JE, De Guzman RN. NMR Model of PrgI-SipD Interaction and Its Implications in 
the Needle-Tip Assembly of the Salmonella Type III Secretion System. J. Mol. Biol. 426, 
2958-2969, 2014] 
 
5.1. Introduction  
The NMR titration experiments outlined in Chapter 4 support the hypothesis that 
PrgI interacts more strongly with SipD in the absence of the N-terminal domain of SipD. 
In those studies, isotopically labeled SipDΔ38 (which contained N-terminal domain) or 
SipDΔ132 (which lacked the N-terminal domain) was titrated with PrgI*, a soluble and 
functional full-length PrgI V65A, V67A mutant1. Protein-protein interaction was clearly 
observed between PrgI* with SipDΔ132 (Fig. 4-3 & Fig. 4-4), but not between PrgI* and 
SipDΔ38 (Fig. 4-1 & Fig. 4-2). The SipD-PrgI interaction was also observed by NMR 
paramagnetic relaxation enhancement experiments between PrgICΔ5 and SipDΔ100, another 
construct of SipD lacking its N-terminal domain2. PrgICΔ5 is a PrgI truncation mutant of 
the last 5 residues of PrgI, which rendered the protein monomeric at sub-millimolar 
concentrations3. However, unlike PrgI*, the PrgICΔ5 mutant is not functional in biological 
invasion assays. The SipDΔ100 construct is an N-terminal domain mutant that contained a 
short helix and random coil (residues 101-131) at the bottom of the coiled-coil. To 
complement our NMR interaction studies, two protein binding assays were developed 
between PrgI* and SipDΔ100 utilizing fluorescence polarization (FP) or Förster resonance 
energy transfer (FRET). Fluorescence based protein binding assays were utilized because 
of the following: i) affinity measurements of SipD mutants to PrgI could be readily 
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tested, and ii) they could potentially be adapted for high throughput screens for inhibitors 
of the SipD/PrgI interaction4. In addition, an in vitro Salmonella invasion assay was used 
to evaluate the ability of SipD with mutations at the coiled-coil region to invade human 
intestinal epithelial Henle-407 cells. In support of our NMR data, which suggested the 
bottom of the SipD coiled-coil was the major interaction site for PrgI (Fig. 4-6), the 
fluorescence binding assays presented here were ultimately used to correlate a decrease in 
bacterial invasion due to SipD coiled-coil mutants with a decrease in SipD/PrgI binding 
affinity.  
 
5.2. Materials and Methods  
5.2.1. Site-Directed Mutagenesis, Protein Expression and Purification 
Fluorescent labeling was achieved by the attachment of maleimide-conjugated 
fluorophore to a cysteine residue in the proteins5. SipD contains a wild-type cysteine, 
C244S, but this cysteine was mutated for NMR studies to generate higher quality NMR 
data. Therefore, C244S was kept as a background SipD mutation in all studies so the 
same construct used for NMR and fluorescent binding assays. PrgI* does not contain a 
wild-type cysteine. Therefore, cysteine mutants were made using a QuikChange kit 
(Stratagene) and confirmed by DNA sequencing. Sites chosen for mutagenesis were non-
conserved residues that were surface exposed based on the known atomic structures of 
SipD6 and PrgI1. Constructs included SipDΔ38/SipDΔ100 K173C and PrgI* L31C. In 
addition, a total of 10 cysteine point mutants, as well as double or triple SipDΔ100 coiled-
coil mutants (along helix α4 or α8) were made for use in the fluorescence polarization 
studies using a QuikChange kit and confirmed by DNA sequencing. All mutant 
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constructs were expressed and purified in LB broth as previously described (Chapter 2 
and Chapter 3 for SipD and Chapter 4 for PrgI*).  
 
5.2.2. Fluorophore Conjugation of Proteins 
Maleimide conjugated fluorophore was used to label SipDΔ38 K173C, SipDΔ100 
K173C and PrgI* L31C at their respective cysteine residue. Before labeling, all proteins 
were dialyzed into 1✕ PBS, pH 7.4. A 10 fold excess of tris(2-carboxyethyl)phosphine 
(TCEP) to protein was used to reduce disulfide bonds for 30 minutes at 25°C. A 20 fold 
excess of dye to protein was resuspended in 1 mL of 1✕ PBS, pH 7.4 for Alexa Fluor 
488-C5-Maleimide or Alexa Fluor 647-C2-Maleimide (Invitrogen), which labeled PrgI* 
and SipD, respectively. Abbreviations for dyes used are AF488 (Alexa Fluor 488-C5-
Maleimide) and AF647 (Alexa Fluor 647-C2-Maleimide). Fluorophore was added drop 
wise to the reduced protein solution while mixing and allowed to react for 3 hours in the 
dark at 25°C. The unreacted dye was removed by dialysis in 1✕ PBS, pH 7.4 followed by 
passage through an Amicon Ultra 3K (Millipore) filtration column. The percent labeling 
efficiency was estimated by acquiring the UV-visible absorption spectra of fluorophore 
labeled protein between 400 and 800 nm. Beer’s Law was then used to determine the 
labeled protein concentration: A = εcl, where A is the absorption maxima, l is the path 
length and ε is the fluorophore extinction coefficient (ε = 265, 000 cm-1 M-1 for AF657; ε 
= 72, 000 cm-1 M-1 for AF488). The percent labeling efficiency was determined by 
calculating the ratio of the fluorophore labeled protein over the initial unlabeled protein 
concentration and multiplying by 100%. 
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5.2.3. Fluorescence Polarization (FP) 
FP provides a readout of the average angular displacement of a fluorophore 
during its excited lifetime. This displacement is dependent on the rate of rotational 
diffusion of the fluorophore labeled molecule4. Therefore, FP provides a measure of 
molecule volume change (or change in rotational diffusion rate) that occurs upon binding. 
FP experiments were performed by titrating 25 nM of AF488 labeled PrgI* L31C with 
increasing concentrations of unlabeled SipDΔ38 or SipDΔ100. The baseline signal of the 
fluorometer was removed by first using the buffer 1✕ PBS, pH 7.4 alone. The average of 
measured data points (n=5) was subtracted from a base polarization value of 25 nM 
PrgI*-AF488 without any unlabeled SipD added. The difference in millipolarization 
(ΔmP) was plotted against increasing concentrations of unlabeled SipD to obtain a 
binding curve. The FP binding curve was fitted with Origin (OriginLab, Northampton, 
MA). All FP data was collected using a Varian Cary Eclipse Fluorescence 
Spectrophotometer at 25°C.  
 
5.2.4. Förster Resonance Energy Transfer (FRET) 
FRET was used to determine distance specific information on the protein-protein 
interactions. Fluorescence emission spectra were examined for different combinations of 
fluorophore labeled proteins. Emission spectra (n = 3) were collected between 500 nm 
and 800 nm using an excitation wavelength of 480 nm, excitation and emission slit 
widths of 5 nm, and an integration time of 0.1 seconds. All data was collected on a 
Varian Cary Eclipse Fluorescence Spectrophotometer at 25°C.  
FRET efficiency was calculated from emission spectra as follows: 
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where E is the energy transfer efficiency, FDA is the donor fluorescence FRET in the 
presence of the acceptor, and FD is the donor fluorescence in the absence of the acceptor. 
Once the FRET efficiency is known, the distance between the FRET dye pairs, r, was 
calculated from the following formula:  
                          
where R0 is the Förster distance between two FRET pairs at which E = 50%. An 
R0 value of 56Å was used for the FRET pairs (AF488 donor with AF647 acceptor) in this 
study (Invitrogen). 
 
5.2.5. Salmonella Invasion Assay 
A Salmonella invasion assay was used to test whether SipD coiled-coil mutants 
influenced the ability of Salmonella to invade a cultured human epithelial cell line (Henle 
407 cells, ATCC #CCL6) following a method previously described6 and using wild-type 
or sipD knock-out Salmonella Typhimurium SL13446. Single, double, or triple point 
mutations were introduced by PCR in the plasmid pRK2-SipD6, which harbors full-length 
SipD. Mutations were confirmed by DNA sequencing. For the invasion assay, 100 ng of 
each pRK2-SipD mutant plasmid was introduced into 45 µL of electrocompetent sipD 
knock out Salmonella cells by electroporation at 1.7 kV for 6 seconds then plated onto 
LB-agar plates. A single bacterial colony was grown for 10 hours without aeration at 
37°C in 10 mL LB broth containing 25 µg/ml trimethoprim, 100 µg/mL carbenicillin and 
25 µg/mL chloramphenicol. The overnight culture was dilution 1:10 in LB media 
















Henle-407 cells were grown in the 24-well plates in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% (v/v) fetal bovine serum at 37°C and 5% CO2. A 1:4 dilution 
of a confluent 75 cm2 flask was used to see the 24-well plates. Prior to addition of 
bacteria, each well was washed with 500 µL DMEM. When the OD600 reached 0.4, 
bacterial cultures were added (~10 µL but the amount added was adjusted to correct for 
differences in the OD600 when multiple cultures were used) to the Henle-407 cells in 300 
µL DMEM and incubated at 37°C for 1 hour in 5% CO2. Wells were then washed three 
times with 500 µL DMEM containing 5% fetal bovine serum and 50 µg/mL Gentamicin 
then incubated for 1.5 hours at 37°C in 5% CO2 to kill any extracellular bacteria. Wells 
were then rinsed with 500 µL DMEM and cells were lysed with 200 µL 1% Triton X-100 
dissolved in 1✕ PBS, pH 7.4 for 10 minutes. Finally, 50 µL of a 1:1000 dilution of the 
cell lysate was spread onto LB agar plates without antibiotics and incubated overnight at 
37°C. Percent invasiveness was calculated by counting the number of colonies on each 
plate. The sipD- strain complemented with the wild-type SipD pRK2 plasmid taken as 
representing 100% invasiveness. Therefore, the percent invasion of all other mutations 
were relative the sipD+ strain. Errors bars representative of three replicate experiments 
are shown. 
 
5.3. Results  
5.3.1. Fluorophore Conjugation to PrgI* and SipDΔ38/SipDΔ100 
Cysteine point mutations were generated by PCR for the attachment of 
maleimide-conjugated fluorophore. These included SipDΔ38 K173C, SipDΔ100 K173C and 
PrgI* L31C. Circular dichroism experiments confirmed that the cysteine point mutant 
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proteins contained similar secondary structure characteristics to their non-cysteine 
containing parent protein (data not shown). PrgI* L31C was labeled with AF488 and 
SipDΔ38/SipDΔ100 K173C were labeled with AF647. AF488 and AF647 were chosen as 
the FRET dye pair because their R0 value of 56Å is in the range that we hypothesized the 
distance between K173C of SipD and L31C of PrgI to be based on our NMR data 
showing that PrgI interacts at the bottom of the SipD coiled-coil. UV-visible absorption 
spectra show that proteins were labeled with their respective fluorophore (Fig. 5-1). 
Protein fluorophore labeling efficiency was estimated to be 70% for PrgI* L31C-AF488 
and 80% for SipDΔ38/SipDΔ100 K173C-AF647. Circular dichroism experiments showed 
that the conjugation of fluorophore to PrgI* and SipD did not greatly change their 
secondary structure characteristics (Fig. 5-2).  
 
5.3.2. Fluorescence Polarization of PrgI* and SipDΔ38/SipDΔ100 
Fluorescence polarization was used as a protein binding assay between PrgI and 
SipD mutant constructs. Titration of 25 nM PrgI* L31C-AF488 with increasing 
concentrations of unlabeled SipDΔ38 resulted in slight changes in polarization, but the 
binding curve was not close to saturation so it could not be fitted to determine a 
dissociation constant (Fig. 5-3). In contrast, titration of PrgI* L31C-AF488 with 
unlabeled SipDΔ100 resulted in larger changes in polarization and the dissociation constant 
between PrgI* and SipDΔ100 was determined to be 108 ± 11 µM (Fig. 5-3). Together, 
these data agree with the conclusion of the NMR experiments in Chapter 4 that the 
removal of the N-terminal domain of SipD allows for a tighter interaction with PrgI* and 
that the interaction is in the µM range.  
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The effect of point mutations along the SipDΔ100 coiled-coil were tested for 
interaction against PrgI*. The dissociation constant for a few of the mutants was within 
five-fold of the original value (S148E was 189 ± 21 µM, V157K was 334 ± 162 µM and 
S313 was 420 ± 294 µM) indicating small changes protein binding affinity (Fig. 5-3). 
The dissociation constant could not be measured for some mutants, such as D320R and 
V323K, because binding curves did not reach saturation, indicating weak interaction 
(Fig. 5-3). Because protein-protein interactions often occur across large surface areas, the 
effect of double or triple mutations in the SipDΔ100 coiled-coil on the interaction with 
PrgI* were additionally tested. All double and triple mutants of SipDΔ100 had small 
changes in fluorescence polarization, indicating weak interaction with PrgI* (Fig. 5-3). 
Importantly, circular dichroism showed that all SipDΔ100 mutants contained similar 
secondary structure characteristics to SipDΔ100, for example θ222/208 ratios near 1, 
indicating that the changes in protein binding were not the result of major changes in 
SipDΔ100 structure (Fig. 5-5).  
 
5.3.3. FRET of PrgI* and SipDΔ38/SipDΔ100 
FRET was used to assay the interaction between PrgI* L31C-AF488 (donor) and 
SipDΔ38 or SipDΔ100 K173C-AF647 (acceptor). In agreement with the results of NMR and 
FP experiments, FRET was observed between PrgI* and SipDΔ100, but not between PrgI* 
and SipDΔ38 (Fig. 5-4). FRET efficiency was used to estimate that the distance between 
PrgI* L31C-AF488 and SipDΔ100 K173C-AF647 was 44Å. In comparison, the distance 
between K173, which is at the top of the SipD coiled-coil, and D320, which is at the 
bottom of the SipD coiled-coil, in the SipD structure6 was 40Å. Therefore, FRET 
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distance measurements are in agreement with the hypothesis that PrgI* interacts with the 
bottom of the coiled-coil surface of SipD.  
 
5.3.4. Salmonella Invasion Assay 
The ability of a Salmonella Typhimurium strain containing single, double or triple 
mutations in the SipD coiled-coiled region to invade human intestinal epithelial cells 
(Henle-407) was tested. Deletion of SipD (sipD-) eliminated the ability of Salmonella to 
invade Henle-407 cells (Fig. 5-6). However, invasion could be rescued by 
complementing Salmonella with a plasmid containing wild-type SipD (sipD+) (Fig. 5-6). 
Salmonella containing SipD S148E resulted in 100% invasion (Fig. 5-6). In contrast, 
Salmonella containing other SipD single mutations, such as V157K, S313E, D320R and 
V323K, had partially decreased invasiveness (Fig. 5-6). Salmonella containing double or 
triple SipD mutants were completely non-invasive (Fig. 5-6). Importantly, these SipD 
mutants were properly folded in circular dichroism studies (Fig. 5-5), indicating that the 
observed decrease in invasion was not due to gross structural changes in SipD brought 
upon by the mutations. Together, these data suggests that SipD coiled-coil mutants 





Fig. 5-1 – UV-Vis Absorption Spectra of Fluorophore Labeled PrgI* and SipDΔ38 
UV-visible absorption spectra of (A) AF488 labeled PrgI* L31C and (B) AF647 labeled 
SipDΔ38 K173C. The maxima of the spectra are labeled and correlate with the expected 
adsorption maxima of their respective fluorophore. 
 
 
Fig. 5-2 – Circular Dichroism of Fluorophore Labeled PrgI* and SipDΔ38 
Far-UV CD spectra of fluorophore labeled (A) SipDΔ38 K173C and (B) PrgI* L31C are 
shown. Both proteins show CD minima at 208 and 222, which is typical of highly α-
helical proteins. CD shows the secondary structure characteristics of fluorophore labeled 
protein (dotted line) are similar to non-fluorophore labeled protein (solid line). Similar 







Fig. 5-3 – Fluorescence Polarization of PrgI*-AF488 and SipDΔ38/SipDΔ100 
FP of 25 nM PrgI* L31C-AF488 with increasing concentrations of unlabeled SipDΔ38 or 
SipDΔ100 (including single, double or triple coiled-coiled SipD mutants) is shown. The 
change in millipolarization is plotted vs. the concentration of SipD added. Each data 
point contains error bars for its replicates (n=5). (A) SipDΔ38 weakly interacted with 
PrgI* (could not determine a Kd), while the PrgI*/SipDΔ100 Kd was determine to be 108 
µM. Single mutations either had a small affect on the Kd of the PrgI-SipD interaction 
(S148E or V157K or S313E) or moderately affected the interaction (D320R or V323K) 
(B) All of the double or triple SipDΔ100 coiled-coiled mutants drastically reduced its 
ability to bind PrgI*. (C) The location of the residues used in FP experiments mapped 
onto the structure of SipDΔ100 as a reference. (D) The crystal structure of SipDΔ38 for 









Fig. 5-4 – FRET of PrgI*-AF488 and SipDΔ38/SipDΔ100-AF647 
(A) FRET performed with PrgI* L31C-AF488 (donor) and SipDΔ100 K173C-AF647 
(acceptor). A clear FRET signal is observed. (B) FRET performed with PrgI* L31C-
AF488 (donor) and SipDΔ38 K173C-AF647 (acceptor). No significant FRET signal was 










Fig. 5-5– Circular Dichroism of SipDΔ100 Mutants 
Far-UV CD spectra of SipDΔ100 coiled-coil mutants used for FP and invasion assay 
experiments are shown. All proteins show CD minima at 208 and 222, which is typical of 
highly α-helical proteins. The θ222/208 ratio for each protein is shown in the bottom right 
handle corner of each spectrum. For comparison, the θ222/208 ratio for SipDΔ100 was 0.96, 
so all the SipDΔ100 coiled-coil mutants contained similar secondary structure 
characteristics, indicating the mutations did not drastically alter the structure of SipDΔ100. 







Fig. 5-6 – Salmonella Invasion Assay of SipD Coiled-Coil Mutants 
Invasion assay between Salmonella Typhimurium strain SL1344 and intestinal epithelial 
Henle-407 cells is shown. Invasion is relative to the knock out Salmonella strain 
complemented with a SipD plasmid (sipD+). The Salmonella sipD- mutant was 
completely non-invasive. Adding back wild-type SipD (sipD+) to the sipD- Salmonella 
strain complemented invasion, but below wild-type (WT) levels. All SipD1-343 coiled-coil 
mutations (except S148E) reduced invasion. Triple SipD Salmonella mutants were 
completely non-invasive. Data in collaboration with Dr. Srirupa Chatterjee.  
 
 
5.4. Discussion  
In Chapter 4, results of solution NMR experiments showed that removal of the N-
terminal domain of SipD (residues 39-131) allowed for tighter binding to PrgI*. Here, 
results of both FP (Fig. 5-3) and FRET (Fig. 5-4) experiments are in agreement with 
solution NMR experiments. Results of FP experiments indicated a dissociation constant 
of 108 ± 11 µM between PrgI* and SipDΔ100, but the interaction between PrgI* and 
SipDΔ38 was much weaker and did not produce a saturated binding curve (Fig. 5-3). 



























































SipDΔ38 (Fig. 5-4). The distance between PrgI* L31 and SipDΔ100 K173 was estimated by 
FRET to be 44Å (Fig. 5-4). Importantly, this is the approximate distance from the top to 
the bottom of the SipD coiled-coil (K173 to D320 is 40Å). Together, NMR, FP and 
FRET data are in agreement that PrgI* interacts more strongly with a SipD lacking its N-
terminal domain and PrgI* interacts at the bottom of the coiled-coil of SipD.  
To correlate the FP and FRET results with a biological assay, invasion assays 
were performed between intestinal epithelial Henle-407 cells and a Salmonella 
Typhimurum sipD- knockout strain complemented with a plasmid containing single, 
double or triple mutations in the SipD. Point mutants, except for S148E, decreased 
invasion, but double and triple mutants completely knocked out the ability of Salmonella 
to invade Henle-407 cells (Fig. 5-6). Importantly, the decrease in invasion results 
correlated well with decreased protein binding affinity between PrgI* and SipD measured 
by FP (Fig. 5-3). For example, the SipD S148 mutant that had a wild-type level of 
invasion (Fig. 5-6) also had a dissociation constant most similar to the PrgI* and 
SipDΔ100 interaction (Fig. 5-3). In addition, the triple mutations that decreased invasion to 
below 1% (Fig 5-6) did not significantly change the polarization of PrgI* (Fig. 5-3). 
Together, invasion assay is in agreement with NMR, FP and FRET experiments, and 





























Chapter 6. CD and NMR Characterization of SipB N-Terminal 
Ectodomain Constructs 
6.1. Introduction  
The atomic structure of full-length SipB, the major translocon protein from 
Salmonella Typhimurium, is currently unknown. Expression and purification of full-
length SipB results in low yields, requires co-expression and subsequent separation from 
its cognate chaperone SicA1, and incorporation into membrane or membrane-like 
environments for stability and proper folding. The N-terminal domain of SipB, which has 
been modeled as an ectodomain upon host membrane insertion2, is known to interact with 
the tip protein SipD3; 4. To determine the interaction surface of the tip-translocon protein-
protein interaction, soluble constructs of the SipB N-terminal ectodomain were designed. 
One N-terminal SipB construct containing residues 82 to 240 (herein called SipB82-240) 
has previously been characterized5. Notably, SipB82-240 contained a similar region to the 
crystal structure of SipB from 82 to 2266. However, a recent report by Dickenson and co-
workers3 suggested that the extreme N-terminal residues IpaB, the SipB homolog in 
Shigella, from 11 to 27 were essential for the interaction with the Shigella tip protein 
IpaD. To test the role of the extreme N-terminal residues of SipB, two additional SipB 
constructs were designed that included the residues 11 to 81. These two constructs were 
SipB11-232 and SipB11-312. The residues from 232 to 312 were included in the latter 
construct because they are predicted to form an α-helix that could potentially increase the 
surface area of SipB for SipD to interact with. Here, the expression, purification and 
characterization of SipB82-240, SipB11-232 and SipB11-312 are described.   
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6.2. Materials and Methods  
6.2.1. Protein Expression and Purification 
Salmonella Typhimurium strain SL1344 SPI-1 major translocon protein SipB11-232 
or SipB11-312 were subcloned using NdeI/XhoI restriction sites into a pET-22b plasmid 
that contained a C-terminal His tag. The forward primer had the sequence 5’ 
AGTTCGCATATGAGCGGATATACCCAA 3’. The reverse primers had the sequence 
5’ GTCGCTCTCGAGTCCCTGGAATTTGGT 3’ (for SipB11-232) and 5’ 
GTCGCTCTCGAGGCGGTTCGTTTCCTC 3’ (for SipB11-312). Subcloning was 
confirmed by DNA sequencing. SipB82-240 was previously subcloned into a pET-22b 
plasmid using a similar protocol. Isotopically 15N/ILV 13C-methyl labeled SipB11-232, 
SipB11-312 or SipB82-240 were expressed in E. coli BL21(DE3) DNAY cells in 1 liter of 1✕ 
M9 minimal media with 30 µg/mL kanamycin and 100 µg/mL carbenicillin at 37°C. 
Cultures additionally contained 1 g/L 15N4CL (Sigma-Aldrich, St. Louis, MO) and 2 g/L 
D-glucose. At an OD600 of 0.4 the growth medium was supplemented with 60 mg/L of 2-
ketobutyric acid-4-13C-sodium salt hydrate (Sigma #571342) and 100 mg/L of 2-keto-3-
(methyl-13C)-butyric-4-13C acid sodium salt (Sigma #571334). Recombinant protein 
expression was induced with 1 mM IPTG at an OD600
 
of 0.8 and cell growth was 
continued overnight at 15°C. 
 Bacterial cells were harvested by centrifugation at 4000 rpm for 10 minutes, 
resuspended with binding buffer (500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole, pH 
8.0, 1 mM phenylmethanesulfonyl fluoride) at 4°C and sonicated while keeping the 
lysate ice-cold. Cells were sonicated using a Branson Digital Sonifier for 5 minutes and 
20 seconds at amplitude 32% with 2 second on pulses and 6 second off pulses. The cell 
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lysate was centrifuged for 10 minutes at 13000 rpm. Next, 700 µL of 5% 
polyethyleneimine was added to the supernatant, which was centrifuged again to remove 
further cellular debris. The supernatant was loaded on a 5 mL Ni2+-affinity 
chromatography column (Gold Biotechnology) and the column was washed with 150 mL 
binding buffer (500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole, pH 8.0) and bound 
protein was eluted using 40 mL elution buffer (500 mM NaCl, 20 mM Tris-HCl, 250 mM 
imidazole, pH 8.0). Fractions containing the target protein were dialyzed into NMR 
buffer (50 mM NaCl, 20 mM sodium phosphate, pH 7.4) and concentrated using Amicon 
Ultra 3K (Millipore) filtration columns. Protein concentrations were determined by 
absorbance at A280. 
 
6.2.2. Size Exclusion Chromatography (SEC) 
To determine the oligomeric state of SipB constructs, size exclusion 
chromatography was performing utilizing a Superdex 75 SEC column with a column 
height of 51 cm and a bed volume of 300 mL (GE Healthcare). The SEC column was 
equilibrated with 300 mL of filtered and de-gassed SEC buffer (150 mM NaCl, 0.5 mM 
DTT, 10 mM Tris-HCl, pH 8.0). Next, 2 mL of 0.4 mM SipB11-232 or SipB11-312 was 
loaded onto the SEC column. Typical parameters used for SEC runs were 1 mL/min flow 
rate and 0.3 MPa pressure while acquiring 6 mL elution fractions. The SEC column was 
calibrated using protein standards of known molecular weights, including Blue Dextran 
(200 kDa), Albumin (66 kDa), Carbonic Anhydrase (29 kDa), Cytochrome C (12.4 kDa) 
and Aprotinin (6.5 kDa). To calculate the partition coefficient (Kav) values for the protein 
standards, the equation Kav = Ve – V0 / Vc – V0 was used, where Ve = elution volume, V0 
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= void volume, Vc = column volume, and Kav = partition coefficient. The logarithm of the 
molecular weight (y-axis) vs Kav (x-axis) for each protein standard was then plotted to 
obtain the standard curve, y = -0.4207x + 2.118, where y = Kav and x = log molecular 
weight in Daltons. The Kav obtained from the SEC run for each SipB construct was then 
used to estimate its molecular weight (or oligomeric state) using the standard curve 
equation.  
 
6.2.3. Circular Dichroism (CD) 
Far-UV CD experiments were acquired using a JASCO J-815 Spectropolarimeter. 
The CD samples for SipB11-232 or SipB11-312 were prepared with 0.05 mg/mL protein in 2 
mL sterile water in a quartz cuvette. A water blank was acquired and subtracted from 
each protein spectra. CD spectra were acquired from 190 to 260 nm in triplicate at 20°C 
with a scan rate of 50 nm/minute. Thermal denaturation experiments were performed by 
measuring ellipticity at 222 nm over a temperature range of 20°C to 80°C with a ramp 
rate of 2°C/minute. The experimental CD values of ellipticity (mdeg) were converted to 
molar ellipticity (θ = deg cm2/dmol). The melting temperature (Tm) was calculated using 
JASCO J-815 software. 
 
6.2.4. NMR Spectroscopy   
All NMR data was collected using a Bruker Avance 800 MHz spectrometer 
equipped with a cryogenic triple resonance probe and were processed using NMRPipe7 
and analyzed using NMRView8. Two-dimensional 1H-15N TROSY spectra were acquired 
at 30°C using 0.3 mM of 15N/ILV 13C-methyl labeled SipB11-232 or SipB11-312 in NMR 
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buffer (50 mM NaCl, 20 mM sodium phosphate, pH 7.4) containing 10% D2O. Typical 
acquisition parameters were 128 scans with 2048 complex points (1H) and 128 complex 
points (15N) with sweep width 10.01 ppm for 1H centered at 4.69 ppm and 17.9 ppm for 
15N centered at 119 ppm. Two-dimensional 1H-13C HSQC spectra were acquired at 30°C 
using 0.3 mM of 15N/ILV 13C-methyl labeled SipB11-232 or SipB11-312 in NMR buffer 
containing 10% (v/v) D2O. Typical acquisition parameters were 16 scans with 1024 
complex points (1H) and 256 complex points (13C) with sweep width 10.01 ppm for 1H 
centered at 4.69 ppm and 20 ppm for 13C centered at 19 ppm.  
 
6.3. Results  
6.3.1. Purification of SipB11-232, SipB11-312 and SipB82-240 
The crystal structure6 of the SipB N-terminal domain contained residues 82 to 226 
(Fig. 6-1) and is similar to a previously SipB construct, SipB82-240, that was characterized 
by solution NMR5. Based on the observation that the extreme N-terminal residues (11 to 
27) of IpaB, the SipB homolog from Shigella, were reported to be important for the 
interaction with the tip IpaD3, two constructs of SipB containing the extreme N-terminal 
residues were subcloned and tested for expression. The IpaB residues 11 to 27 are 
homologous to SipB residues 13 to 34 based on primary protein sequence alignment. 
Therefore, both SipB11-232 and SipB11-312 contained the N-terminal residues reported to be 
essential for the interaction with the tip protein3. SipB11-232 and SipB11-312, as well as 
SipB82-240, expressed in high amounts and were easily purified by affinity 
chromatography (Fig. 6-1B). The molecular weights were 25.2 kDa for SipB11-232, 34.2 
kDa for SipB11-312 and 18 kDa for SipB82-240. Therefore, the SipB constructs that were 
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purified showed the correct molecular weights by SDS-PAGE (Fig. 6-1B). Interestingly, 
some SipB11-312 protein came out in the flow through, which was possibly due to the 
saturation of the binding capacity of the nickel column (Fig. 6-1B, lane 5). The protein 
gel results for the purification for SipB11-232 and SipB11-312 showed single band purity 
compared to the purification for SipB82-240 (Fig. 6-1B). However, dialysis of SipB82-240 
led to removal of most residual host cell impurities5.  
 
6.3.2. SEC of SipB11-232 and SipB11-312 
Following purification, proteins were concentrated to sub-millimolar 
concentrations and loaded onto a size exclusion chromatography (SEC) column to 
determine the oligomeric state of SipB11-232 and SipB11-312. Passage of proteins through an 
SEC column showed two major elution peaks for SipB11-232 (Fig. 6-2A) and one peak for 
SipB11-312 (Fig. 6-2B). The SipB11-232 peaks were estimated to be populations of trimers 
and dimers (Fig. 6-2A) based on a standard curve constructed using proteins of known 
molecular weights, whereas the SipB11-312 peak was estimated to be a trimer (Fig. 6-2B). 
An SDS-PAGE gel of the SEC column elutions showed oligomeric populations could 
revert to monomeric species in the presence of SDS detergent (Fig. 6-2). In comparison, 
SEC of SipB82-240 also showed two major elution peaks, one that was estimated to be a 
trimer and one that was estimated to be a larger oligomeric population5. Together, this 
data suggests SipB N-terminal domain constructs have a tendency to oligomerize in 




6.3.3. CD of SipB11-232 and SipB11-312 
Circular dichroism was used to determine the secondary structure characteristics 
of SipB11-232 and SipB11-312. The far-UV CD spectra of SipB11-232 and SipB11-312 
overlapped and showed minima at 208 and 222 nm, which are characteristics of highly α-
helical proteins (Fig. 6-3A). SipB11-232 and SipB11-312 showed θ222/208 ratios of 1.03 and 
1.04, respectively, indicative of coiled-coil containing proteins9. Terminal denaturation 
curves of SipB11-232 and SipB11-312 were also similar and both proteins contained a single 
thermal melt (Fig. 6-3B). The thermal melt was calculated as 59.3°C for SipB11-232 and 
57.5°C for SipB11-312. In comparison, SipB82-240 had a θ222/208 ratio of 1.14 and a thermal 
melt of 59.8°C5.  Together, these data suggest that the inclusion of the extreme N-
terminal residues (11 to 81) did not result in gross structural changes of the N-terminal 
ectodomain of SipB.   
 
6.3.4. NMR Spectroscopy of SipB11-232, SipB11-312 and SipB82-240 
My aim was to develop an optimal construct of SipB for NMR titration studies 
with SipB. To this end, NMR data were acquired on 15N/ILV 13C-methyl labeled SipB11-
232, SipB11-312 and SipB82-240 to determine which construct provided the best quality NMR 
spectra. The optimal temperature for the experiments were determined to be 30°C based 
on 1D 1H experiments. In two-dimensional 1H-15N TROSY experiments, amide peaks 
were observed for all three SipB constructs (Fig. 6-4). However, the highest resolution 
and largest 1H dispersion was achieved with SipB82-240 (Fig. 6-4C), whereas the lowest 
resolution and smallest 1H dispersion was observed with SipB11-312 (Fig. 6-4B). The 
number of amide peaks that were expected were ~230 for SipB11-232 and ~300 for SipB11-
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312. However, less than half of the expected peaks were observed with both constructs and 
furthermore many of the amide peaks observed were broad (Fig. 6-4A & Fig. 6-4B). In 
contrast, the 2D 1H-15N TROSY spectrum of SipB82-240 showed more than 50% of 
expected amide peaks and peaks were well resolved (Fig. 6-4C).  Two-dimensional 1H-
13C HSQC experiments are in agreement with TROSY experiments, showing that the 
most well resolved ILV methyl peaks were observed with SipB82-240 (Fig. 6-5C). 
Together, the results suggest SipB82-240 showed better quality NMR spectra compared to 






Fig. 6-1 – Purification of SipB N-Terminal Domain Constructs 
(A) The crystal structure of SipB82-226 (PDB ID 3TUL). Regions of unknown structure 
(11 to 81 and 226-312) are indicated with dotted red line. Residues 226-312 are predicted 
to form an α-helix. (B) SDS-PAGE gels showing purification of His-tagged SipB11-232 
(25.2 kDa), SipB11-312 (34.2 kDa) and SipB82-240 (18 kDa). L is the protein ladder. Lanes 
1, 5 and 9 are the flow through from loading the cell lysate after sonicated onto the Ni2+ 
column. Lanes 2, 6, 10 and 11 are from Ni2+ column after washes with binding buffer. 





Fig. 6-2 – SEC of SipB N-Terminal Domain Constructs 
(A) SEC elution profile of SipB11-232 shows two major peaks estimated to form trimers 
(75.6 kDa) and dimers (50.4 kDa). The SDS-PAGE gel of SEC column elutions shows 
SipB11-232 as a monomer (25.2 kDa). (B) SEC elution profile of SipB11-312 shows one 
major peak that was estimated to form trimers (102.6 kDa). The SDS-PAGE gel of SEC 
column elutions shows SipB11-312 as a monomer (34.2 kDa). (C) SEC elution protein of 






Fig. 6-3 – CD of SipB N-Terminal Domain Constructs 
(A) Far-UV CD spectrum of SipB11-232 (solid line) compared with SipB11-312 (dotted line). 
Both proteins show minima at 208 and 222 nm and θ222/208 ratios near 1, characteristic of 
α-helical and coiled-coil containing proteins. (B) Thermal denaturation experiments show 









Fig. 6-4 – 1H-15N TROSY of SipB N-Terminal Domain Constructs 
Two-dimensional 1H-15N TROSY spectra of (A) SipB11-232, (B) SipB11-312 (C) SipB82-240. 
The amide peaks of SipB82-240 are well dispersed (> 1 ppm for 1H), well-resolved and the 
spectrum contains more than 50% of expected amide peaks. In contrast, amide peaks of 
SipB11-232 and SipB11-312 are not as well dispersed (< 1 ppm for 1H), many are broad and 








Fig. 6-5 – 1H-13C HSQC of SipB N-Terminal Domain Constructs 
Two-dimensional 1H-13C HSQC spectra of (A) SipB11-232, (B) SipB11-312, (C) SipB82-240. 
SipB82-240 ILV methyl peaks are well dispersed (~ 1 ppm for 1H), well resolved and 
contains more than 70% of expected ILV methyl peaks. SipB11-232 and SipB11-312 are not 
as well dispersed (< 0.4 ppm for 1H), have broad peaks and contain less than 50% of 
expected ILV methyl peaks. Expected number of peaks is 52 for SipB82-240 (4 Ile, 18 Leu, 
6 Val), 71 for SipB11-232 (5 Ile, 23 Leu, 10 Val) and 93 for SipB11-312 (7 Ile, 30 Leu, 13 






Fig. 6-6 – Positions of ILV residues on SipB82-226 
 
Position of Ile (blue), Leu (green) and Val (magenta) residues on the crystal structure of 
the N-terminal domain of SipB82-226 (PDB ID 3TUL). The structure of the regions 11-81 
and 226-312 have not yet been solved, but contain additional ILV residues.  
 
 
6.4. Discussion  
SipB11-232 and SipB11-312 express in high yields, can be purified by Ni2+ affinity 
chromatography (Fig. 6-1) and are soluble up to sub-millimolar concentrations. Results 
from SEC experiments suggest that SipB11-232 exits in populations of dimers and trimers 
(Fig. 6-2A), whereas SipB11-312 exists in primarily populations of trimers (Fig. 6-2B). An 
SDS-PAGE gel of the SEC column elutions could reduce the oligomeric state of both 
constructs back to their monomeric form in the presence of detergent (Fig. 6-2). These 
data are in agreement with the observation of trimeric species of Shigella IpaB (SipB 
homolog) constructs10; 11. Circular dichroism experiments suggest both SipB11-232 and 
SipB11-312 contain α-helical characteristics with the presence of a coiled-coil because they 







thermal melts: 59.3°C for SipB11-232 and 57.5°C for SipB11-312 (Fig. 6-3B). Unfortunately, 
SipB11-232 and SipB11-312 are not optimal NMR constructs. Two-dimensional 1H-15N 
TROSY (Fig. 6-4) and 1H-13C HSQC (Fig. 6-5) experiments showed less peaks than 
would be expected for both amide and ILV methyl experiments. First, this could be due 
to populations of high-molecular weight oligomeric SipB in solution as observed by SEC 
experiments. Dimers or trimers of SipB would likely not be optimal for NMR 
experiments due to slower molecular tumbling resulting in relaxation. Second, broad 
NMR peaks might be observed because the residues 11-81 are disordered (as suggested 
by secondary structure prediction) and mask the NMR signal of the remaining structured 
regions. This is likely a contributing factor, because SipB82-240, which also forms 
oligomers in solution, has much better 1H signal dispersion and peak resolution in NMR 
experiments (Fig. 6-4C & Fig. 6-5C). Unfortunately, SipB82-240 spectra are still lacking 
many of the expected peaks (~30%), so assignment of amide or ILV methyl resonances 
of SipB82-240 would be challenging.  
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Chapter 7. Identification of the Binding Surfaces Involved in the 
Salmonella Tip-Translocon Protein-Protein Interaction 
[Some of the data in this chapter has been published with the following citation:	McShan 
AC, Kaur K, Chatterjee S, Knight KM, De Guzman RN. NMR Identification of the 
Binding Surfaces Involved in the Salmonella and Shigella Type III Secretion Tip-
Translocon Protein-Protein Interactions. Proteins. In press, 2016] 
 
7.1. Introduction  
How the Salmonella SPI-1 T3SS tip protein SipD and the translocon protein SipB 
interact is poorly understood. The N-terminal ectodomain of SipB has been suggested to 
interact with SipD due to homology with the Shigella IpaB/IpaD system, where N-
terminal domain of IpaB was shown to interact with IpaD by fluorescence spectroscopy1. 
Although the atomic structure of full-length SipB is unavailable, the crystal structure of a 
protease resistant core of the SipB N-terminal domain (residues 82-226) has been solved2. 
Dickenson and co-workers1 reported that residues 11-27 of the IpaB were essential for 
the interaction with the Shigella tip protein IpaD. IpaB residues 11-27 are homologous to 
SipB residues 13-34 based on primary protein sequence alignment. In Chapter 6 two 
constructs of the N-terminal ectodomain of SipB containing the extreme N-terminal 
residues were subcloned and characterized: SipB11-232 and SipB11-312. The residues 232-
312 were included in the latter construct because they are predicted to form an α-helix, 
which could potentially increase the surface area of SipB for SipD to interact with. 
Chapter 2 and Chapter 3 described the assignment of amide and ILV methyl resonances 
of SipDΔ38 and SipDΔ132. Here, NMR titration experiments were performed between 
isotopically 15N/ILV 13C-methyl labeled SipDΔ38 or SipDΔ132 with unlabeled SipB11-232 or 
SipB11-312. NMR results show the distal region of tip protein SipD is the surface that 
interacts with the N-terminal ectodomain of SipB.  
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7.2. Materials and Methods  
7.2.1. Protein Expression and Purification 
Isotopically 15N/ILV 13C-methyl labeled SipDΔ38 or SipDΔ132 were prepared as 
described in Chapter 2 and Chapter 3 in 1L of 1✕ M9 medium. Unlabeled SipB11-232 or 
SipB11-312 were prepared in E. coli BL21(DE3) DNAY cells in 1L of LB media 
containing 30 µg/mL kanamycin and 100 µg/mL carbenicillin at 37°C. Protein expression 
was induced with 1 mM IPTG at an OD600 of 0.8 and cell growth was continued 
overnight at 15°C. SipB11-232 and SipB11-312 constructs were purified as described in 
Chapter 6.  
 
7.2.2. 1H-15N TROSY of SipDΔ38 and SipDΔ132 
All NMR data was collected using a Bruker Avance 800 MHz spectrometer 
equipped with a cryogenic triple resonance probe and were processed using NMRPipe3 
and analyzed using NMRView4. Two-dimensional 1H-15N TROSY spectra were acquired 
at 30°C using 0.2 mM of 15N/ILV 13C-methyl labeled SipDΔ38 or SipDΔ132 in NMR buffer 
(50 mM NaCl, 10 mM sodium phosphate, pH 7.4 and 10% D2O). Typical acquisition 
parameters were 128 scans with 2048 complex points (1H) and 128 complex points (15N) 
with sweep width 10.01 ppm for 1H centered at 4.69 ppm and 17.9 ppm for 15N centered 
at 119 ppm.  
 
7.2.3. 1H-13C HSQC of SipDΔ38 and SipDΔ132 
Two-dimensional 1H-13C HSQC spectra were acquired at 30°C using 0.2 mM of 
15N/ILV 13C-methyl labeled SipDΔ38 or SipDΔ132 in NMR buffer. Typical acquisition 
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parameters were 16 scans with 1024 complex points (1H) and 256 complex points (13C) 
with sweep width 10.01 ppm for 1H centered at 4.69 ppm and 20 ppm for 13C centered at 
19 ppm.  
 
7.2.4. NMR Titrations and Data Analysis 
For NMR titration experiments, 0.2 mM of isotopically 15N/ILV 13C-methyl 
labeled SipDΔ38 or SipDΔ132 were titrated with unlabeled SipB11-232 or SipB11-312 at 
SipD:SipB mole ratios of 1:0, 1:0.5, 1:1 and 1:2. To determine whether temperature 
affected the new SipD peaks that appeared upon titration with SipB, 2D 1H-13C HSQC 
spectra of the SipDΔ38:SipB11-232 complex at a 1:2 mole ratio were acquired using the 
parameters outlined in section 7.2.2. with the temperatures 10°C, 20°C, 30°C and 40°C. 
Affected residues were mapped onto the crystal structure of SipD5 (PDB ID 3NZZ).  
 
7.3. Results  
7.3.1. Titration of 15N/ILV SipDΔ38 with SipB11-232  
NMR methods were used to identity the surfaces involved in the tip-translocon 
interaction by titrating the Salmonella SipB11-232 major translocon protein into 15N/ILV 
labeled SipDΔ38 tip protein and monitoring the titrations by acquiring 2D 1H-15N TROSY 
data sets. Results of NMR titrations showed a concentration dependent decrease in 
intensities of many SipDΔ38 amide peaks (Fig. 7-1A) indicating complex formation to be 
primarily in the intermediate exchange NMR time scale. In addition, some SipDΔ38 
residues, such as N211, K302 and G220 (Fig. 7-1A), showed chemical shift deviations 
with increasing concentrations of SipB11-232 indicating these residues were in the fast 
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exchange NMR time scale. Importantly, there were also many SipDΔ38 peaks, such as 
A99, G176, S270, that did not undergo signal broadening, even at a SipDΔ38:SipB11-232 
mole ratio of 1:2, indicating that complex formation did not result in protein aggregation, 
which would have broadened out all of the amide peaks of SipDΔ38. To identify the 
SipDΔ38 residues that were most perturbed by SipD11-232, the peak intensity ratio (I1:1/I1:0) 
was calculated for each non-overlapped SipDΔ38 peak at a SipDΔ38:SipB11-232 molar ratio 
of 1:1 (Fig. 7-1B). Residues with peak intensity ratios lower than the average minus one 
standard deviation were mapped onto the structure of SipD (Fig. 7-1C). SipDΔ38 residues 
that were most affected by SipB11-232 were primarily hydrophobic (L78, L116, A132, 
L150, G151, V156, L178, L240, L258 and L326) and some polar (S114, N211, K246, 
N316) residues. The affected residues clustered in the distal region of SipD (Fig. 7-1C), 
suggesting that this region of SipD is involved in the interaction with SipB. 
The simultaneous labeling of SipDΔ38 with 15N and ILV methyls allowed the 
titration with SipB11-232 to be monitored firstly by 2D 1H-15N TROSY data sets to query 
the effect of the interaction on the 15N amides of SipDΔ38, the results of which are shown 
above (Fig. 7-1), and secondly by 2D 1H-13C HSQC to query the effect of SipB11-232 on 
the ILV methyls of SipDΔ38. Like the results of the amide titrations (Fig. 7-1), most of the 
affected SipDΔ38 ILV methyl peaks showed decreased peak intensities with a few 
residues showing chemical shift deviations, such as I46 (Fig. 7-2A) and I129. To identity 
which SipDΔ38 ILV methyl peaks were perturbed upon complex formation with SipB11-232, 
the peak intensity ratio (I1:1/I1:0) was plotted as the difference from 1, which signified no 
change in peak intensity upon complex formation (Fig. 7-2B). In agreement with the 
results of amide titration (Fig. 7-1C), the affected ILV methyl residues clustered at the 
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distal region of SipDΔ38 (Fig. 7-2C). Importantly, there were residues that were affected 
in ILV methyl titrations that were also affected in 15N titrations, such as V156, L178 and 
L240 (Fig. 7-1B & Fig. 7-2B). 
Unlike the 15N titrations, the appearance of new slow-exchange ILV methyl peaks 
was observed in the 2D 1H-13C HSQC SipDΔ38 spectra upon titration with SipB11-232 (Fig. 
7-3B, arrows). These slow exchange peaks are most likely due to conformational change 
of methyl groups upon binding6. Slow exchange peaks are also indicative of tighter 
binding interaction in the nanomolar range. However, the measured affinity of the SipD-
SipB interaction is in the range of 30 to 60 µM (Fig. 8-3A, B). EXSY (or ZZ-exchange) 
NMR experiments7 were performed with a range of mixing times in an attempt to identity 
the new SipDΔ38 ILV methyl peaks, but were unsuccessful. Because exchange is a 
temperature dependent phenomenon, 2D 1H-13C HSQC data sets of the titration of ILV 
SipDΔ38 with SipB11-232 at a mole ratio of 1:2 were acquired at different temperatures to 
see if an increase in temperature would lead to signal broadening into the intermediate 
exchange range, leading to coalescence of signals6. Two-dimensional 1H-13C HSQC 
experiments were acquired at 10°C, 20°C, 30°C and 40°C (Fig. 7-4A). An increase 
temperature resulted in chemical shift deviations for most resonances, including both 
original SipDΔ38 ILV peaks (Fig. 7-4A) and the new ILV peaks (Fig. 7-4B). Based on 
these data, it is difficult to say whether the new SipDΔ38 ILV methyl peaks are truly due 








7-1 – 15N Titration of SipDΔ38 with SipB11-232 
(A) Overlay of four 2D 1H-15N TROSY spectra of 15N/ILV SipDΔ38 with increasing 
concentrations of unlabeled SipB11-232. (B) Plot of the peak intensity ratio of complex 
(I1:1) vs free (I1:0) for the SipDΔ38:SipB11-232 complex at is shown with the average peak 
intensity ratio (dash gray line) and one standard deviation from the average (1σ, dashed 
red line). (C) Residues (colored red) with peak intensity ratio (I1:1/I1:0) lower than 1σ 
were mapped onto the crystal structure of SipD [N-terminal hairpin is green, the coiled-








7-2 – ILV Titration of SipDΔ38 with SipB11-232 
(A) Overlay of four 2D 1H-13C HSQC spectra of 15N/ILV SipDΔ38 titrated with increasing 
concentrations of unlabeled SipB11-232. (B) Plot of peak intensities ratios subtracted from 
one (1 – I1:1/I1:0) of the SipDΔ38:SipB11-232 complex with the average value (dashed gray 
line) and one standard deviation from the average (1σ, dashed red line). (C) Residues 
(colored red) with (1 – I1:1/I1:0) value greater than 1σ were mapped onto the crystal 
structure of SipD [N-terminal hairpin is green, the coiled-coil is gray and the mixed α/β 












7-3 – New SipDΔ38 ILV Methyl Peaks Appear Upon Titration with SipB11-232 
Two-dimensional 1H-13C HSQC spectra of 15N/ILV labeled SipDΔ38 alone (A) or in the 
presence of SipB11-232 at a SipDΔ38:SipB11-232 molar ratio of 1:2 (B). New ILV methyl 















7-4 – Effect of Temperature on the 1H-13C HSQC of the SipDΔ38:SipB11-232 Complex 
(A) Four 2D 1H-13C HSQC spectra of 15N/ILV labeled SipDΔ38 titrated with SipB11-232 at 
a SipDΔ38:SipB11-232 mole ratio of 1:2 at various temperatures. New ILV peaks that 
appeared upon titration with SipB11-232 are indicated in boxes. (B) An expansion of four 
selected new ILV peaks taken from (A). Peak assignment is unknown so they are 





7.3.2. Titration of 15N/ILV SipDΔ38 with SipB11-312 
SipB11-312 was titrated into 15N/ILV SipDΔ38 to query the effect of SipB residues 
232-312, which are predicted to form an α-helix, on the tip-translocon interaction. 
Unfortunately, titration of 15N/ILV SipDΔ38 with SipB11-312 resulted in spectral collapse 
and signal broadening of most SipDΔ38 peaks in both 2D 1H-15N TROSY (Fig. 7-5A) and 
2D 1H-13C HSQC experiments (Fig. 7-5B). In the 2D 1H-15N TROSY experiments, many 
new amide peaks were observed between 124 to 132 ppm (15N axis) and 7.5 to 8.3 ppm 
(1H axis) (Fig. 7-5A). Spectral collapse first appeared during the first titration point at a 
SipDΔ38:SipB11-312 mole ratio of 1:0.5, but many more peaks were broadened out at the 
1:2 ratio (Fig. 7-5). Therefore, titration analysis was not plausible at any molar ratio. 
From these experiments alone it is unclear why the SipDΔ38 spectra collapsed upon 
titration with SipB11-312, though it is likely due to protein aggregation induced upon 
binding of oligomeric SipB. 
 
7.3.3. Titration of 15N/ILV SipDΔ132 with SipB11-232 and SipB11-312 
Residues in the distal region of SipD are affected upon titration with SipB11-232 
(Fig. 7-1C & Fig. 7-2C), while residues in the proximal region of SipD, the bottom of 
the coiled-coil, are important for the interaction with the needle protein PrgI8. Therefore, 
it was hypothesized that removal of the N-terminal α-helical domain of SipD (residues 
39-131) would not have a large effect on the tip-translocon interaction. To test the role of 
the N-terminal α-helical domain of SipD in the interaction of the tip and translocon, 
NMR titrations were performed between 15N/ILV SipDΔ132, which lacks the N-terminal 
domain, and unlabeled SipB11-232 or SipB11-312. NMR titrations between 15N/ILV SipDΔ132 
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with unlabeled SipB11-232 monitored by 2D 1H-15N TROSY showed a concentration 
dependent decrease in the peak intensity of specific SipDΔ132 amide peaks, such as L189, 
D190 and Y252 (Fig. 7-6A), indicating complex formation to be primarily in the 
intermediate exchange NMR time scale. In addition, some SipDΔ132 residues showed 
chemical shift deviations, such as G251 (Fig. 7-6A). Furthermore, unlike in the 15N 
titration of SipDΔ38 and SipB11-232 (Fig. 7-1A), new SipDΔ132 amide peaks were observed 
upon titration with SipB11-232 (Fig. 7-6A, arrows). Together, this data suggest the 
SipDΔ132 and SipB11-232 complex to contain a mix of slow, intermediate and fast exchange 
on an NMR time scale, with most residues in intermediate exchange. Importantly, there 
were also many peaks that did not undergo significant signal broadening up to a 
SipDΔ132:SipB11-232 molar ratio of 1:2, indicating that complex formation did not result in 
protein aggregation. Because there were only a few residues with significant chemical 
shift deviations, only intensity reduction was quantified. The peak intensity ratio (I1:1/I1:0) 
was calculated for each non-overlapping SipDΔ132 amide peak (Fig. 7-6B). Residues with 
peak intensity lower than the average intensity minus one standard deviation were 
mapped onto the structure of SipDΔ132 (Fig. 7-6C). SipDΔ132 residues that were affected 
were primarily hydrophobic (L190, L240, V254) or polar (D169, N196, Q233, Q266) 
residues (Fig. 7-6C). As with the results of 15N titration between SipDΔ38 and SipB11-232 
(Fig. 7-1C), the affected residues of SipDΔ132 upon titration with SipB11-232 clustered in 
the distal end (Fig. 7-6C). NMR titrations were additionally performed between 15N/ILV 
SipDΔ132 and unlabeled SipB11-312, which contained additional residues 232-312 that are 
predicted to form an α-helix, and monitored by 2D 1H-15N TROSY experiments. 
Interestingly, unlike the 15N titration of SipDΔ38 with SipB11-312, which resulted in spectral 
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collapse (Fig. 7-5A), titration of 15N/ILV SipDΔ132 with SipB11-312 resulted in a 
concentration dependent decrease in the peak intensity of specific SipDΔ132 amide 
resonances without spectral collapse (Fig. 7-7A). In agreement with 15N titrations 
between SipDΔ132 and SipB11-232 (Fig. 7-6A), most of the affected SipDΔ132 amides 
showed a decrease in peak intensity due to signal broadening (Fig. 7-7A). The peak 
intensity ratio (I1:1/I1:0) for each non-overlapping SipDΔ132 residue was calculated (Fig. 7-
7B) and affected residues were mapped onto the structure of SipDΔ132 (Fig. 7-7C). 
Residues that were affected were primarily hydrophobic (L178, A217, L240) or polar 
(N196, Q233, K286) residues (Fig. 7-7B). As with the other amide titrations (Fig. 7-1C 
& 7-6C), the affected residues clearly clustered in the distal end of SipDΔ132 (Fig. 7-7C). 
NMR titrations were additionally monitored by 2D 1H-13C HSQC experiments to 
query the effect of SipB11-232 or SipB11-312 on the ILV methyl resonances of SipDΔ132. 
Like the results of the amide titrations (Fig. 7-6 & Fig. 7-7), ILV titration of 15N/ILV 
SipDΔ132 with unlabeled SipB11-232 (Fig. 7-8A) or unlabeled SipB11-312 (Fig 7-9A) 
resulted in a concentration dependent decrease in the peak intensity of specific SipDΔ132 
ILV methyl peaks. As in the ILV titration of SipDΔ38 and SipB11-232 (Fig. 7-3B), the 
titration of SipDΔ132 with SipB11-232 (Fig. 7-8A, arrows) or SipB11-312 (Fig. 7-9A, 
arrows) resulted in the appearance of new ILV methyl peaks. In agreement with amide 
titrations, intensity ratio analysis showed that affected ILVs clustered at the distal end of 
SipDΔ132 (Fig. 7-8C & Fig. 7-9C). Together, ILV methyl and amide titrations are in 
agreement that the distal end of SipDΔ132 is the surface utilized for the tip-translocon 
interaction and that removal of the SipD N-terminal domain did not largely affect the 




7-5 – 15N/ILV Titration of SipDΔ38 with SipB11-312 
(A) 2D 1H-15N TROSY and (B) 2D 1H-13C HSQC of 15N/ILV labeled SipDΔ38 titrated 
with unlabeled SipB11-312 at 1:0, 1:0.5, 1:1 and 1:2 mole ratios. Spectral collapse and 





7-6 – 15N Titration of SipDΔ132 with SipB11-232 
(A) Overlay of four 1H-15N TROSY spectra of 15N/ILV labeled SipDΔ132 titrated with 
unlabeled SipB11-232 at molar ratios of 1:0, 1:0.5, 1:1 and 1:2. Four affected residues are 
expanded as representative interacting residues. (B) Plot showing the peak intensities 
ratios of the SipDΔ132: SipB11-232 titration at 1:1 over 1:0 mole ratio. (C) Affected residues 
(color red) are mapped onto the structure of SipDΔ132 [gray (coiled-coil) and orange 










7-7 – 15N Titration of SipDΔ132 with SipB11-312 
(A) Overlay of four 1H-15N TROSY spectra of 15N/ILV labeled SipDΔ132 titrated with 
unlabeled SipB11-312 at molar ratios of 1:0, 1:0.5, 1:1 and 1:2. New peaks are indicated 
with arrows. (B) Plot showing the peak intensities ratios of the SipDΔ132:SipB11-312 
titration at 1:1 over 1:0 mole ratio. (C) Residues that were affected (colored red) are 









7-8 – ILV Titration of SipDΔ132 with SipB11-232 
(A) Overlay of four 1H-13C HSQC experiments of 15N/1ILV SipDΔ132 titrated with 
unlabeled SipB11-232 at mole ratios of 1:0, 1:0.5, 1:1 and 1:2. New peaks are indicated 
with arrows. (B) Plot showing the peak intensities ratios of the SipDΔ132:SipB11-232 
titration at 1:1 over 1:0 mole ratio. (C) Residues that were affected (colored red) are 










7-9 – ILV Methyl Titration of 15N-13CH3-ILV SipDΔ132 and Unlabeled SipB11-312 
(A) Overlay of four 1H-13C HSQC experiments of 15N/ILV SipDΔ132 titrated with 
unlabeled SipB11-312 at mole ratios of 1:0, 1:0.5, 1:1 and 1:2. New peaks are indicated 
with arrows. (B) Plot showing the peak intensities ratios of the SipDΔ132:SipB11-312 
titration at 1:1 over 1:0 mole ratio. (C) Residues that were affected (colored red) are 






7.4. Discussion  
A comparison of the results from both amide and ILV methyl titrations of 15N/ILV 
SipDΔ38 or SipDΔ132 with unlabeled SipB11-232 or SipB11-312 suggest that the distal region 
of SipD, which includes the mixed α/β domain, is the primary interaction surface with the 
N-terminal ectodomain of SipB (Fig. 7-9). Although NMR experiments showed a wide 
range of chemical exchange, most SipD residues were in intermediate exchange upon 
titration with the N-terminal domain of SipB, suggesting a weak interaction in the µM 
range. New SipD peaks were observed in both amide (Fig. 7-6A & Fig 7-7A) and ILV 
methyl (Fig. 7-3B, Fig 7-8A & Fig 7-9A) titrations upon addition of SipB11-232 or SipB11-
312, though unfortunately whether these resonances were due to true slow exchange could 
not be determined because they could not be assigned. Removal of the N-terminal α-
helical domain (residues 39-132) of SipD had little affect on the ability of SipD amides 
(Fig. 7-1 & Fig. 7-6) or ILV methyls (Fig. 7-2 & Fig. 7-8) to interact with SipB11-232. 
Furthermore, both amide and ILV methyl titrations of SipDΔ38 and SipDΔ132 with SipB11-
232 resulted in a similar affected surface, the distal region of SipD (Fig. 7-9). The titration 
of SipDΔ132 with SipB11-312 is in agreement with those results as well (Fig. 7-9). However, 
the titration of SipDΔ38 and SipB11-312 could not be analyzed due to spectral collapse and 
extensive signal broadening (Fig. 7-5). Interestingly, removal of the N-terminal domain 
of SipD allowed for interaction between SipDΔ132 and SipB11-312 without special collapse 
(Fig. 7-7 & Fig. 7-9). Why the presence of the SipD N-terminal domain affected the 







7-10 – Comparison of results from 15N and ILV Titrations of SipD with SipB 
Comparison of the results from amide and ILV methyl titrations of SipDΔ38 or SipDΔ132 
with SipB11-232 or SipB11-312. Residues that were affected in each titration are mapped 
onto the atomic structure of SipD. In all cases, affected residues cluster at the distal 
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Chapter 8. Characterization of the Interaction Between SipD and the 
SipB N-Terminal Domain by Fluorescence Spectroscopy 
[Some of the data in this chapter has been published with the following citation: McShan 
AC, Kaur K, Chatterjee S, Knight KM, De Guzman RN. NMR Identification of the 
Binding Surfaces Involved in the Salmonella and Shigella Type III Secretion Tip-
Translocon Protein-Protein Interactions. Proteins. 2016]  
8.1. Introduction  
The NMR titrations performed in Chapter 7 showed that the N-terminal 
ectodomain of SipB interacted with the tip protein SipD by solution NMR. To 
complement our NMR interaction studies between SipD and SipB, two protein binding 
assays were developed to examine the interaction between SipB82-312 with SipDΔ38 (which 
contains the N-terminal α-helical domain) or SipDΔ100 (which lacks the N-terminal α-
helical domain). The assays I developed were based on fluorescence polarization (FP) 
and Förster resonance energy transfer (FRET). Fluorescence based protein binding assays 
were utilized because of the following advantages: i) affinity measurements of SipD 
mutants and SipB could be readily tested, and ii) they could potentially be adapted for 
high throughput screens for inhibitors of the SipD/SipB interaction1. In addition, an in 
vitro Salmonella invasion assay was used to evaluate the ability of mutations in the SipD 
mixed α/β domain to invade human intestinal epithelial Henle-407 cells. In support of our 
NMR studies, results of fluorescence-based assays show that SipD interacts with the N-
terminal domain of SipB and removal of the N-terminal α-helical domain of SipD does 
not largely affect the tip-translocon interaction.  
 
8.2. Materials and Methods  
8.2.1. Site-Directed Mutagenesis, Protein Expression and Purification 
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Proteins were labeled for fluorescence spectroscopy by the attachment of 
maleimide-conjugated fluorophore to a cysteine residue in the protein2. SipD contains a 
wild-type cysteine, C244S, but it was mutated for to obtain higher quality NMR data of 
SipDΔ38 so it was kept as a background mutation in all studies. SipB82-312 and PrgI* do 
not contain a wild-type cysteine. Therefore, a single cysteine mutation was introduced 
using a QuikChange kit (Stratagene) into SipB82-312 and PrgI* and confirmed by DNA 
sequencing. Sites chosen for mutagenesis were non-conserved residues that were surface 
exposed based on the atomic structures of SipD3, PrgI4 and SipB5. The point mutations 
used in this study included SipB82-312 A109C, SipB82-312 D207C, SipB82-312 N283C, 
SipB82-312 E303C, SipDΔ38 E230C, SipDΔ100 K173C and PrgI* L31C. All wild-type and 
mutant constructs were expressed and purified in LB media as previously described in 
Chapter 2 and Chapter 3 for SipD, Chapter 4 for PrgI* and Chapter 6 for SipB82-312. 
 
8.2.2. Fluorophore Conjugation of Proteins 
Maleimide conjugated fluorophore was used to label SipDΔ38 E230C, SipDΔ100 
K173C, PrgI* L31C and the SipB82-312 point mutants (A109C, D207C, N283C or E303C) 
at their respective cysteine residue. All proteins were dialyzed into 1✕ PBS, pH 7.4. A 10 
fold excess of tris(2-carboxyethyl)phosphine (TCEP) to protein was used to reduce 
disulfides for 30 minutes at 25°C. A 20 fold excess of dye to protein was resuspended in 
1 mL of 1✕ PBS, pH 7.4 for Alexa Fluor 488-C5-Maleimide, Fluorescein-C5-Maleimide 
or Alexa Fluor 647-C2-Maleimide (Invitrogen), which labeled PrgI*/SipD and SipB, 
respectively. Abbreviations for dyes used are AF488 (Alexa Fluor 488-C5-Maleimide), 
FM (Fluorescein-C5-Maleimide) and AF647 (Alexa Fluor 647-C2-Maleimide). 
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Fluorophore was added drop wise to the reduced protein solution while mixing and 
allowed to react for 3 hours in the dark at 25°C. The unreacted dye was removed by 
dialysis in 1✕ PBS, pH 7.4 followed by passage through an Amicon Ultra 3K (Millipore) 
filtration column. The labeling efficiency was estimated by acquiring UV-visible 
absorption spectra with a scan between 400 and 800 nm (Fig. 8-1). Beer’s Law was then 
used to determine labeled protein concentration: A = εcl, where A is the absorption 
maxima, l is the path length and ε is the fluorophore extinction coefficients (ε = 265, 000 
cm-1 M-1 for AF647; ε = 72, 000 cm-1 M-1 for AF488; ε = 83, 000 cm-1 M-1 for FM). The 
percent labeling efficiency was then determined by calculating the ratio of dye labeled 
protein over the initial unlabeled protein concentration and multiplying by 100%. 
 
8.2.3. Circular Dichroism (CD)  
CD was performed on proteins at 0.05 mg/mL in 2 mL of sterile H2O. 
Experimental parameters were the same as those described in Chapter 3.  
 
8.2.4. Fluorescence Polarization (FP) 
FP provides a readout of the average angular displacement of a fluorophore 
during its excited lifetime. This displacement is dependent on the rate of rotational 
diffusion of the fluorophore labeled molecule1. Therefore, FP provides a measure of 
change in the molecular volume/the rotational diffusion rate that occurs upon binding. FP 
experiments were performed by titrating 25 nM of AF647 labeled SipB82-312 (A109C, 
D207C, N283C or E303C) with increasing concentrations of unlabeled SipDΔ38 or 
SipDΔ100. FP experiments were also performed with 25 nM of AF488 labeled PrgI* L31C 
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titrated with increasing concentrations of unlabeled SipB82-312. In all FP experiments, the 
baseline signal of the fluorometer was obtained by using the buffer 1✕ PBS, pH 7.4 alone. 
The average of measured data points (n=5) was subtracted from a base polarization value 
of 25 nM SipB82-312 (A109C, D207C, N283C or E303C)-AF647 or 25 nM PrgI* L31C-
AF488. The difference in millipolarization (ΔmP) was plotted against increasing 
concentrations of binding protein partners to obtain a binding curve. The FP binding 
curve was fitted with Origin (OriginLab, Northampton, MA). All FP data was collected 
using a Varian Cary Eclipse Fluorescence Spectrophotometer at 25°C. 
 
8.2.5. Förster Resonance Energy Transfer (FRET) 
FRET was used to determine distance specific information on the protein-protein 
interactions. Fluorescence emission spectra were examined using different combinations 
of fluorophore labeled proteins. Emission spectra (n = 3) were collected between 500 nm 
and 800 nm using an excitation wavelength of 480 nm, excitation and emission slit 
widths of 5 nm, and an integration time of 0.1 seconds. All data was collected on a 
Varian Cary Eclipse Fluorescence Spectrophotometer at 25°C.  
FRET efficiency was calculated from emission spectra as follows: 
              
where E is the energy transfer efficiency, FDA is the donor fluorescence FRET in the 
presence of the acceptor, and FD is the donor fluorescence in the absence of the acceptor. 
The distance between the FRET dye pairs, r, was calculated from the following formula:  
















where R0 is the Förster distance between two FRET pairs at which E = 50%. An 
R0 value of ~56Å was used for the FRET pairs (FM or AF488 donor with AF647 
acceptor) in this study (Invitrogen). 
 
8.2.6. Salmonella Invasion Assay 
A Salmonella invasion assay was used to test whether mutations in the SipD 
mixed α/β domain affected the ability of Salmonella to invade a cultured human epithelial 
cell line (Henle 407 cells, ATCC #CCL6) following a method described in Chapter 5. 
Single, double, or triple point mutations in SipD were introduced by PCR in the plasmid 
pRK2-SipD, which harbors full-length SipD, and confirmed via DNA sequencing. The 
sipD- knock-out strain complemented with the wild-type SipD pRK2 plasmid was taken 
as 100% relative invasiveness. Therefore, the percent invasion of all other strains were 
relative the sipD+ strain. Error bars were obtained from with three replicate experiments. 
 
8.2.7. Western Immunoblot Analysis 
ΔSipD, +SipD and SipD mutant strains of Salmonella typhimurium were grown in 
15 mL of LB broth containing 0.3 M NaCl and 1 mM IPTG. Cell growth was continued 
at 37°C at 80 rpm until the OD600 reached 0.9. Bacterial cells were harvested by 
centrifugation at 4000 rpm for 20 minutes then passed through a 0.45 µm pore-size filter. 
Proteins from the cultured supernatants were precipitated by incubating with 10% (v/v) 
trichloroacetic acid at 4°C for 1 hour and recovered by centrifugation at 4000 pm for 40 
minutes. Pellets were resuspended in 2 mL 10% (v/v) SDS and 8 mL ice-cold acetone 
then incubated overnight at -20°C. After centrifugation at 4000 pm for 40 minutes, the 
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pellets were dried and resuspended in 100 µL 8M Urea and 100 µL 2✕ SDS-loading dye. 
Proteins from whole-cell lysates (cell pellets) were resuspended in 1 mL 1✕ PBS and 
recovered by centrifugation at 13000 rpm for 15 minutes. The pellets were resuspended 
in 50 µL 1✕ PBS and 50 µL 2✕ SDS-loading dye.  
For Western immunoblotting analysis, proteins were separated by SDS-PAGE 
and transferred to a PVDF membrane for 1.5 hours at 70 mA using an ECL Semi-Dry 
Blotter (Amersham Biosciences). After transfer, the membrane was incubated in 5% (v/v) 
non-fat dry milk with shaking for 1 hr at room temperature and then incubated with 
primary antibody solution (1% non-fat dry milk, 0.1% Tween-20, 1✕ TBS, rat anti-SipD 
IgG antibody) with shaking at 4°C overnight. Following this incubation step, the 
membrane was rinsed three times with wash buffer (0.1% Tween-20, 1✕ TBS pH 7.4). 
Membrane was then incubated in the secondary antibody solution (anti-rat IgG antibody 
conjugated to Alexa Fluor-680 in wash buffer) for 1 hr at room temperature with shaking. 
The membrane was then rinsed three times with wash buffer. The blot was analyzed 
using an ODYSSEY Infrared Imaging System (LI-COR Biosciences). 
 
8.3. Results  
8.3.1. Fluorophore Conjugation to Proteins 
Cysteine point mutants of T3SS proteins were generated by PCR for the covalent 
attachment of maleimide-conjugated fluorophore. CD spectropolarimetry was used to 
confirm that the cysteine point mutantation of recombinant proteins retained similar 
secondary structure characteristics to their non-cysteine containing counterparts (data not 
shown).  All SipB82-312 cysteine mutant proteins were labeled with AF647 and 
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SipDΔ38/SipDΔ100 cysteine mutants were labeled with AF488 or FM. FM/AF488 and 
AF647 were chosen as the dye pair for FRET because their R0 value of ~56Å is within 
the expected protein-protein interaction distance based on our hypothesis that the coiled-
coil of SipB82-312 interacts with the distal region of SipD as discussed in Chapter 7. UV-
visible absorption spectra show that SipB82-312 cysteine mutants were labeled with their 
respective fluorophore (Fig. 8-1). The labeling efficiency was estimated to be 87% for 
SipB82-312 A109C-AF647, 91% for SipB82-312 D207C-AF647, 85% for SipB82-312 N283C-
AF647 and ~81% for SipB82-312 E303C-AF647. Furthermore, CD experiments showed 
that the conjugation of fluorophore to SipB82-312 did not significantly alter its secondary 
structure characteristics (Fig. 8-2). Conjugation of fluorophore to SipD and PrgI* showed 
similar results (data not shown).  
 
8.3.2. FP of SipB82-312 and SipDΔ38/SipDΔ100 
FP was used to determine the in vitro binding affinity between SipDΔ38 (which 
contains the N-terminal α-helical domain) or SipDΔ100 (which lacks the N-terminal α-
helical domain) with SipB82-312. FP of 25 nM AF647 labeled SipB82-312 A109, D207C, 
N283C or E303 titrated with increasing concentrations of unlabeled SipDΔ38 resulted in 
saturated binding curves (Fig. 8-3). The estimated dissociation constants for SipB82-312 
titrated with unlabeled SipDΔ38 were 36 ± 5 µM (with SipB82-312 A109C), 67 ± 12 µM 
(with SipB82-312 D207C), 38 ± 7 µM (with SipB82-312 N283C) and 44 ± 6 µM (with SipB82-
312 E303C) (Fig. 8-3). In Chapter 7, NMR titrations showed that the distal region of SipD 
is the primary surface for the interaction with SipB. Therefore, I hypothesized that the 
removal of the N-terminal α-helical domain of SipD (residues 39-100) would not 
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drastically affect the affinity between SipD and the N-terminal ectodomain of SipB. 
Indeed, removal of the N-terminal domain of SipD had little effect on the binding affinity 
between SipDΔ100 with SipB82-312 (Fig. 8-3). The estimated dissociation constants for 
SipB82-312 titrated with unlabeled SipDΔ100 were 42 ± 7 µM (with SipB82-312 A109C), 61 ± 
7 µM (with SipB82-312 D207C), 37 ± 3 µM (with SipB82-312 N283C) and 48 ± 7 µM (with 
SipB82-312 E303C) (Fig. 8-3). Together these data suggest that the dissociation constant 
between SipDΔ38/SipDΔ100 with SipB82-312 is in the range of 30 to 60 µM, though 
placement of AF647 at D207 on SipB82-312 results in a slight increase in the dissociation 
constant (Fig. 8-3).   
 
8.3.3. FRET of SipB82-312 and SipDΔ38/SipDΔ100 
FRET was used to estimate the distance between the donor labeled SipD cysteine 
and the acceptor labeled SipB82-312 cysteinee. Either AF488 or FM fluorophore was 
attached to the distal region of SipD; at E230C for SipDΔ38 and at K173C for SipDΔ100 
(Fig. 8-4). The AF647 fluorophore was attached towards the middle of the trimeric 
coiled-coil (D207) or C-terminus (N283) of SipB82-312 (Fig. 8-4). FRET signal was 
observed for both SipDΔ38 E230C-AF488 (Fig. 8-4A) and SipDΔ100 K173C-FM (Fig. 8-
4B) with SipB82-312 D207C-AF647. FRET signal was also observed for SipDΔ38 E230C-
AF488 (Fig. 8-4D) with SipB82-312 N283C-AF647. However, less FRET signal was 
observed between SipDΔ100 K173C-FM and SipB82-312 D207C-AF647 (Fig. 8-4C). The 
FRET efficiencies, E, and the estimated molecular distance, r, between each FRET pair 
are shown in Table 8-1. Together, these results agree with results of FP that showed 
SipDΔ38 and SipDΔ100 interact with SipB82-312 in vitro. Results of FRET experiments also 
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suggest that the C-terminus of SipB82-312 is further away from the interaction interface 
with the distal region of SipD than the trimeric coiled-coil of SipB82-312. 
 
 
Fig. 8-1 – UV-Vis Absorption Spectra of Fluorophore Labeled SipB82-312 
UV-Vis absorption spectra of AF647 labeled (A) SipB82-312 N283C and (B) SipB82-312 
D207C. The maxima of the spectra are shown and correlate with the expected adsorption 




Fig. 8-2 – Circular Dichroism of Fluorophore Labeled SipB82-312 
Far-UV CD spectra of non-fluorophore labeled and fluorophore labeled (A) SipB82-312 
N283C and (B) SipB82-312 D207C and. Both proteins show CD minima at 208 and 222, 
which is typical of highly α-helical proteins. CD shows the secondary structure 
characteristics of fluorophore labeled SipB82-312 (dotted line) is similar to non-fluorophore 
labeled SipB82-312 (solid line). Similar results were observed for SipB82-312 A109C or 












Fig.  8-3 – Fluorescence Polarization of SipB82-312-AF647 and SipDΔ38/Δ100 
FP of 25 nM (A) SipB82-312 A109C-AF647 or E303C-AF647 and (B) SipB82-312 D207C-
AF647 or N283C-AF647 with increasing concentrations of unlabeled SipDΔ38 or 
SipDΔ100 is shown. The change in millipolarization (ΔmP) is shown and each data point 
contains error bars for its replicates (n=5). The apparent dissociation constant for all 
SipB82-312 and SipDΔ38/SipDΔ100 are shown, with values ranging from 37 to 67 µM. (C) 
The location of the residues that were mutated is mapped onto the structure of SipB82-226 
(PDB ID 3TUL) as a reference. The structure of SipB from 226-312 is unknown, but is 






Fig. 8-4 – FRET of SipB82-312-AF647 and SipDΔ38/Δ100-AF488/FM 
FRET performed with SipB82-312 (D207C or N283C)-AF647 (acceptor) and SipDΔ38 
E230C-AF647 or SipDΔ100 K173C-FM (donor). The difference between the emission 
spectra of the acceptor alone and the acceptor in the presence of the donor is shown. The 
position of the fluorophore label on the structure of SipDΔ38 and SipB82-312 is shown. SipD 
has the N-terminal domain colored in green, coiled-coil in gray and mixed α/β domain in 




Table 8-1 – Calculations of SipB/SipD FRET Efficiency 






















8.3.4. FP and FRET of SipB82-312 and PrgI* 
The needle and translocon have not been reported to interact, presumably due to 
being separated in space by the tip protein SipD. To test whether PrgI* interacted with 
SipB82-312, FP and FRET experiments were performed. No FRET signal was observed 
between PrgI* L31C-AF488 and SipB82-312 D207C-AF647 or SipB82-312 N283C-AF647 
(Fig. 8-5A & Fig. 8-5B). Furthermore, increasing concentrations of unlabeled SipB82-312 
up to 800 µM showed no significant increase in polarization with 25 nM PrgI* L31C-
AF488, suggesting a lack of interaction between PrgI* and SipB82-312 in vitro by FP (Fig. 
8-5C). These results serve as control experiments for FP & FRET studies of needle, tip 
and translocon proteins.  
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8.3.5. Invasion Assay with SipD Mixed α/β Domain Mutants 
Based on NMR, FP and FRET results, as well as the observation that the proximal 
end of SipD (the bottom of the coiled-coil) interacts with the needle protein PrgI 
(discussed in Chapter 4 and Chapter 5), I hypothesized that the distal region of SipD (the 
top of the coiled-coil and the mixed α/β domain) would be the primary surface for the 
interaction with the N-terminal ectodomain of SipB. To test whether the distal region of 
SipD is important for the interaction with SipB, single, double or triple point mutations 
were introduced into the mixed α/β domain of SipD (Fig. 8-6) and tested for their ability 
to effect invasion of intestinal epithelial Henle-407 cells by Salmonella. Removal of the 
sipD gene (ΔSipD) completely knocked out the ability for Salmonella Typhimurium to 
invade Henle-407 cells (Fig. 8-6). Invasion was complemented by the addition of a 
plasmid containing wild-type sipD (SipD+) (Fig. 8-6). Two single mutations, L271D and 
L280D, had no effect on invasion (Fig. 8-6). In contrast, other single mutations, such as 
N196D and V191D, or double mutations, such as V191D/N196 and L271D/L280D, 
moderately decreased invasion (Fig. 8-6). Double and triple point mutations affecting a 
larger surface area of SipD drastically reduced invasion (Fig. 8-6). Invasion was reduced 
below 1% with the SipD double mutant L280D+A285D and the triple mutants 
N196D+L280D+A285D or N196D+V265D+L271D (Fig. 8-6). Western immunoblot 
analysis of cultured supernatants (Fig. 8-7A) and whole-cell lysates (Fig. 8-7B) showed 
that, other than N196+V265D+L271D (Fig. 8-7A, B), the SipD mutant proteins were 
expressed. This suggests that the drop in invasion observed (Fig. 8-6) was not due to 
failure of SipD mutant protein to express, except for N196+V265D+L271D. Together, 
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the results of invasion assays support the hypothesis that the distal region of SipD is 
essential for Salmonella invasion into host cells. 
 
8.4. Discussion  
The data presented here show that the N-terminal ectodomain of SipB (82-312) 
interacts with SipD with a micromolar affinity range (Fig. 8-3). The slight decrease in 
affinity of SipB82-312 D207C for SipDΔ38/SipDΔ100 suggests the possibility that α-helix 3 
of SipB trimeric coiled-coil is at the interaction surface, if indeed the fluorophore 
placement inhibited the interaction (Fig. 8-3). However, this hypothesis has yet to be 
experimentally tested. The SipD/SipB affinity range of 30 to 60 µM is in agreement with 
the binding affinity estimated by intermediate exchange timescale observed in NMR 
titrations of SipD and SipB (see Chapter 7). However, it is a factor of ~200 times lower 
than the reported value for the Shigella homologs IpaD/IpaB6. FRET experiments suggest 
that placement of the fluorophore on the SipB82-312 coiled-coil (D207C) shows more 
efficient FRET signal than placing the fluorophore towards the C-terminus of SipB82-312 
(N283C) (Fig. 8-4 & Table 8-1). Additionally, this suggests that the SipB N-terminal 
domain trimeric coiled-coil is primarily involved in the interaction with SipD. In support 
of the initial hypothesis, mutations in the distal region of SipD decreased invasion of 
Salmonella Typhimurium with Henle-407 cells (Fig. 8-6). Finally, both FP and FRET 





Fig. 8-5 – FP and FRET of SipB82-312 and PrgI* 
PrgI* L31C-AF488 does not show FRET with either A. SipB82-312 D207C-AF647 or B. 
SipB82-312 N283C-AF647. C. There is no change in polarization value of 25 nM PrgI* 
L31C-AF488 upon the addition of unlabeled SipB82-312. The position of the fluorophore 














Fig. 8-6 – Salmonella Invasion Assay with SipD Mixed α/β Domain Mutants 
(A) Invasion assay between Salmonella Typhimurium strain SL1344 and human 
intestinal epithelial Henle-407 cells is shown. The Salmonella sipD- mutant 
(ΔSipD) was completely non-invasive. Adding back wild-type SipD (+SipD) to 
the sipD- Salmonella strain complemented invasion. SipD mixed α/β mutations 
were tested for their ability to decrease invasion. L271D and L280D had no affect 
on invasion. N196D, V191D, V191D+N196D, L271D+L280D and 
V265D+L271D had a moderate decrease in invasion. In contrast, L280D+A285, 
N196D+L280D+A285 or N196D+V265D+L271D completely reduced the ability 
of Salmonella to invade Henle-407 cells. (B) The location of mutants used for 




Fig. 8-7 – Western Immunoblot Analysis of SipD Mixed α/β Domain Mutants 
Western immunoblot analysis of (A) cultured supernatants and (B) whole-cell lysates of 
ΔSipD, +SipD, and SipD mutant Salmonella Typhimurium strains. Blots were treated 
with a monoclonal antibody specific to SipD. Recombinant GB1-SipDΔ38 was used as a 
positive control.  
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Chapter 9. The Bacterial Type III Secretion System as a Target for 
Developing New Antibiotics 
[This chapter is a review on T3SS inhibitors that has been published with the following 
citation: McShan AC, De Guzman RN. The Bacterial Type III Secretion System as a 
Target for Developing New Antibiotics. Chem. Biol. Drug. Des. 85, 30-42, 2015. A 
figure from the paper was chosen as the cover for the issue in which it was published, 
shown on page 173.] 
 
9.1. Introduction  
Pathogenic Gram-negative bacteria pose a significant global health impact with an 
estimated 2 million infections and 23,000 deaths per year in just the United States1.  
Examples of these organisms include Pseudomonas, Shigella, Salmonella, Chlamydia, 
enteropathogenic E. coli (EPEC), and Yersinia. The appearance and rapid evolution of 
multidrug resistant bacterial strains has become of great concern for public health2-4.  
Unfortunately, the development of new antibiotics presents a difficult challenge.  Since 
2009 three antibiotics targeting Gram-negative bacteria, though not exclusively, have 
been approved as the deadline approaches for the initiative of the Infectious Diseases 
Society of America’s for at least 10 new antibiotics by 20205. The rate of entry of new 
antibiotics into the pipeline is extremely slow6-9. This is largely due to several factors, 
namely, (i) the lack of novel antibiotic targets10, (ii) high throughput screens often turn up 
known targets or novel targets that do not make it past early stages of drug development 
due to toxicity or off target effects11, and (iii) the disinterest of big pharmaceutical 
companies to discover new antibiotics or conduct clinical trials due the problem of 
antibiotic resistance and poor investment return has only exacerbated the situation11,12.  
The rapid emergence of multidrug resistant strains coupled with the dearth of novel 
antibiotics suggests a need for identifying novel targets for development of antibiotics. 
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Traditional antibiotics often fall into two classes: bactericidal compounds that 
cause cell death and/or bacteriostatic compounds that inhibit cellular growth11.  In either 
case, these drugs often induce a selection pressure on bacteria to develop drug resistance, 
which is usually obtained via horizontal gene transfer between bacteria or by de novo 
mutations selected by evolution11.  Targeting virulence pathways of pathogenic bacteria 
has been suggested as an alternative strategy13,14.  One current theory is that the use of 
antivirulence or anti-infective drugs, in contrast to antibiotics, will dampen the selection 
pressure for the emergence of resistant strains because these drugs do not directly harm 
the organism15,16.  Notably, there have been documented cases of resistance to 
antivirulence drugs, though it has been argued that the existence of such mechanisms for 
resistance does not suggest it will become a problem in a clinical setting15.  Another 
advantage is that because virulence mechanisms are used by pathogenic bacteria, 
antivirulence drugs are hypothesized to have less of an influence on the host commensal 
flora when compared to traditional broad spectrum antibiotics17. 
 
9.2. The Type III Secretion System – Multiple Targeting Opportunities  
9.2.1. Overview of the T3SS 
The type III secretion system functions as a conduit for delivery of virulence 
factors by translocating proteins from the bacterial cytoplasm into the eukaryotic host cell 
cytoplasm to facilitate infection18.  The structural component of the T3SS, the needle 
complex, was first visualized by Galan & coworkers in 199819 and since then the 
structures and functions of many T3SS proteins have been elucidated [reviewed in20-23].  
T3SS proteins are highly homologous in sequence, structure and function among 
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different bacteria20,24,25.  Therefore, protein-protein interactions within the system among 
different bacteria and with host cells are thought to occur through similar mechanisms.  
This theory is supported by the similarities observed between the assembly of the 
Salmonella and Shigella T3SS needles26 and conserved structural motifs within the basal 
structure27.  Importantly, disruption of many aspects of the T3SS often abolishes 
pathogenicity.  For these reasons, the potential of using the T3SS as a pseudo-broad 
spectrum antivirulence target is of great interest13.  As the T3SS is complex, there are 
many different potential targeting strategies relating to various aspects of the system, 
which are outlined in 9-1 and described below. 
 
9.2.2. The T3SS Needle Apparatus.   
The T3SS needle apparatus is made up of around 25 different proteins that 
assemble together to regulate and facilitate the secretion of effector proteins into host 
cells21.  Together, the membrane-embedded export apparatus controls the secretion of 
proteins and anchors the apparatus into the bacterial membrane28.  An ATPase provides 
recognition for chaperone/effector complexes and is thought to provide energy for 
insertion and unfolding of effector proteins into the apparatus29.  The needle provides a 
~25Å diameter extracellular channel for the secretion of partially unfolded effector 
proteins26,28.  The tip complex regulates secretion and is a scaffold for translocon 
assembly30.  Finally, the translocon creates a pore in host cell membrane31.  Many 
subsections of the apparatus, such as the tip, needle, inner ring and outer ring, are 
assembled by oligomers of a single protein whose affinities are governed by the sum of 
weak protein-protein interactions32. Furthermore, the structures of T3SS proteins are 
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homologous between different organisms20.  Two possible modes of targeting the needle 
apparatus directly could be protein-protein interactions within each component parts such 
as the needle monomer interactions or interactions between subsections such as the tip-
translocon interaction (Fig. 9-1).  Salmonella contains genetic loci that encode three 
T3SS operons with distinct functions.  The Salmonella pathogenicity island-1 (SPI-1) 
encoded T3SS is the most studied and functions primarily in the initial invasion of non-
phagocytic cells33,34.  The SPI-2 T3SS is involved in the maintenance of Salmonella 
containing vacuoles and bacterial replication within host cells, though it’s structure has 
not been as extensively characterized35.  In addition, there is a flagellar T3SS (24). Other 
T3SS families include the Ysc and Ysa T3SS of Yersinia and the Sct T3SS of 
Chlamydia36.   
 
9.2.3. Chaperones and Effectors 
T3SS effectors have a wide range of functions within the host cell, but often 
involve manipulating host cell signaling, secretory trafficking, cytoskeletal dynamics, or 
the inflammatory response23,37.  It has been shown that effectors work in concert for 
infection38.  Regardless, deletions of many effectors attenuate virulence so they are 
considered potential drug targets39-41. While in the bacterial cytoplasm, effectors are often 
in complex with chaperone proteins that target them to the export apparatus and protect 
from aggregation42,43.  Disrupting chaperone/effector interactions could prevent secretion 
of effector proteins. However, some effectors, such as YopE and SopE, have been shown 
to retain partial secretion even the absence of their chaperone binding domain43,44. 
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Therefore, disruption of the chaperone/effector interactions may not necessarily result in 
a decrease in infectivity.  
 
9.2.4. T3SS Gene Transcription 
As stated above, the T3SS is organized into genetic loci whose gene expression is highly 
regulated by various transcription factors.  Transcriptional regulators of both SPI-145 and 
SPI-246 loci have been identified in Salmonella. T3SS transcriptional regulators have also 
been characterized in other bacteria, such as Pseudomonas21,47, Yersinia48 and Shigella49.  
Deletions of various T3SS transcription factors lead to the disappearance of the needle 
apparatuses on the bacterial surface due to essential constituents not being expressed50.  
For this reason, transcription factors are potential drug targets as well.  
 
9.3. Literature of T3SS Inhibitors 
9.3.1. Salicylidene Acylhydrazides 
Many different classes of structurally diverse small molecule compounds have 
been identified as inhibitors of the T3SS (Fig. 9-2 & Table 9-1).  The most well studied 
class of T3SS inhibitors is the salicylidene acylhydrazides (SAHs). One of the first 
reports comes from Kauppi et al.51,52 where they performed a whole-cell assay screen 
against T3SS gene expression using a reporter of the effector protein YopE fused with 
luciferase in Yersinia. Out of 9,400 compounds tested, a few compounds were identified, 
including SAHs.  A disadvantage of the assay was that it was based on coupling between 
Yop effector expression and secretion of the negative regulator LcrQ, therefore it was 
unclear whether the compounds acted directly against the T3SS51.  A follow up study 
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showed that their SAH compounds directly blocked effector secretion of the T3SS in a 
dose-dependent manner and they were suggested to act at the level of the T3SS 
machinery52,53. SAHs have been shown to broadly inhibit the T3SS of many bacteria 
genera, including Chlamydia54-57, Shigella58, Salmonella59-63 and pathogenic E. coli64-66.  
Notably, most SAHs have been shown to have no negative affect on bacterial 
growth51,55,61.  Interestingly, some SAHs derivatives inhibited bacterial motility by acting 
on the flagella51,59,60, while others did not affect bacterial motility64. 
 The specific targets within the T3SS itself of many SAHs remain unknown or 
ambiguous, though putative targets have been suggested.  First, it has been suggested that 
these compounds target the formation or assembly of the SPI-1 needle apparatus 
directly58.  Veenendaal et al.58 showed by electron microscopy that Shigella needles were 
reduced in number by ~40% and the distribution of observed needle lengths was altered 
by one compound.  Martinez-Argudo et al.59 isolated SAH resistant Salmonella strains 
with a mutation in FlhA, a flagellar inner membrane protein, suggesting the compounds 
target the conserved basal body.  Second, it has been suggested that SAHs target 
transcription factors or induce changes in cellular metabolism that affect the T3SS65,66.  
Wang et al. used affinity chromatography of conjugated beads of SAHS against E. coli 
lysate and identified three specific binding partners involved in bacterial cellular 
metabolism, WrbA, Tpx and FolX, and speculated targeting these proteins result in 
changes in T3SS gene expression by altering cellular metabolism66.  Importantly, binding 
was observed between the SAHs and homologs of WrbA and Tpx from other T3SS 
containing bacterial pathogens such as Salmonella and Pseudomonas66.  Since then, the 
crystal structure of Tpx has been solved and models of its binding to SAHs have been 
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described67. Finally, it has been suggested SAHs interfere with the T3SS through indirect 
methods, such as altering iron availability due to chelation61,63.  In Salmonella and 
Chlamydia, the addition of exogenous iron attenuates the inhibitory effect of SAHs55,63,68.  
Furthermore, a mutation in hemG, an enzyme involved with heme synthesized, conferred 
resistance to SAHs in Chlamydia69.  In addition, changes in gene expression of iron 
metabolism related genes has been reported in Salmonella, but not observed in E. coli, 
which suggests other mechanisms are at work63,65.  Recently, a gallium(III)–salicylidene 
acylhydrazide complex has been shown to disrupt secretion and expression of T3SS 
proteins in addition to inhibiting biofilm formation in Pseudomonas70.  The current data 
on SAHs suggest they target the T3SS through multiple mechanisms or that different 
SAH derivatives inhibit the system by different mechanisms.  
 
9.3.2. Thiazolidinones 
Another well-studied class of T3SS inhibitors is the thiazolidinones.  Felise et 
al.71 identified thiazolidinone from a whole-cell screen assay in Salmonella against 
protein secretion using a reporter construct of the effector SipA fused to the Yersinia 
phospholipase YplA. Cleavage of a supplied substrate, PED6, by the reporter construct 
resulted in measurable fluorescence, which was proportional to the amount of the 
secreted SipA71. Out of 92,000 screened compounds, a 2-imino-5-arylidene 
thiazolidinone was identified as a promising candidate, as it did not affect bacterial 
growth or T3SS transcription, and therefore was suggested to target formation or 
assembly of the needle apparatus71. The compound was additionally shown to inhibit the 
T3SS of Yersinia, as well as the type II secretion system in Pseudomonas and the type IV 
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pili secretion system of Francisella, though it did not target the flagellar-specific T3SS71. 
Because of the broad range of action, it was hypothesized that the thiazolidinones target 
the conserved outer membrane Secretin protein. A follow up study showed that 
thiazolidinone dimers inhibited the T3SS more potently and it was suggested that the 
compounds act along a large oligomeric protein-protein interaction surface72. 
 
9.3.3. Other Classes of T3SS Inhibitors 
Many other chemically and structurally diverse classes of chemical inhibitors that 
affect the T3SS have been identified (Fig. 9-2). Although the specific targets within the 
T3SS for most of these inhibitors have not been elucidated, the putative targets of a few 
compounds have been hypothesized.  Yop secretion was inhibited by 2,2’-thiobis-(4-
methylphenol) through an interaction with the minor translocon protein YopD of 
Yersinia76.  Unfortunately, this compound was shown to be toxic to eukaryotic cells and 
requires structural modification to be considered a suitable drug candidate76. Mutations in 
the needle protein PscF of Pseudomonas conferred resistance against phenoxyacetamide 
inhibitors, suggesting PscF as their molecular target88,89. However, no biochemical 
binding assays showing a direct interaction between the two have been reported.  
Benzimidazoles have been shown to target the T3SS through inhibition of DNA binding 
by transcription factors such as LcrF in Yersinia79,80 and the Pseudomonas homolog 
ExsA81. Similarly, 1-butyl-4-nitromethyl-3-quinolin-2-yl-4H-quinoline inhibited the 
DNA binding of the Shigella transcription factor VirF, which controls transcription of 
Shigella T3SS genes74.  A variety of compounds have been shown to inhibit ATPases, 
such as YscN in Yersinia and its homolog BsaS in Burkholderia100.  Further, omeprazole 
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inhibited the ATPase of the SPI-2 T3SS of Salmonella, possibly through regulation of 
nitric oxide production87.  Pseudolipasin A inhibited phospholipase A2 activity of the 
Pseudomonas effector ExoU106. 
 There are many small molecule inhibitors without known specific targets within 
the T3SS as shown in Table 9-1.  A screen in Yersinia by Harmon et al.99 identified 
various chemically diverse hydrophobic compounds that inhibited translocation of 
effectors into eukayrotic cells, but not in vitro secretion or expression, suggesting they 
disrupted the formation of a functional translocon or that they inhibited interaction with 
the host cell.  Various compounds showing inhibition of T3SS-mediated hemolysis, such 
as aurodox and the gaudinomines, have also been identified78,86.  Other compounds, such 
as salicylanilides, salicylideneanilines, sulfonylaminobenzanilides, cytosporone B, and 
citrus flavonoids are hypothesized to broadly inhibit T3SS gene transcription through 
unknown mechanisms53,64,84,85,92.  
 
9.3.4. Non-Small Molecule Inhibitors of T3SS 
 Non-small molecule inhibitors of T3SS have been reported.  These include 
polymers, proteins and polypeptide mimics.  Ohgita et al.107 reported that the proton-
motive force dependent rotation of the Pseudomonas T3SS was inhibited by the addition 
of the viscous polymer polyethylene glycol (PEG) 8000 and this was hypothesized to 
occur by the resistance of physical rotation due to solution viscosity. This hypothesis was 
further supported by a follow up study showing that other viscous polymers, such as 
alginate and mucin, inhibited T3SS rotation while low viscosity polymers such as 
PEG200 do not101.  PEG derivatives are commonly used excipients in drug formulations 
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108 and because these experiments showed a direct correlation between the rotation of the 
T3SS needle apparatus and secretion of effectors, the addition of viscous polymers such 
as PEG as excipients to future antivirulence drug formulations is of interest101,108.  
 Proteins and polypeptides have also been reported as inhibitors of T3SS. For 
example, the glycoprotein Lactoferrin has been shown to decrease virulence of 
Salmonella, Shigella and E. coli by targeting the T3SS109-112. In Shigella, Lactoferrin 
induced the loss and degradation of the translocon proteins IpaB and IpaC at the bacterial 
surface111.  Similarly, Lactoferrin caused the loss and degradation of the E. coli tip and 
translocon proteins (EspA, EspB and EspD) at the bacterial surface109,110,113.  Lactoferrin-
mediated inhibition of the T3SS is thought to occur through two mechanisms. First, its 
ability to bind lipopolysaccharide on the bacterial surface is thought to cause instability 
of virulence proteins at the bacterial surface by disrupting essential protein-protein 
interactions102.  Second, the degradation of T3SS proteins occurs via the intrinsic serine 
protease activity of Lactoferrins102.   Additionally, Lactoferrin inhibits infection and has a 
bacteriostatic effect due to its ability to sequester iron, which is an essential micronutrient 
needed by many bacterial pathogens102.  
 Polypeptide mimics targeting T3SS components have also been described. In 
Chlamydia, a 28 amino acid polypeptide mimic targeting the CdsN ATPase via its 
interaction with the putative inner membrane-tethering protein CdsL inhibited bacterial 
invasion of eukaryotic host cells104. In Salmonella, Hayward et al.114 showed that a 
polypeptide derived from the C-terminus of the translocon protein SipB was shown to be 
a potent inhibitor of the membrane fusion activity of both wild-type SipB and the 
Shigella homolog IpaB in vitro.  This polypeptide mimic also blocked the entry of 
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Salmonella and Shigella into cultured eukaryotic cells114. Finally, coiled-coiled peptides 
designed against the EPEC tip protein EspA inhibited T3SS-mediated hemolysis, EspA 
polymerization and secretion of effector proteins105. 
 
9.3.5. Small Molecules That Bind T3SS Proteins 
 Biologically relevant small molecules interact with structural and effector proteins 
of the T3SS and could potentially be used as scaffolds for drug design.  These small 
molecules include sterols and lipids. Bile salts in the intestines of hosts are thought to act 
as environmental sensors for infection by Salmonella and Shigella115. In Shigella, bile 
salts increase invasiveness to epithelial cells116, while in Salmonella bile salts decrease 
invasiveness117. Because the tip protein is present on top of the needle at the bacterial 
surface prior to host cell contact, it has been suggested to function as a sensor for the host 
environment by interacting with bile salts115.  NMR titrations suggested different 
interaction sites for bile salts such as deoxycholate and chenodeoxycholate on the 
Salmonella SipD and the Shigella IpaD tip proteins118,119. This is further supported by 
differences in the binding of deoxycholate in co-crystal structures with SipD120 or 
IpaD121. Interestingly, binding of bile salts was reported to induce a conformation change 
in IpaD, but not SipD121, which possibly explains the difference in the responses 
observed between Salmonella and Shigella in the presence of bile salts.  
  The translocon proteins interact with sterols, for example, the Shigella IpaB 
translocon protein interacts with cholesterol and sphingolipids on host cell lipid rafts to 
mediate infection122,123.  Binding of IpaB to sterol was proposed to cause the 
disorganization of the Golgi and other recycling networks by altering the distribution of 
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cholesterol on the cell membrane and the sorting of the eukaryotic cell surface that 
promoted bacterial uptake124.  Interaction of cholesterol with homologous translocon 
proteins in other bacteria such as the Salmonella SipB and the Pseudomonas PopB/PopD 
proteins is required for infection125,126.  Data also suggests interaction of translocon 
proteins with cholesterol is essential after initial infection. For example, the T3SS 
effectors IcsB from Shigella and BopA from Burkholderia bound to cholesterol leading 
to evasion of autophagy in host cells127. In Salmonella, the SPI-2 effector SseJ caused 
esterification of cholesterol to maintain the Salmonella containing vacuole128.  Currently, 
a detailed mechanism of the molecular interactions of T3SS proteins with cholesterol or 
sphingolipids and their role in pathogenesis remain to be worked out.  
 
9.4. Future Directions  
9.4.1. Identification of T3SS Targets 
Drug discovery and development of small molecule inhibitors is lengthy and 
costly, with a potential drug candidate taking an average of over 10 years and costing 
millions of dollars to reach the market as an approved drug.  The process often begins 
with a high throughput screen to identify potential hits.   This is followed by target 
identification and validation, often in parallel with structure activity relationships to 
identify the most potent lead compound.  Next, in vivo animal models are tested.  If 
successful, pharmacokinetics and dynamics are analyzed and product is formulated as 
needed.  Finally, clinical trials are performed.  
The most pressing concern in the field is the identification and characterization of 
specific targets within the many protein components of the T3SS.  Even with the most 
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well studied classes of inhibitors, SAHs and thiazolidinones, the specific T3SS targets 
remain unknown or ambiguous. This is likely due to the fact that most high throughout 
screens utilized assays that broadly monitored the secretion of effectors or gene 
transcription rather than using a targeted approach, such as a specific protein-protein 
interaction involved in the assembly of the T3SS needle apparatus.  In addition, 
derivatives within a class of T3SS inhibitors have unique chemical structure that could 
potentially interact with non-T3SS targets in other organisms leading to differences in 
potency or mechanisms of action.  This could explain the complex nature of the results 
observed in the literature of SAHs. A targeted and more specific approach for future high 
throughout screens could help solve this problem.  Many binding assays have been 
developed to monitor protein-protein interactions of the structural proteins of the T3SS 
needle apparatus that could be adapted for drug screening.  For example, fluorescence 
polarization and FRET assays show binding of the tip and translocon protein in 
Shigella129 and NMR spectroscopy showed binding of the tip and needle protein in 
Salmonella130. 
 
9.4.2. SAR Design 
Structure-activity relationships (SAR) provide a direct link between the chemical 
structure of a molecule and its observed activity to create a potent lead compound. The 
identification of a target facilitates SAR studies especially when the mechanism of 
interaction is known, although they can be performed in the absence of a target131.  SAR 
studies have been initiated for a few T3SS inhibitor classes and extensively with SAHs. 
The data from SAR analysis of SAHs is complex and difficult to interpret. The salicylic 
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phenol group is necessary for inhibiting activity, but substitutions in other positions are 
generally tolerable52,132. SAR based optimization of future SAHs compounds could be 
complicated if they target T3SS through multiple mechanisms as suggested in the 
literature52,132.  SAR data on other classes of small molecule inhibitors of T3SS are 
available as well.  Thiazolidinone analogs show sensitivity against substitutions at the 
imino N-2, amido N-3, and 5-arylidene groups and SAR analysis led to the identification 
of a more soluble derivative71.  Hydrophobicity and lipophilicity were shown to be 
important factors for inhibition of the T3SS by sulfonylaminobenzanilides53.  
Cytosporone derivatives with extensive carbon chains containing a phenyl acetic acetate 
ester group were most potent85.   Derivatives of 8-hydroxyquinoline required a fused 
pyridine ring and an aromatic hydroxyl group for inhibition of T3SS function77.  
Benzimidazoles are sensitive to substitutions in the linker ringer and the middle phenyl 
ring79.  Finally, phenoxyacetamides were sensitive to changes on the A ring (where 2,4-
dichlorophenyl is preferred) and their stereocenter was critical for T3SS inhibition and 
SAR analysis led to the identification of an 8-fold more potent compound than found in 
initial screens88,89.  
 
9.4.3. Animal Models, Pharmacokinetics and Formulation 
Preliminary studies using animal models have shown the effectiveness of different 
T3SS inhibitors against infection in vivo and validated the approach of targeting T3SS 
61,78,80,95. However, evaluation of pharmacokinetic parameters and formulation of 
potential drug molecule for delivery into host organisms is an essential step of drug 
discovery.  Challenges with small molecule drug development include efflux, metabolism 
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and membrane permeability.  Notably, most of the literature describes relatively small 
and hydrophobic compounds that were identified through whole-cell screening, and 
therefore these compounds are likely to be able to pass through cellular membranes.  A 
study examined the pharmacokinetics of SAHs in a mouse model95.  Many compounds 
were shown to have a short half-life, suggesting rapid metabolism or clearance, as well as 
problems with compound stability and solubility95.  Attempts at formulation with the 
non-ionic surfactant Poloxamer 407 and the polysaccharide (2-hydroxypropyl)-β-
cyclodextrin95,133 were unsuccessful in improving efficacy.  The ability of academia and 
the pharmaceutical industry to work together will speed the entry of new drugs into the 
pipeline by allowing for more extensive SAR optimization, pharmacokinetic analysis, 
formulation and in vivo testing of small molecule compounds134. 
  
9.5. Conclusion 
The clinical application of small molecule inhibitors of bacterial virulence as anti-
infectives remains to be exploited.  Small molecule T3SS inhibitors that have been 
identified could be used to treat bacterial infection on their own because most of them are 
non-toxic to eukaryotic cells while still preventing secretion of effector proteins.  A 
drawback of virulence drugs is that they will not inhibit bacterial proliferation and 
therefore the bacteria must be cleared by other means such as the host immune system. In 
contrast, these drugs may lead to increased immune cell memory. It is also possible that 
antivirulence drugs will need to be used in combination with other antibiotics for 
clearance.  The discovery and validity of many classes of small molecule inhibitors 
targeting different aspects of the type III secretion systems of Gram-negative bacteria 
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suggest that it is a promising approach that will applicable to clinical settings in the 
future.  
 
Compound Structure #  
(Figure 2) 
Organism T3SS Target Reference 
(-)-Hopeaphenol 4 Yersinia, Pseudomonas, Chlamydia ? 73 
1-butyl-4-nitromethyl-3-quinolin-2-yl-
4H-quinoline [SE-1] 
10 Shigella VirF / transcription factor 74 
2-imino-5-arylidene 
thiazolidinone 
13 Yersinia, Salmonella 
 
also inhibits T2S of Pseudomonas 
and 









YopD / translocon 76 
8-hydroxyquinolines [INP1750] 1 Yersinia, Chlamydia ? 77 
Aurodox 5 EPEC, Citrobacter ? 78 
Benzimidazole  Yersinia 
 
Pseudomonas 
LcrF / transcription factor 
 




Caminoside A-D 7 EPEC ? 82,83 
Citrus Flavonoids 11 Vibrio ? 84 
Cytosporone B 8 Salmonella ? 85 
Gaudinomine A-D 12 EPEC ? 86 
Omeprazole 15 Salmonella ATPase inhibitor, effects 
through nitric oxide 
production 
62,87 
Phenoxyacetamide 16 Pseudomonas PscF / needle protein 88,89 
Piericidin A1 3 Yersinia ? 90 
Pseudoceramine 18 Yersinia ? 91 
Pseudolipasin A 9 Pseudomonas ExoU / effector  10 



















FlhA / flagellar inner 
membrane protein  
 
?, possibly due to non-
T3SS cell metabolism 











Salicylideneaniline 19 Yersinia, EPEC ? 64 
Sulfonylaminobenzanilide 17 Yersinia ? 51,53 
Thiohydrazones of Thiohydrazide 6 Chlamydia ? 96 
Various Compounds not shown Yersinia, EPEC ? 97,98 
Various Compounds not shown Yersinia ? 99 
Various Compounds  not shown Yersinia 
Burkholderia 
YscN / ATPase 
BsaS / ATPase 
100 
Viscous Polymers [PEG8000 / 
Alginate / Mucin] 
not shown Pseudomonas inhibits T3SS apparatus 
rotation 
101 
Lactoferrin not shown Shigella, EPEC, Salmonella Degradation of tip and 
translocon proteins 
102 
Polypeptide Mimics not shown Salmonella/Shigella 
EPEC 
SipB, IpaB / Translocon 
CdsN ATPase 
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Chapter 10. Characterization of the Binding of Hydroxyindole, Indoleacetic acid 
and Morpholinoaniline to the Salmonella Type III Secretion System Proteins SipD 
and SipB 
[Some data in this chapter has been published with the following citation: McShan AC, 
Anbanandam A, Patnaik S, De Guzman RN. Characterization of the Binding of 
Hydroxyindole, Indoleacetic acid and Morpholinoaniline to the Salmonella Type III 
Secretion System Proteins SipD and SipB. ChemMedChem. 2016] 
 
10.1. Introduction 
Salmonella, a causative agent of food borne illness and typhoid fever that is 
responsible for millions of infections each year worldwide1, and other Gram-negative 
bacteria belonging to the Pseudomonas, Shigella, Chlamydia and Yersinia genera 
assemble the type III secretion system (T3SS) to initiate infectious diseases in humans2. 
The rise of antibiotic resistance among these pathogens coupled with the dearth of new 
antibiotics necessitates the development of new anti-bacterials3. The T3SS is an attractive 
target for developing new anti-bacterials because of its essential role in virulence, its 
exposure on the bacterial surface, and its presence only among pathogens3. 
The function of the T3SS is to inject effector proteins into the host cytoplasm to 
manipulate host-signaling pathways for the benefit and survival of bacteria2. The 
structure component of the T3SS is a mega-Dalton assemblage of over 20 proteins that 
form the needle apparatus, which consists of a base, an extracellular needle, a tip 
complex and a translocon4. In Salmonella, the tip protein is SipD and the translocon 
proteins are the membrane proteins SipB and SipC. The tip protein SipD is exposed to the 
extracellular environment prior to contact with host cells5. Upon contact with the host cell, 
the translocon assembles on the tip complex to form a pore on the host cell membrane to 
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allow the passage of effectors into the host cell cytoplasm5. The crystal structure of SipD6 
and other tip proteins7 are known. SipD contains an N-terminal α-helical hairpin, an 
elongated central coiled-coil and a domain of mixed α-helices and β-strands6. The crystal 
structures of the N-terminal ectodomains of the Shigella IpaB74-224 and Salmonella 
SipB82-226 translocon proteins show coiled-coils of three anti-parallel α-helices8, and the 
IpaB and SipB ectodomains interact directly with their tip proteins9. 
Currently, the only known small molecules that bind to the tip protein and 
translocon proteins are bile salts (to SipD and its Shigella homolog, IpaD)10 and 
sphingolipids and cholesterol (to SipB)11. To identity other molecular fragments that 
could bind to SipD and SipB that could potentially be used as potential scaffolds for 
development of novel T3SS inhibitors, we screened a library of 288 compounds from a 
Zenobia library. We identified that 5-hydroxyindole (Structure 1, Fig. 10-1) binds to 
both SipDΔ38 and SipB82-240, 3-indole acetic acid (2, Fig. 10-1) binds to SipB82-240 and 4-
morpholinoaniline (10, Fig. 10-1) binds to SipDΔ38. Our results revealed new small 
scaffolds based on indole and morpholinoaniline that can bind to SipD and SipB.  
 
10.2. Materials and Methods  
10.2.1. Protein Expression and Purification 
Isotopically labeled 15N/ILV SipDΔ38 and 15N/ILV SipB82-240 were expressed and 
purified as previously described (Chapter 4 for SipD and Chapter 6 for SipB).  
 
10.2.2. Surface Plasmon Resonance (SPR) Screening 
Surface Plasmon Resonance (SPR) was used for screening using a BIACORE 3000 
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instrument (GE Healthcare Life Science). The amine coupling kit (#BR-110633) and 
CM5 sensor chip (#BR-100399) were purchased from GE Healthcare. The target proteins 
SipDΔ38 and SipB82-240 were covalently immobilized to the sensor chip surface by 
standard amine coupling chemistry with 1.05✕ PBS buffer as the running buffer. There 
were four flow cells available for immobilization of the target protein per CM5 chip. 
Flow cell 1 was kept as a reference flow cell without immobilized protein. The remaining 
3 flow cells were loaded with target proteins. All four flow cells were activated for 7 
minutes with a mixture of N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) at 1:1 ratio and at a flow rate of 15 µL/min at 
25°C. Proteins at a concentration of 50 µg/mL in 10 mM sodium acetate pH 4.3 were 
injected for 7 minutes resulting in 2,727 response units (RU) for SipB82-240 and 10,110 
RU for SipD. All four flow cell surfaces were treated with a 7 minute injection of 1M 
ethanolamine pH 8.0 to eliminate all the unbound proteins and unreacted esters of 
NHS/EDC from the flow cells.  
A library of 288 compounds (Fragment Library 2, Zenobia, San Diego) was 
obtained in three 96-well microplates with each compound at a concentration of 100 mM 
stock in 100% DMSO. Compounds were diluted to a final concentration of 1 mM in 5% 
DMSO and 1.05✕ PBS. Biacore 3000 allowed the automate injection of compounds from 
96-well plates. The compounds were injected over the chip surface for 60 sec at a flow 
rate of 60 µL/min and the dissociation was monitored for 60 sec. Running buffer (1.05✕ 
PBS) was used as negative control. The surface was not regenerated between sample 
injections. The flow system, except sensor surface, was washed with 1:1 mixture of 
DMSO and water to remove any unbound compound from the flow system. Running 
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buffer was injected between each compound run to monitor carryover effects. Eight 
DMSO calibration solutions with varying concentrations (4-6%) were injected 
sequentially at the beginning and end of the experiments, using the same slow rate as the 
compounds. 
 
10.2.3. NMR Spectroscopy and Data Analysis 
NMR data were acquired using a Bruker Avance 800 MHz spectrometer equipped with a 
cryogenic triple resonance probe and were processed using NMRpipe12 and analyzed 
using NMRview13. Saturation transfer difference (STD) NMR data were acquired using 
Bruker Avance 600 MHz spectrometer equipped with a TXI-RT probe and processed 
using Topspin. Two-dimensional 1H-15N TROSY and 1H-13C HSQC spectra were 
acquired at 30°C using 0.3 mM of 15N/ILV SipDΔ38 or 0.5 mM of 15N/ILV SipB82-240 
dissolved in buffer (10% D2O, 20 mM NaCl, 10 mM sodium phosphate, pH 7.4). For 
NMR titrations, the compounds were dissolved in d6-DMSO (Cambridge Isotope 
Laboratories, Inc., Andover, MA). All titration samples contained 1.5% (v/v) d6-DMSO 
for SipDΔ38 or 2.5% (v/v) d6-DMSO for SipB82-240. Typical 2D 1H-15N TROSY 
acquisition parameters were 16 scans with 2048 complex points (1H) and 400 complex 
points (15N) with sweep width 17.9 ppm for 1H centered at 4.7 ppm and 30 ppm for 15N 
centered at 118 ppm. For 2D 1H-13C HSQC experiments acquisition parameters were 8 
scans with 1024 complex points (1H) and 256 complex points (13C) with sweep width 
10.01 ppm for 1H centered at 4.69 ppm and 18 ppm for 13C centered at 18 ppm. Chemical 



























Dissociation constants were estimated from plots of chemical shift deviation vs. 
compound concentration for multiple residues and curve fitting using GraphPad Prism 
Version 5 (GraphPad Software, Inc., USA). The R2 values for the fits were ≥ 0.99. 
One-dimensional 1H saturation transfer difference (STD) NMR experiments 
NMR15 data were acquired at 30°C on samples that contained protein plus compound at a 
1:100 ratio (40 µM protein, 4000 µM compound, 10% D2O, 0.4% d6-DMSO) or 
compound only (4000 µM compound in 100% d6-DMSO). The protein saturation pulse 
(Gaussian) was 50 ms over a period of 2 sec with the center of the on-resonance pulse 
varied from -0.2 to 0.1 ppm to give an optimal STD signal, where the off-resonance 
center was kept at 40 ppm. Typical acquisition parameters were 128 scans, 16 ppm 1H 
sweep width centered at 4.70 and 2 sec recycle delay.  
 
10.3. Results 
10.3.1. SPR screening 
The expression and purification of SipDΔ38 and SipB82-240 yielded milligram amounts of 
proteins and their solubility allowed for SPR screening followed by NMR 
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characterization. SPR is a label free method of screening for small molecule fragments 
that bind to proteins16. The SPR screen of 288 compounds from a structurally diverse 
library of fragment-like compounds (Zenobia Library 2) identified the binding of 5-
hydroxyindole (1, Fig. 10-1) to both SipDΔ38 and SipB82-240; 3-indoleacetic acid (2, Fig. 
10-1) to SipB82-240; and 4-morpholinoaniline (10, Fig. 10-1) to SipDΔ38 (Fig. 10-2). 
Results of the SPR screen also identified the important functional groups within the 
scaffolds in binding to SipDΔ38 and SipB82-240. Regarding the binding of the indole 
scaffold to SipDΔ38 and SipB82-240, other functional groups, such as hydroxyl and acetyl 
groups, were needed for binding, as the indole ring compounds containing other 
modifications were incapable of binding (Fig. 10-3). Replacing the 5-hydroxy group with 
a 5-cyano group (4, Fig. 10-1) abrogated the interaction suggesting that the 5’-hydroxy 
group in might be needed for hydrogen bonding with SipDΔ38 and SipB82-240 (Fig. 10-3). 
The acetate methylene group (2, Fig. 10-1) was needed for binding SipB82-240 as its 
removal (5 & 6, Fig. 10-1) resulted in loss of binding (Fig. 10-3). Likewise, the acetate 
carbonyl group (2, Fig. 10-1) was important for binding as its removal (7, 8, 9, Fig. 10-1) 
resulted in loss of binding (Fig. 10-3). Regarding the binding of the morpholinoaniline 
(10, Fig. 10-1) scaffold to SipDΔ38, hydroxylation or removal of the amino group (11, Fig. 
10-1) or introducing a methylene group between the two rings (12, Fig. 10-1) resulted in 
loss of binding (Fig. 10-3).  
 
10.3.2. NMR titrations of SipDΔ38 with 5-hydroxyindole 
 NMR was used to characterize the interaction of SipDΔ38 with 5-hydroxyindole. 
SipDΔ38 uniformly labeled with both 15N and ILV was titrated with 5-hydroxyindole at 
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increasing molar ratios of 1:0, 1:25, 1:50 and 1:100 and the titration was monitored by 
acquiring 2D 1H-15N TROSY and 2D 1H-13C HSQC datasets. Titration of SipDΔ38 with 5-
hydroxyindole resulted in chemical shift perturbations of specific SipDΔ38 amide peaks in 
a concentration dependent manner (Fig. 10-4). SipDΔ38 residues that were affected by 
binding (e.g. E133, M174, G175, L179, N211 and W234ε) showed progressive changes 
in their peak positions indicating interaction in fast exchange NMR time scale. In 
addition to the 15N resonances of SipDΔ38, the ILV 13C methyl groups of SipDΔ38 were 
also used as probes of the interaction. Like the results of the 15N titrations, titration with 
5-hydroxyindole resulted in chemical shift perturbations of specific SipDΔ38 ILV peaks in 
a concentration dependent manner (Fig. 10-5). Based on the chemical shift deviations of 
15N data (for E133, M174, G175 and L179, Fig. 10-4B) and ILV data (for L48, L178 and 
V187, Fig. 10-5B), the dissociation constant for the binding of 5-hydroxyindole to 
SipDΔ38 was estimated to be 32 ± 8 mM.  
 The chemical shift deviation for each non-overlapped amide (Fig. 10-6A) and 
ILV (Fig. 10-6B) peak of SipDΔ38 identified that residues were strongly affected by 
binding of 5-hydroxyindoel. Results of the 15N titration showed that the SipDΔ38 residues 
affected by 5-hydroxyindole ranged from hydrophobic (L97, A115, I134, L171, G175, 
L179, V187) to polar (R106, R126, E133, K188, K302) residues (Fig. 10-6A). The ILV 
titration confirmed the results of the 15N titration as many residues, such as I134, L171 
and V187 identified in the 15N titration also showed significant chemical shift deviations 
in the ILV titration with 5-hydroxyindole. Additionally, the ILV titrations identified other 
residues (I45, V253, V323, Fig. 10-6B) that were not previously identified in the 15N 
titration that showed significant chemical shift deviation upon binding to 5-
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hydroxyindole. The methyl side chains of I45, V253 and V323 were likely involved in 
the hydrophobic contacts with 5-hydroxyindole.  
The residues that showed significant chemical shift deviations clustered on two 
surfaces on SipD. One surface maps to the mixed α/β domain (involving residues G175, 
L178 and V187) (Fig. 10-7). The second largest surface maps near the bottom of the 
coiled-coil and is formed by S110, S114, R126 in the 23-residue loop spanning residues 
110-132 that connects the α-helical hairpin to the coiled-coil (Fig. 10-7). I45 in the α-
helical hairpin and I134 in the coiled-coil also showed strong chemical shifted deviations. 
Our results suggest that 5-hydroxyindole binds at the bottom of the coiled-coil and the 
loop 110-132 because most of the residues affected by interaction are in this region. The 
other site that showed chemical shift deviations perhaps indicate transient, weaker 
interactions with 5-hydroxyindole.  
 
10.3.3. STD NMR of 5-hydroxyindole with SipDΔ38  
Results of 1H STD NMR experiments identified which parts of 5-hydroxyindole 
were needed for binding to SipDΔ38.  As expected, the off-resonance reference spectrum 
showed NMR peaks from both SipDΔ38 and 5-hydroxyindole (Fig. 10-8A). The resulting 
1H STD NMR spectrum showed all the NMR peaks corresponding to 5-hydroxyindole 
remained above noise level (Fig. 10-8B). This indicated that, with the exception of the 
OH group for which there was no NMR peak in the STD NMR, all the protons in 5-
hydroxyindole were affected by the interaction with SipDΔ38. This suggested that the 
entire molecule of 5-hydroxyindole was embedded in SipDΔ38 upon binding. As a control 
experiment, irradiation of 5-hydroxyindole using the same conditions in the absence of 
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SipDΔ38 did not result in STD peaks, indicating that the observed STD peaks were not 







10-1 – Structure of Small Molecule Scaffolds 
SPR identified the binding of 5-hydroxyindole (1) to SipDΔ38 and SipB82-240, 3-
indoleacetic acid (2) to SipB82-240, and 4-morpholinoaniline (10) to SipB82-240. The non-
binding or relatively weaker binding of other similar scaffolds revealed the important 















10-2 – SPR Screening of SipDΔ38 and SipB82-240 
SPR sensorgrams showing the binding of (A) 5-hydroxyindole to SipDΔ38, (B) 4-
morpholinoaniline to SipD, (C) 5-hydroxyindole to SipB82-240, and (D) 3-indoleacetic 












10-3 – Further SPR Screening of SipDΔ38 and SipB82-240 
SPR sensorgrams from the screening of small molecules against (A) SipB82-240 and (B) 









10-4 – 15N NMR Titration of SipDΔ38 with 5-hydroxyindole 
(A) Overlay of five 2D 1H-15N TROSY spectra of 15N/ILV labeled SipDΔ38  
titrated with increasing molar ratios of 5-hydroxyindole, with expanded sections for 
selected SipDΔ38 residues affected by the interaction with 5-hydroxyindole. (B) Plot of 








10-5 – ILV Methyl Titration of SipDΔ38 with 5-hydroxyindole  
(A) Overlay of five 2D 1H-13C HSQC spectra of 15N/ILV labeled SipDΔ38 titrated wth 
increasing mole ratios of 5-hydroxyindole. (B) Plots of chemical shift deviation (CSD) vs 




10-6 – Plots of Chemical Shift Deviations of SipDΔ38 with 5-hydroxyindole 
Chemical shift deviations for (A) 15N and (B) ILV titrations of SipDΔ38 with 5-







10-7 – SipD Surfaces Affected by Binding of 5-hydroxyindole 
Cα of SipD colored according to 15N and ILV chemical shift deviations as follows: 1σ 
(yellow), 2σ (orange), 3σ (red); where σ is the standard deviation from the average CSD 








10-8 – STD NMR of 5-hydroxyindole with SipDΔ38 
(A) Off-resonance, (B) on-resonance STD NMR spectra of 5-hydroxyindole with SipDΔ38, 






10.3.4. SipDΔ38 binds to 4-morpholinoaniline 
In addition to 5-hydroxyindole, SPR identified the binding of another scaffold, 4-
morpholinoaniline, to SipDΔ38 (Fig. 10-2B). Titration of 15N/ILV labeled SipDΔ38 with 4-
morpholinoaniline at molar ratios of 1:0, 1:25, 1:50 and 1:100 resulted in distinct 
chemical shift deviations of specific SipDΔ38 amide peaks in a concentration dependent 
manner as monitored by 15N TROSY and 13C HSQC (Fig. 10-9 & Fig. 10-10). 
Representative panels from the 15N titration (S110, A111, F117, E133, V187 and K188, 
Fig. 10-9A) and ILV titrations (L138, L171, L178, V187 and L194, Fig. 10-10A) showed 
peaks in fast exchange NMR time scale. Plots of the weighted chemical shift deviations 
(Fig. 10-11A, B) identified SipDΔ38 residues that were strongly affected by 4-
morpholinoaniline. These residues ranged from hydrophobic (G94, A111, F117, V138, 
L150, V156, L179, V213) to polar (D131, E133, K188, K279) residues (Fig. 10-11A, B). 
The dissociation constant, however, could not be estimated, as plots of the chemical shift 
deviations vs concentrations of 4-morpholinoaniline did not reach saturation (Fig. 10-9B, 
Fig. 10-10B). STD NMR signals were not observed because SipDΔ38 could not be 
selectively saturated, as there are proton resonances of 4-morpholinoaniline near the STD 
NMR irradiation frequency. Nevertheless, mapping the SipDΔ38 residues affected by 4-
morpholinoaniline showed two distinct surfaces: the top of the mixed α/β domain and 
near the bottom of the coiled-coil (Fig. 10-12), similar to the surface maps of SipDΔ38 
interaction with 5-hydroxyindole (Fig. 10-7). Results with 5-hydroxyindole and 4-
morpholinoaniline suggest that these surfaces in SipD could be hotspots for binding small 
molecule fragments.  
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10.3.5. SipB82-240 binds to 5-hydroxyindole and 3-indoleacetic acid  
We also screened for small molecules that will bind to the major translocon protein SipB 
using the N-terminal soluble domain, SipB82-240. SPR identified the binding of 5-
hydroxyindole (Fig. 10-2C) and 3-indoleacetic acid (Fig. 10-2D) to SipB82-240. NMR 
titrations of SipB82-240 with 5-hydroxyindole at protein to compound ratios of 1:0, 1:25 
and 1:50 monitored by 2D 1H-15N TROSY resulted in distinct chemical shift 
perturbations of specific SipB82-240 amide peaks in a concentration dependent manner 
(Fig. 10-13A). Likewise, stepwise titration of SipB82-240 with 3-indoleacetic acid at 
protein to compound ratios of 1:0, 1:4 and 1:8 resulted in distinct chemical shift 
perturbations of specific SipB82-240 amide peaks in a concentration dependent manner 
(Fig. 10-13B). In addition, the ILV methyl resonances of SipB82-240 were affected by 
titration with 5-hydroxyindole (Fig. 10-14A) and 3-indoleacetic acid (Fig. 10-13B). 
There are currently no NMR assignments available for SipB82-240, thus, it is not possible 
to use NMR chemical shift perturbation methods to identify which parts of SipB82-240 are 
involved in the interaction with 5-hydroxyindole and 3-indoleacetic acid. NMR 
assignments of SipB82-240 would have been challenging and not carried out because only 
~50% of the expected amide resonances were observed.  
 STD NMR confirmed the binding of 5-hydroxyindole and 3-indoleacetic acid to 
SipB82-240. Further, STD NMR identified how 5-hydroxyindole and 3-indoleacetic acid 
bound to SipB82-240. The off-resonance reference spectra show both compound and 
SipB82-240 signals present (Fig. 10-15A, B). The resulting 1H STD NMR spectra show 
many of the signals corresponding to 3-indoleacetic acid (Fig 10-15B) and 5-
hydroxyindole (Fig. 10-15E) remained above noise level. This suggests that most of 5-
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hydroxyindole or 3-indoleacetic acid are interacting with or in close proximity to SipB82-
240. In contrast, irradiation of compounds using the same conditions in the absence of 
SipB82-240 resulted in no observable STD signals, indicating that SipB82-240 must be 
present to observe the STD signals of the compound (Fig. 10-15C, F).  
 
10.4. Discussion 
There are currently only a few small molecules that are known to bind to the T3SS tip 
and translocon proteins. Bile salts, such as deoxycholate, are sterol-like compounds that 
bind to SipD and its Shigella homolog IpaD6; 10; 17. Cholesterol and sphingolipids bind to 
the translocon protein SipB and its homolog IpaB11; 18. Finally, 2,2’-thiobis-(4-
methylphenol) binds to the translocon protein YopD of Yersinia pestis19. Here, we 
identified new small molecule scaffolds (Fig. 10-1) that bind to SipDΔ38 (5-hydroxyindole 
and 4-morpholinoaniline) and SipB82-240 (5-hydroxyindole and 3-indoleacetic acid).  
Comparison of the results of NMR titrations suggest that 5-hydroxyindole and 4-
morpholinoaniline perturbed similar surfaces on SipD. Both compounds affected SipD 
residues near the mixed α/β domain and the bottom region of the coiled-coil (Fig. 10-7 & 
Fig 10-12). The bottom of the coiled-coil of SipD has been previously identified an as 
important surface for the interaction with the needle protein PrgI20. Therefore, it may be 
possible to block the SipD:PrgI interaction by developing a compound that will bind to 
SipD with higher affinity. Our efforts at co-crystallization of SipDΔ38 or SipB82-240 with 
their interacting compounds has so far failed. Development of tighter binding compounds 
should allow for co-crystallization for the characterization of binding by X-ray diffraction.  
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The observation that two surfaces on SipD were affected by the compounds could 
be because both compounds have weak affinity to SipD (~30 mM for 5-hydroxyindole) 
and are therefore not very selective for a specific binding surface. The perturbation of 
ILV methyl resonances of SipDΔ38 with both 5-hydroxyindole (Fig. 10-5A) and 4-
morpholinoaniline (Fig. 10-10A) suggests that the protein-small molecule interaction 
included hydrophobic contacts. However, the small molecules also bound to SipDΔ38 by 
polar interactions (perhaps by hydrogen bonding or ionic contacts) because many charged 
SipDΔ38 residues were affected as well (Fig. 10-4A & Fig. 10-9A). This interaction with 
hydrophobic and hydrophilic surfaces is possible because the compounds contain 
hydrophobic rings as well as hydrophilic groups that are available for hydrogen bonding, 
such as OH and NH (Fig. 10-1).  
Indole-like chemical scaffolds have not been identified as inhibitors of T3SS3. In 
contrast, molecules that are somewhat chemically related to the aniline scaffold have 
been previously shown to inhibit type III secretion, such as salicylideneaniline and the 8-
hydroxyquinoline derivative INP17503. Salicylideneanilines (salicylidene + aniline like 
scaffold) have been suggested to function as a transcriptional inhibitor of the E. coli 
T3SS21, although the specific molecular target has not been identified, while the 
mechanism of INP1750 (quinoline + piperazine + aniline like scaffold) is currently 
unknown22. Because the tip and translocon proteins are conserved in many bacterial 
pathogens, it may be possible that more potent binding versions of indole and 
morpholinoaniline scaffolds might interact with homologs of SipD, such as IpaD from 
Shigella, BipD from Burkholderia, LcrV from Yersinia and PcrV from Pseudomonas. 
Indeed, some T3SS inhibitors, such as thiazolidinones and salicylidene acylhydrazides, 
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have been shown to be active against a broad range of bacteria, suggesting their target is 
a conserved T3SS protein3. Efforts are currently underway to determine if 5-
hydroxyindole, 3-indoleacetic acid or 4-morpholinoaniline interact with proteins from 
other bacterial T3S systems.  
To summarize, the significance of this work is that we have identified new small 
molecules based on the indole and morpholinoaniline scaffolds that interact with the 
Salmonella translocon protein SipB and the tip protein SipD. These scaffolds could be 
used as potential starting structures in the rational design of inhibitors of type III 
secretion.   
 
 
10-9 – 15N Titration of SipDΔ38 with 4-morpholinoaniline 
Titration of 15N/ILV labeled SipDΔ38 with 4-morpholinoaniline monitored by 2D 1H-15N 




10-10 – ILV Titration of SipDΔ38 with 4-morpholinoaniline 






10-11 –NMR Titration Analysis of SipDΔ38 with 4-morpholinoaniline 
Plots of chemical shift deviations (CSD) of SipDΔ38 with 4-morpholinoaniline based on 




10-12 –SipD Surfaces Affected by Binding with 4-morpholinoaniline 
Cα of SipD colored according to 15N and ILV chemical shift deviations as follows: 1σ 
(yellow), 2σ (orange), 3σ (red); where σ is the standard deviation from the average CSD 


































10-15 – STD NMR of SipB82-240 with (A-C) 3-indoleacetic acid and (D-F) 5-
hydroxyindole 
(A, D) Off-resonance and (B, E) on-resonance STD NMR spectra of SipB82-240 with the 




1. Majowicz, S. E., Musto, J., Scallan, E., Angulo, F. J., Kirk, M., O'Brien, S. J., 
Jones, T. F., Fazil, A., Hoekstra, R. M. & International Collaboration on Enteric 
Disease 'Burden of Illness, S. (2010). The global burden of nontyphoidal 
Salmonella gastroenteritis. Clin Infect Dis 50, 882-9. 
2. Galan, J. E., Lara-Tejero, M., Marlovits, T. C. & Wagner, S. (2014). Bacterial 
Type III Secretion Systems: Specialized Nanomachines for Protein Delivery into 
Target Cells. Annual Review of Microbiology, Vol 68 68, 415-438. 
3. McShan, A. C. & De Guzman, R. N. (2015). The Bacterial Type III Secretion 
System as a Target for Developing New Antibiotics. Chemical Biology & Drug 
Design 85, 30-42. 
	 226	
4. Chatterjee, S., Chaudhury, S., McShan, A. C., Kaur, K. & De Guzman, R. N. 
(2013). Structure and Biophysics of Type III Secretion in Bacteria. Biochemistry 
52, 2508-2517. 
5. Lara-Tejero, M. & Galan, J. E. (2009). Salmonella enterica Serovar Typhimurium 
Pathogenicity Island 1-Encoded Type III Secretion System Translocases Mediate 
Intimate Attachment to Nonphagocytic Cells. Infection and Immunity 77, 2635-
2642. 
6. Chatterjee, S., Zhong, D., Nordhues, B. A., Battaile, K. P., Lovell, S. & De 
Guzman, R. N. (2011). The crystal structures of the Salmonella type III secretion 
system tip protein SipD in complex with deoxycholate and chenodeoxycholate. 
Protein Sci 20, 75-86. 
7. Chaudhury, S., Battaile, K. P., Lovell, S., Plano, G. V. & De Guzman, R. N. 
(2013). Structure of the Yersinia pestis tip protein LcrV refined to 1.65 A 
resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun 69, 477-81. 
8. Barta, M. L., Dickenson, N. E., Patil, M., Keightley, A., Wyckoff, G. J., Picking, 
W. D., Picking, W. L. & Geisbrecht, B. V. (2012). The Structures of Coiled-Coil 
Domains from Type III Secretion System Translocators Reveal Homology to 
Pore-Forming Toxins. Journal of Molecular Biology 417, 395-405. 
9. Dickenson, N. E., Arizmendi, O., Patil, M. K., Toth, R. T. t., Middaugh, C. R., 
Picking, W. D. & Picking, W. L. (2013). N-Terminus of IpaB Provides a Potential 
Anchor to the Shigella Type III Secretion System Tip Complex Protein IpaD. 
Biochemistry. 
10. Wang, Y., Nordhues, B. A., Zhong, D. & De Guzman, R. N. (2010). NMR 
characterization of the interaction of the Salmonella type III secretion system 
protein SipD and bile salts. Biochemistry 49, 4220-6. 
11. Hayward, R. D., Cain, R. J., McGhie, E. J., Phillips, N., Garner, M. J. & 
Koronakis, V. (2005). Cholesterol binding by the bacterial type III translocon is 
essential for virulence effector delivery into mammalian cells. Molecular 
Microbiology 56, 590-603. 
12. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J. & Bax, A. (1995). 
NMRPipe: a multidimensional spectral processing system based on UNIX pipes. 
J Biomol NMR 6, 277-93. 
13. Johnson, B. A. (2004). Using NMRView to visualize and analyze the NMR 
spectra of macromolecules. Methods Mol Biol 278, 313-52. 
14. Grzesiek, S., Stahl, S. J., Wingfield, P. T. & Bax, A. (1996). The CD4 
determinant for downregulation by HIV-1 Nef directly binds to Nef. Mapping of 
the Nef binding surface by NMR. Biochemistry 35, 10256-61. 
15. Mayer, M. & Meyer, B. (1999). Characterization of ligand binding by saturation 
transfer difference NMR spectroscopy. Angewandte Chemie-International Edition 
38, 1784-1788. 
16. Arkin, M. R. & Wells, J. A. (2004). Small-molecule inhibitors of protein-protein 
interactions: Progressing towards the dream. Nature Reviews Drug Discovery 3, 
301-317. 
17. Barta, M. L., Guragain, M., Adam, P., Dickenson, N. E., Patil, M., Geisbrecht, B. 
V., Picking, W. L. & Picking, W. D. (2012). Identification of the bile salt binding 
	 227	
site on IpaD from Shigella flexneri and the influence of ligand binding on IpaD 
structure. Proteins-Structure Function and Bioinformatics 80, 935-945. 
18. Lafont, F., Tran Van Nhieu, G., Hanada, K., Sansonetti, P. & van der Goot, F. G. 
(2002). Initial steps of Shigella infection depend on the cholesterol/sphingolipid 
raft-mediated CD44-IpaB interaction. EMBO J 21, 4449-57. 
19. Jessen, D. L., Bradley, D. S. & Nilles, M. L. (2014). A Type III Secretion System 
Inhibitor Targets YopD while Revealing Differential Regulation of Secretion in 
Calcium-Blind Mutants of Yersinia pestis. Antimicrobial Agents and 
Chemotherapy 58, 839-850. 
20. Rathinavelan, T., Lara-Tejero, M., Lefebre, M., Chatterjee, S., McShan, A. C., 
Guo, D. C., Tang, C., Galan, J. E. & De Guzman, R. N. (2014). NMR model of 
PrgI-SipD interaction and its implications in the needle-tip assembly of the 
Salmonella type III secretion system. J Mol Biol 426, 2958-69. 
21. Gauthier, A., Robertson, M. L., Lowden, M., Ibarra, J. A., Puente, J. L. & Finlay, 
B. B. (2005). Transcriptional inhibitor of virulence factors in enteropathogenic 
Escherichia coli. Antimicrobial Agents and Chemotherapy 49, 4101-4109. 
22. Enquist, P. A., Gylfe, A., Hagglund, U., Lindstom, P., Norberg-Scherman, H., 
Sundin, C. & Elofsson, M. (2012). Derivatives of 8-hydroxyquinoline-
antibacterial agents that target intra- and extracellular Gram-negative pathogens. 
Bioorganic & Medicinal Chemistry Letters 22, 3550-3553. 
 
	 228	
Chapter 11. CD and NMR Characterization of Chaperone/Translocon 
Complexes 
11.1. Introduction  
Currently, the only known atomic structure of T3SS translocon proteins have been 
restricted to small domains (SipB82-226, IpaB74-224, YopD278-300, AcrH+AopB40-264)1; 2; 3 
and peptides with their cognate chaperones (YopD56-65+SycD, PopB51-59+PcrH, PopD47-
55+PcrH)4; 5. This is presumably because the translocon proteins are stable and properly 
folded only upon insertion into the host membrane environment, or in complex with their 
cognate chaperone. Two proteins, a major and a minor translocon, form the T3SS 
translocon complex. Here, full-length translocon proteins from Salmonella and 
Pseudomonas were subcloned, expressed and purified with their cognate chaperone for 
the purpose of structural characterization and use in studies of protein-protein interaction. 
Preliminary structural and biophysical analyses were performed, including size exclusion 
chromatography, circular dichroism and NMR spectroscopy. Data suggest that the full-
length translocon-chaperone complexes are not ideal candidates for NMR studies, and in 
the future should be separated from their chaperone for insertion into membrane or 
membrane-like environments to determine their structure or used in studies of protein-
protein interaction. 
 
11.2. Materials and Methods  
11.2.1. Subcloning, Protein Expression and Purification 
PCR primers were designed to amplify the genes for SicA, SipC and SipB from 
Salmonella Typhimurium strain SL1344. Full-length SicA and SipC were subcloned into 
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cloning site 1 (using EcoRI/HindIII restriction sites for SicA) and cloning site 2 (using 
NdeI/XhoI restriction sites for SipC) of the vector pET-DUET1 and confirmed by DNA 
sequencing. Similarly, full-length SicA and SipB were subcloned into cloning site 1 
(using EcoRI/HindIII restriction sites for SicA) and cloning site 2 (using NdeI/XhoI 
restriction sites for SipB) of pET-DUET1 and confirmed by DNA sequencing.  
PCR primers were designed to amplify the genes for PcrH, PopD and PopB from 
Pseudomonas aeruginosa strain PAO1. Full-length PcrH and PopD were subcloned into 
cloning site 1 (using BamHI/HindIII restriction sites for PcrH) and cloning site 2 (using 
NdeI/XhoI restriction sites for PopD) of the vector pET-DUET1 and confirmed by DNA 
sequencing. Similarly, full-length PcrH and PopB were subcloned into cloning site 1 
(using BamHI/HindIII restriction sites for PcrH) and cloning site 2 (using NdeI/XhoI 
restriction sites for PopB) of pET-DUET1 and confirmed by DNA sequencing. 
All unlabeled proteins were expressed in E. coli BL21(DE3) DNAY cells in 1L of 
LB media with 100 µg/mL carbenicillin at 37°C. Protein expression was induced at an 
OD600 of ~0.8 with 0.5 mM IPTG and expressed at 15°C overnight. Isotopically labeled 
co-expression of chaperone/translocon constructs were expressed in E. coli BL21(DE3) 
DNAY cells in 1L of 1✕ M9 minimal media with antibiotics at 37°C containing 1 g/L 
15N4Cl (Sigma-Aldrich, St. Louis, MO) and 2 g/L D-glucose. At an OD600 of ~ 0.4 the 
growth medium was supplemented with 60 mg of α-ketobutyric acid, sodium salt 
(methyl-13C) (δ methyl group of Ile) (Cambridge Isotope Laboratories, Inc., Andover, 
MA) dissolved in 1 mL autoclaved water. Protein expression was induced with 0.5 mM 
IPTG at an OD600
 
of 0.8 and cell growth was continued overnight at 15°C. Bacterial cells 
were harvested by centrifugation at 4000 r.p.m. for 10 minutes, resuspended with binding 
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buffer (500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole, pH 8.0, 1 mM 
phenylmethanesulfonyl fluoride) at 4°C and sonicated while keeping the lysate ice-cold. 
Cells were sonicated using a Branson Digital Sonifier for 5 minutes and 20 seconds at 
amplitude 32% with 2 second on pulses and 6 second off pulses. The cell lysate was 
centrifuged for 10 mins at 13,000 r.p.m. Next, 700 µL of 5% polyethyleneimine was 
added to the supernatant, which was centrifuged again to remove further cellular debris. 
The supernatant was loaded onto a 10 mL Ni2+-affinity chromatography column (Gol.d 
Biotechnology), and the column was washed with 150 mL binding buffer (500 mM NaCl, 
20 mM Tris-HCl, 5 mM imidazole, pH 8.0) and bound protein was eluted with 40 mL 
elution buffer (500 mM NaCl, 20 mM Tris-HCl, 250 mM imidazole, pH 8.0). All purified 
proteins were dialyzed into NMR buffer and concentrated using Amicon Ultra 3K 
(Millipore) filtration columns. Protein concentrations were measured by the absorbance 
at A280. 
 
11.2.2. Size Exclusion Chromatography (SEC)  
Purified chaperone/translocon complexes containing 1 mM EDTA and 0.5 mM 
DTT were loaded onto a Superdex 75 SEC column (column height 51 cm and bed 
volume 300 mL) (GE Healthcare) to determine their oligomeric state(s) and to separate 
chaperone/translocon complexes from unbound chaperone. The SEC column was 
equilibrated with 1 column volume of 150 mM NaCl, 0.5 mM DTT, 10 mM Tris-HCl, 
pH 8.0. Typical parameters used for SEC runs were 1 mL/min flow rate, 0.3 MPa 
pressure and 6 mL elution fraction size. The SEC column was calibrated using protein 
standards of known molecular weights, including Blue Dextran (200 kDa), Albumin (66 
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kDa), Carbonic Anhydrase (29 kDa), Cytochrome C (12.4 kDa) and Aprotinin (6.5 kDa). 
To calculate the partition coefficient (Kav) values for the protein standards, the equation 
Kav = Ve – V0 / Vc – V0 was used, where Ve = elution volume, V0 = void volume, Vc = 
column volume, and Kav = partition coefficient. The logarithm of the molecular weight 
(y-axis) vs Kav (x-axis) for each protein standard was then plotted to obtain the standard 
curve, y = -0.4207x + 2.118, where y = Kav and x = log molecular weight in Daltons. The 
Kav obtained from the SEC run for each peak could then be used to determine the 
estimated molecular weight using the standard curve.  
 
11.2.3. Circular Dichroism (CD)  
Far-UV CD experiments were acquired using a JASCO J-815 Spectropolarimeter. 
The chaperone/translocon complexes for CD were prepared with 0.05 mg/mL protein in 2 
mL sterile water in a quartz cuvette. A water blank was acquired and subtracted from 
each protein spectra. CD spectra were acquired from 190 to 260 nm in triplicate at 20°C 
with a scan rate of 50 nm/minute. Thermal denaturation experiments were performed by 
measuring ellipticity at 222 nm over a temperature range of 20°C to 90°C and a ramp rate 
of 2°C/minute. The experimental CD values of ellipticity (mdeg) were converted to molar 
ellipticity (θ = deg cm2/dmol). The melting temperature (Tm) was calculated using 
JASCO J-815 software. 
 
11.2.3. NMR Spectroscopy  
All data was collected using a Bruker Avance 800 MHz spectrometer equipped 
with a cryogenic triple resonance probe and were processed using NMR pipe6 and 
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analyzed using NMRview7. Two-dimensional 2D 1H-15N TROSY spectra were acquired 
at 40°C using 0.5 mM of 15N/13C-Ile (isoleucine 13C-methyl side-chain) labeled 
chaperone/translocon complex in NMR buffer (100 mM NaCl, 1 mM DTT, 10 mM 
sodium phosphate, pH 7.4, 10% D2O). Typical acquisition parameters were 200 scans 
with 2048 complex points (1H) and 256 complex points (15N) with sweep width 10.01 
ppm for 1H centered at 4.69 ppm and 17.9 ppm for 15N centered at 119 ppm. Two-
dimensional 1H-13C HSQC spectra were acquired at 40°C using 0.5 mM 15N/13C-Ile 
labeled chaperone/translocon complex in NMR buffer. Typical acquisition parameters 
were 128 scans with 1024 complex points (1H) and 100 complex points (13C) with sweep 
width 10.01 ppm for 1H centered at 4.69 ppm and 20 ppm for 13C centered at 19 ppm. 
 
11.3. Results 
11.3.1. Purification of hisSicA/SipC 
Originally, the chaperone/translocon constructs were subcloned in a dual 
expression system8 where the chaperone was inserted into multiple cloning site 1 (MCS1) 
of pET-DUET1 and the translocon was inserted into MCS2 of pACYC- DUET1. 
However, this dual expression system resulted in significant overexpression of the 
chaperone protein relative to minor expression of the translocon proteins. Therefore, the 
chaperones were kept in MCS1 of pET-DUET1, while the translocon was inserted into 
MCS2 of the pET-DUET1 vector containing the chaperone. This single vector system 
resulted in much better expression of the translocon relative to the chaperone.  
HisSicA/SipC complex was expressed and purified by affinity chromatography. 
The elution from the Ni2+ column was loaded onto an SEC column to separate any free 
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chaperone from the sample. SEC results showed two primary peaks: one corresponding 
to the hisSicA/SipC complex and one corresponding to monomeric hisSicA (Fig. 11-1A). 
An SDS-PAGE gel of the SEC column sample elutions resulted in two bands 
representing purified hisSicA (20.9 kDa) and SipC (42.9 kDa), suggesting that the 
hisSicA/SipC complex was successfully isolated (Fig. 11-1B). CD of the hisSicA/SipC 
complex showed in minima at 208 and 222 nm with a θ222/208 ratio of 1.02, indicating 
highly α-helical content (Fig. 11-2A). Thermal denaturation experiments showed that the 
hisSicA/SipC complex had a single thermal melt at 55°C (Fig. 11-2B).  
Unfortunately, although hisSicA/SipB was subcloned and verified by DNA 
sequencing, experiments showed that the plasmid containing hisSicA/SipB resulted only 
in expression of hisSicA, but never SipB (data not shown). Many expression experiments 
were performed with varying parameters (growth temperature, IPTG concentration), but 
full-length SipB did not express under any attempted condition. Therefore, our 
biophysical characterization of the Salmonella translocon proteins was limited to the 
HisSicA/SipC complex. 
 
11.3.2. NMR Spectroscopy of hisSicA/SipC 
 Isotopically 15N/13C-Ile labeled HisA/SipC complex was prepared to observe 
whether amide or isoleucine methyl resonances of HisA/SipC complex good quality 
NMR data. Unfortunately, two-dimensional 1H-15N TROSY and 1H-13C HSQC 
experiments showed that hisSicA/SipC NMR peaks were broad and not well-resolved 
(Fig. 11-3A, B). The 2D 1H-15N TROSY spectrum showed < 20% of expected amide 
peaks and the 1H resonance dispersion was < 1 ppm, indicating the presence of many 
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disordered regions (Fig. 11-3A).  Similarly, the 2D 1H-13C HSQC spectrum showed 8 out 
of 29 expected isoleucine peaks for the complex (Fig. 11-3B, 12 to 15 ppm 13C range). 
Together, these data suggest that the hisSicA/SipC is not an optimal complex for 







Fig. 11-1 – Purification of hisSicA/SipC 
(A) SEC of hisSicA shows two peaks; one for the hisSicA/SipC complex at a 1:1 protein 
ratio and one for monomeric hisSicA. (B) SDS-PAGE gel of sample elutions from the 
























Fig. 11-2 – Circular Dichroism of hisSicA/SipC 
(A) Far-UV CD of hisSicA/SipC shows minima at 208 and 222 nm, indicating the 
prescence of α-helical character. (B) Thermal denaturation of the hisSicA/SipC complex 









Fig. 11-3 – NMR Spectroscopy of hisSicA/SipC 
(A) 2D 1H-15N TROSY of the 15N/13C-Ile labeled hisSicA/SipC complex shows <1 ppm 
1H dispersion, broad resonances and less than 40% of expected amide resonances. (B) 
The 2D 1H-13C HSQC of the 15N/13C-Ile labeled hisSicA/SipC complex shows ~8 out of 





11.3.3. Purification of hisPcrH/PopD and hisPcrH/PopB 
HisPcrH/PopD expressed and was purified by affinity chromatography. The 
elution from the Ni2+ column was loaded onto an SEC column to separate free chaperone 
hisPcrH from the sample. The SEC column showed two peaks; one corresponding to the 
hisPcrH/PopD complex and one corresponding to monomeric hisPcrH (Fig. 11-4A). An 
SDS-PAGE gel of the SEC column elutions showed two bands representing purified 
hisPcrH (19.5 kDa) and PopD (31.3 kDa) (Fig. 11-4B). In contrast to hisSicA/SipB, 
which didn’t express, hisPcrH/PopB expressed and was purified by affinity 
chromatography. SEC showed two primary peaks; one corresponding to the 
hisPcrH/PopB complex and one corresponding to monomeric hisPcrH (Fig. 11-5A). 
Furthermore, SEC of hisPcrH/PopB resulted in much more free hisPcrH (Fig. 11-5A) 
compared to SEC of hisPcrH/PopD (Fig. 11-4A). An SDS-PAGE of the SEC elutions 
showed bands representing purified hisPcrH (19.5 kDa) and PopB (62.4 kDa) (Fig. 11-
5B). CD of the hisPcrH/PopD and hisPcrH/PopB complexes resulted in minima at 208 
and 222 nm with a θ222/208 ratio of 1.00, indicating highly α-helical content (Fig. 11-6A). 
Thermal denaturation experiments estimated that the hisPcrH/PopD and hisPcrH/PopB  
complexes had a single thermal melt around 55°C (Fig. 11-6B).  
 
11.3.4. NMR of Free hisPcrH, hisPcrH/PopB and hisPcrH/PopD 
 NMR experiments were performed on the isotopically 15N/13C-Ile labeled 
hisPcrH/PopD complex. Two-dimensional 1H-15N TROSY and 1H-13C HSQC 
experiments showed that hisPcrH/PopD NMR peaks were very broad and not well 
resolved (Fig. 11-7A, B). The 2D 1H-15N TROSY spectrum showed < 20% of expected 
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amide resonances and the 1H resonance dispersion was < 1 ppm, indicating the presence 
of many disordered regions (Fig. 11-7A).  Likewise, the 2D 1H-13C HSQC spectrum 
showed 5 out of 18 expected isoleucine methyl peaks (Fig. 11-7B, 11 to 15 ppm 13C 
range). Together, these data suggest that the hisPcrH/PopD complex is not ideal for 
typical TROSY/HSQC NMR experiments. Similarly, NMR experiments were performed 
on 15N/13C-Ile labeled hisPcrH/PopB complex. As with other the chaperone/translocon 
constructs, the 2D 1H-15N TROSY spectrum of hisPcrH/PopB showed NMR peaks that 
were broad and not well resolved (Fig. 11-8B). In contrast, the 2D 1H-15N TROSY 
spectrum of free hisPcrH showed 1H resonance dispersion of >3 ppm and the resonances 
were well resolved (Fig. 11-8B), unlike the broad amide peaks of hisPcrH/PopB or 
hisPcrH/PopD. Together, these data suggest that the hisPcrH/PopB complex is not ideal 
for typical TROSY/HSQC experiments and that the presence of the translocon, not the 














Fig. 11-4 – Purification of hisPcrH/PopD 
(A) SEC of hisPcrH/PopD shows two peaks; one is the hisPcrH/PopD complex and one is 
free hisPcrH. (B) SDS-PAGE gel SEC column elutions showing purified hisPcrH/PopD 





Fig. 11-5 – Purification of Free hisPcrH and hisPcrH/PopB 
(A) SEC of hisPcrH/PopB shows two peaks; one is the hisPcrH/PopB complex and one is 
free hisPcrH. (B) SDS-PAGE gel of SEC column elutions showing purified 

















Fig. 11-6 – Circular Dichroism of hisPcrH/PopD and hisPcrH/PopB 
(A) Far-UV circular dichroism of hisPcrH/PopD and hisPcrH/PopB shows minima at 208 
and 222 nm. (B) Thermal denaturation of hisPcrH/PopD and hisPcrH/PopB estimates a 






Fig. 11-7 – NMR Spectroscopy of hisPcrH/PopD 
(A) 2D 1H-15N TROSY of the 15N/13C-Ile labeled hisPcrH/PopD complex shows <1 ppm 
1H dispersion, broad resonances and less than 40% of expected amide peaks. (B) 2D 1H-
13C HSQC of the 15N/13C-Ile labeled hisPcrH/PopD complex shows 5 out of 18 expected 





Fig. 11-8 – NMR Spectroscopy of Free hisPcrH and hisPcrH/PopB 
(A) 2D 1H-15N TROSY of the 15N/13C-Ile labeled hisPcrH/PopB complex shows <1 ppm 
1H dispersion, broad resonances and less than 40% of expected amide peaks. (B) 2D 1H-
15N TROSY of the 15N/13C-Ile labeled free hisPcrH shows >3 ppm 1H dispersion and well 






In the chapter, chaperone/translocon complexes were successfully co-expressed 
and co-purified, including hisSicA/SipC (Fig. 11-1) from Salmonella Typhimurium and 
hisPcrH/PopD (Fig. 11-4) and hisPcrH/PopB (Fig. 11-5) from Pseudomonas aeruginosa. 
CD experiments of hisSicA/SipC (Fig. 11-2A) and hisPcrH/PopD or hisPcrH/PopB (Fig. 
11-6A) showed that the chaperone/minor translocon complexes contained α-helical 
coiled-coils due to their θ222/208 nm ratio near 1.0. Furthermore, both had a single melting 
point of 55°C (Fig. 11-2B & Fig. 11-6B). Unfortunately, all of the chaperone/translocon 
complexes tested here gave poor NMR spectrum in both 2D 1H-15N TROSY and 2D 1H-
13C HSQC experiments. HisSicA/SipC (Fig. 11-3), hisPcrH/PopD (Fig. 11-7) and 
hisPcrH/PopB (Fig. 11-8A) resonances were broad and not well resolved, and many of 
the expected amide or isoleucine methyl peaks were not observed. First, the poor quality 
NMR spectra observed could be due to the high molecular weight of the 
chaperone/translocon complexes; HisSicA/SipC is 64 kDa, hisPcrH/PopD is 50.8 kDa 
and hisPcrH/PopB is 59.5 kDa. It is not surprising to see broad resonances for large 
protein complexes9. However, with some experimental optimization and perdeuteration it 
is likely that the resolution may be increased somewhat. Second, poor quality NMR data 
could be due to the presence of disordered regions in the translocon protein. Interestingly, 
free hisPcrH an gave excellent 2D 1H-15N TROSY data with >3 ppm 1H dispersion and 
well resolved resonances, unlike hisPcrH/PopD and hisPcrH/PopB (Fig. 11-8B). 
Therefore, it is likely the presence of disordered regions in the translocon protein, not the 
chaperone, which dictates the poor quality of the chaperone/translocon complexes. The 
chaperones bind to only a small region of the translocon, leaving the rest of the 
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translocon mobile in solution and hydrophobic translocon proteins that are not in their 
native conformation likely harbor unfolded regions. Together, these data suggest that 
chaperone/translocon complexes are not ideal for NMR experiments. Instead, the 
chaperone and translocon proteins should be separated by use of detergents8 or changes 
in pH10. In all constructs, the chaperone contains a His tag while the translocon doesn't, 
making affinity purification following separation plausible. Following separation and 
isolation from the chaperones, the translocon proteins should then be put into a 
membrane, such as a nanodisc, or membrane-like environments, such as micelles, for 
structure analysis or protein interaction experiments.  
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Chapter 12. Overall Discussion and Future Directions 
12.1. Overall Discussion and Future Directions  
 The T3SS is an essential virulence factor used by many Gram-negative bacterial 
pathogens, including the causative agents of food poisoning/typhoid (Salmonella 
Typhimurium /Typhi), dysentery (Shigella flexneri), pneumonia (Pseudomonas 
aeruginosa), bubonic plague (Yersinia pestis), and trachoma/sexually-transmitted disease  
(Chlamydia trachomatis) (Table 1-1). Since the visualization of the needle apparatus in 
1998 by Galan and co-workers1, extensive effort has gone into characterizing the 
structure and function of the more than 20 proteins that assemble to form the structural 
component of the T3SS. The needle apparatus is composed of a bacterial membrane 
spanning base, an extracellular needle, a tip complex, and a translocon that creates a pore 
in the host cell membrane. The protein-protein interactions involved at the needle-tip and 
tip-translocon interfaces of the needle apparatus are poorly understood. Therefore, work 
described in this dissertation was directed towards characterizing the interactions of the 
Salmonella needle protein PrgI and the tip protein SipD; as well as the interaction 
between SipD and the major translocon protein SipB. In addition, because the T3SS is 
utilized among pathogenic bacteria and parts of the needle apparatus are exposed to the 
extracellular environment, the T3SS represents an attractive target for the development of 
new antibiotics2. Therefore, work described in this dissertation was additionally directed 
at discovering small molecule fragments that bound to T3SS proteins that could serve as 




12.1.1. Isotopic 13C Labeling of ILV Side-Chain Methyls in T3SS Proteins 
 Many proteins needed for the assembly of the T3SS apparatus, such as the tip and 
translocon, are large molecules in the range of 40 kDa or more, especially when they 
form complexes with their binding partners. Therefore, structural and biophysical studies 
of large molecular weight T3SS proteins and characterizing T3SS protein-protein 
interactions by NMR spectroscopy require unique experimental strategies. One such 
strategy is the isoleucine, leucine and valine (ILV) side-chain 13C-methyl isotopic 
labeling scheme developed by Lewis Kay and co-workers3. In this method, α-ketoacids, 
such as α-ketobutyrate and α-ketoisovalerate, serve as biosynthetic precursors for 
specifically labeled Ile and Leu/Val side-chain methyl carbons, respectively4. Compared 
to amide labeling, ILV 13C-methyl labels are useful probes because they contain 
favorable relaxation properties for high molecular weight systems, are more sensitive due 
to averaging of three proton signals, and they reduce complexity of protein NMR 
spectra5; 6; 7.  
In Chapter 2, the ILV methyl resonances of the Salmonella Typhimurium T3SS 
SPI-1 tip protein SipDΔ38 were completely assigned (Fig. 2-6). This represents the first 
report of ILV methyl resonance assignments for a T3SS protein. The 2D 1H-13C HSQC 
spectrum (Fig. 2-6) of SipDΔ38 is far less complex than the 2D 1H-15N TROSY spectrum 
(Fig. 3-2) of SipDΔ38. This allowed for simpler analysis of NMR titration experiments. 
The ILV methyl assignments of SipDΔ38 were useful in elucidating the interaction of 
SipD with both the needle protein PrgI (Chapter 4) and the N-terminal ectodomain of the 
major translocon protein SipB (Chapter 7). Simultaneous labeling of T3SS proteins with 
15N and ILV probes allowed for comparison between affected amide and ILV methyl 
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resonances.  Importantly, the protein interaction surfaces identified from 15N titrations 
were in agreement with the surfaces identified from ILV methyl titrations.  
Two-dimensional 1H-13C HSQC spectra of ILV labeled PrgI* (Fig. 4-8) and 
SipB82-240 (Fig. 10-14) helped either confirm or deny the presence of a molecular 
interaction with other molecules, even in the absence of NMR assignments. ILV methyl 
peaks of PrgI* could plausibly be assigned in the future due to the high quality spectra 
and observation of the expected number of resonances (Fig. 4-8). In contrast, many 
expected ILV methyl peaks of SipB82-240, SipB11-232, and SipB11-312 were absent from the 
2D 1H-13C HSQC spectra (Fig. 6-5) so their complete assignment is currently not 
plausible. Likewise, 2D 1H-13C HSQC spectra of ILV labeled of chaperone/translocon 
complexes, such as SicA/SipC, PcrH/PopB and PcrH/PopD, resulted in poor quality data 
with broad resonances, <1 ppm 1H dispersion and less than the expected number of 
resonances, likely due to presence of disordered or unfolded regions in the translocon 
(Chapter 11).  
In summary, ILV labeling of T3SS proteins is a robust and useful strategy to aid 
in the elucidation of T3SS protein structure and protein-protein interactions.  
 
12.1.2. Comparison of SipDΔ38 and SipDΔ132  
 The N-terminal α-helical domain of the Salmonella tip protein SipD is known to 
be a self-chaperone domain8, but is also hypothesized to regulate the interaction of SipD 
with other T3SS proteins9. To determine the role of the N-terminal domain of SipD in the 
context of its interactions with other T3SS proteins, a SipD construct lacking its N-
terminal α-helical domain, SipDΔ132, was compared to a construct of SipD containing its 
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N-terminal α-helical domain, SipDΔ38. Circular dichroism showed that SipDΔ38 and 
SipDΔ132 had similar secondary structure characteristics (Fig. 3-1A), but slightly different 
thermal denaturation profiles (Fig. 3-1B). Data suggested that the Tm at 61°C was due to 
the N-terminal domain and the Tm at 75°C was due to the other domains of SipD (Fig. 3-
1). The 2D 1H-15N TROSY spectra and 1H-13C HSQC spectra of SipDΔ38 and SipDΔ132 
were similar to each other with many peaks overlapping (Fig. 3-4 & Fig. 3-7). This 
allowed for transfer of both amide (Fig. 3-5) and ILV methyl (Fig. 3-8) resonance 
assignments from SipDΔ38 to SipDΔ132. I was able to assign 82% of amide and 76% of 
ILV methyl resonances for SipDΔ132. The amide and ILV methyl assignments were useful 
in elucidating the interaction of SipDΔ132 with PrgI (Chapter 4) and SipB (Chapter 7). 
 
12.1.3. Summary of the needle-tip and tip-translocon interactions  
 The N-terminal α-helical hairpin of SipD is hypothesized to regulate the 
interaction of SipD with other T3SS proteins, such as the needle protein PrgI9. In support 
of this hypothesis, PrgI was shown by NMR spectroscopy and fluorescence spectroscopy 
to bind tighter to SipDΔ132 or SipDΔ100 (both lack the N-terminal α-helical domain) than to 
SipDΔ38 (contains N-terminal domain). PrgI did not show signs of interaction with 
SipDΔ38 by solution NMR (Fig. 4-1 & Fig 4-2). Results of FP and FRET detected a very 
weak interaction between PrgI and SipDΔ38 (Fig 5-3A & Fig. 5-4B), but the binding of 
PrgI to SipDΔ100 was much stronger (Fig. 5-3A & Fig. 5-4A). Results of NMR titrations 
between PrgI and SipDΔ132 in Chapter 4 elucidated the following: i) a cluster of affected 
residues near the bottom of the SipDΔ132 coiled-coil (Fig. 4-6A, B) and ii) a cluster of 
affected residues near the middle of the α-helical hairpin and both the N- and C-termini 
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of PrgI* (Fig. 4-7B). The PrgI*/SipDΔ100 interaction was estimated to be 108 ± 11 µM in 
FP experiments (Fig. 5-3A) and removal of the SipD N-terminal domain resulted in 
higher FRET signal with PrgI* (Fig. 5-4A). SipD mutations along the bottom of the 
coiled-coil domain decreased the ability of Salmonella Typhimurium to invade intestinal 
epithelial Henle-407 cells (Fig 5-6). Importantly, this observed decrease in invasion 
correlated well with a decrease in binding affinity between PrgI* and SipDΔ100 (Fig 5-3A, 
B).  
 Because the proximal end of SipD (defined as the bottom of coiled-coil, Fig 7-1C) 
interacted with PrgI, it was hypothesized that the distal end of SipD (defined as top of 
coiled-coil and mixed α/β domain, Fig 7-1C) would interact with the N-terminal 
ectodomain of SipB, which is modeled to extend into the extracellular environment upon 
insertion into the host cell membrane10; 11; 12. Results of NMR titrations between 15N/ILV 
labeled SipDΔ38 or SipDΔ132 and unlabeled SipB11-232 or SipB11-312 are shown in Chapter 7. 
In support of this hypothesis, results of NMR titration between 15N/ILV labeled SipDΔ38 
with SipB11-232 showed a cluster of affected residues in the distal region of SipD (Fig. 7-
1C & Fig. 7-2C). Unlike the results of NMR titrations between PrgI and SipD, removal 
of the N-terminal domain of SipD was not expected to affect the tip-translocon 
interaction. To test this hypothesis, NMR titrations were performed between 15N/ILV 
SipDΔ132 and unlabeled SipB N-terminal domain. As expected, removal of the N-terminal 
α-helical hairpin of SipD did not significantly affect the surface of the interaction of SipD 
with the N-terminal domain of SipB in 15N titrations (Fig. 7-6C & Fig 7-7C) or ILV 
titrations (Fig. 7-8C & Fig. 7-9C). There were no major differences in the interaction 
between SipB11-232 and SipB11-312 with SipDΔ38 as observed by solution NMR (Fig. 7-6C 
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& Fig 7-7C). This suggested that residues 232-312, which contain a predicted α-helix, 
did not result in higher affinity binding with SipD. Overall, titration data suggests the 
distal region of SipD is the primary interaction surface with the N-terminal ectodomain of 
SipB.  
Fluorescence polarization was used to estimate the binding affinity of SipB82-312 to 
SipDΔ38/SipDΔ100 and was determined to be in the range of 30 to 60 µM (Fig. 8-3A, B). 
Furthermore, FRET experiments estimated that the coiled-coil of SipB82-312 is closer in 
space to the distal end of SipD than the C-terminus of SipB82-312 (Table 8-1 & Fig. 8-4). 
In agreement with these results, mutations along the mixed α/β domain of SipD reduced 
the ability of Salmonella Typhimurium to invade intestinal epithelial Henle-407 cells 
(Fig. 8-6A). In both FP and FRET experiments, SipB82-312 did not interact with the needle 
PrgI (Fig. 8-5). The FP and FRET data are in agreement with the results from solution 
NMR.  
   
12.1.4. Model of the T3SS Needle/Tip/Translocon Interface 
Together, the results from solution NMR and FP/FRET allowed for a model of the 
Salmonella SPI-1 T3SS needle-tip and tip-translocon interactions (Fig. 12-1). First, the 
needle protein PrgI interacts with the proximal end of the SipD coiled-coil, which is 
oriented as pointed down towards the needle (Fig. 12-1). In this model, the N-terminal 
domain of SipD is proposed to swing away from the assembled tip and needle to allow 
for binding of PrgI to the SipD coiled-coil (Fig. 12-1). However, there is no current 
experimental evidence to support this theory, except for a lack of electron density 
observed for the N-terminal domain of IpaD (SipD homolog) in electron microscopy 
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experiments of the T3SS tip complex in Shigella flexneri13. A current hypothesis in the 
literature is that the tip complex exists as a tetramer13; 14 with five copies of SipD that 
each interact with two copies of PrgI. Therefore, each SipD molecule is expected to insert 
between two PrgI molecules in the needle-tip model (Fig. 12-1). Second, the N-terminal 
ectodomain of SipB interacts with the distal region of the SipD, the mixed α/β domain, 
which is oriented as pointed away from the needle and towards the host cell membrane 
(Fig. 12-1). Six to eight total translocon subunits have been estimated to compose the 
T3SS translocon from results of atomic force microscopy in E. coli15. Therefore, the 
model presented here estimates five copies of SipB could be present in the host cell 
membrane to interact with five copies of SipD at a 1:1 stoichiometry (Fig. 12-1). 
However, there is no current consensus on the in vivo stoichiometry of the SipD-SipB 
interaction. The minor translocon, SipC, is not included in the model because it has not 
been reported to interact with SipD. Because SipB and PrgI are separated in space by the 
presence of SipD, they do not interact, as was confirmed here by FP/FRET experiments.  
 
12.1.5. Fluorescence based binding assays of T3SS proteins 
 FP and FRET are binding assays that can be used to probe protein-protein 
interactions and can be adapted for high-throughput screening to discover inhibitors of 
protein-protein interactions16; 17. Here, FP and FRET based protein-protein binding assays 
were reported for both the SipD/PrgI interaction (Fig. 5-3 & Fig. 5-4) and the SipD/SipB 
interaction (Fig. 8-3 & Fig. 8-4). In the FP assays, 25 nM of labeled protein was not 
saturated until around 400 µM of unlabeled protein. Therefore, high-throughput screening 
of such a weak interaction would likely require milligram quantities of unlabeled protein. 
	 253	
Likewise, FRET experiments required µM amounts of proteins for each FRET 
experiments. FP and FRET as high-throughput screens have a drawback of required 
labeling protein and leading to a high-amount of false positives16; 17. For these reasons, a 
more direct approach was used in Chapter 10 where surface plasmon resonance was used 
in a fragment based screen to identify small molecules that bound directly to T3SS 
proteins. Regardless of their potential use for high-throughput screening, FP and FRET 
assays developed in this dissertation were used as quick and efficient protein binding 
assays, especially for the testing of mutant proteins to identify important protein 
interaction surfaces. The FP and FRET assays presented here would be easily adaptable 
for other T3SS protein interaction systems as well.  
 
12.1.6. Comparison of SipB82-240, SipB11-232 and SipB11-312 Constructs  
 Three constructs of the N-terminal ectodomain of SipB were prepared to 
determine an optimal SipB construct for NMR experiments. SipB lacking its extreme N-
terminal residues, SipB82-240, was compared to two SipB constructs containing the 
extreme N-terminal residues, SipB11-232 and SipB11-312. SEC experiments showed SipB11-
232 and SipB11-312 were primarily populations of dimers or trimers in solution (Fig. 6-2). 
CD spectra showed that SipB11-232 and SipB11-312 had similar secondary structure 
characteristics (Fig. 6-3A) and a single thermal melt between 57 and 59°C (Fig. 6-3B). 
However, SipB82-240 gave much higher quality NMR data compared to SipB11-232 and 
SipB11-312 (Fig. 6-4 & Fig. 6-5). Up to 70% of amide resonances were observed with 
SipB82-240 in 2D 1H-15N TROSY experiments (Fig. 6-4C), while less than half of expected 
resonances were observed in 2D 1H-15N TROSY experiments with SipB11-232 and SipB11-
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312 (Fig. 6-4A, B). Similar conclusions were observed with 2D 1H-13C HSQC spectra of 
ILV methyl labeled proteins (Fig. 6-5). The most likely explanation is that the residues 
11-81 are disordered or contain random coiled character, as suggested by secondary 
structure prediction servers, resulting in small 1H dispersion and broad resonances. For 
these reasons, SipB82-240 was used in validation of small molecule binding hits from 
surface plasmon resonance screens.  
 
12.1.7. Small Molecule Binders of SipDΔ38 and SipB82-240  
 A surface plasmon resonance (SPR) screen identified small molecule fragments 
that bound to SipDΔ38 and SipB82-240 (Chapter 10). SPR identified that 5-hydroxyindole 
bound to both SipDΔ38 and SipB82-240, 3-indoleacetic acid bound to SipB82-240, and 4-
morpholinoaniline bound to SipDΔ38 (Fig. 10-2). Titration and 1H saturation transfer 
difference (STD) NMR experiments validated the hits from the SPR screen. These indole 
and morpholinoaniline scaffolds are the first small molecules (other than bile salts18 and 
host cell lipids19) to be reported to interact with the T3SS tip or major translocon protein. 
NMR titration showed an interaction between SipDΔ38 or SipB82-240 with the small 
molecule fragments in the mM range; 32 ± 8 mM for the binding of 5-hydroxyindole to 
SipDΔ38. The 15N and ILV assignments of SipDΔ38 were utilized to characterize the 
interaction between SipDΔ38 and small molecules by chemical shift mapping. Both 5-
hydroxyindole and 4-morpholinoaniline affected similar SipD surfaces – the bottom of 
the coiled-coil and portions of the distal region (Fig. 12-2), suggesting these SipD 
surfaces are potential hotspots for drug interaction. Together, these data suggest that 
indole and morpholinoaniline may be suitable scaffolds for the development of higher 
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affinity small molecule binders for the tip and translocon. In the future, a chemically 
diverse library of indole or morpholinoaniline based small molecules should be 
developed and tested for binding to SipDΔ38 or SipB82-240 by SPR and then subsequently 
validated by NMR experiments. Ideally, binding in the nM or low µM range should be 
achieved to test for biological inhibition activity. These tighter binding molecules can be 
tested for T3SS inhibition by either in vitro Salmonella invasion assay or protein-protein 



























Fig. 12-1 – Proposed Model of the PrgI, SipD and SipB Interface 
Five copies of SipD (blue) are expected to insert between PrgI (cyan). Data presented in 
this dissertation suggests the proximal end of SipD (i.e. the bottom of the coiled-coil) 
interacts with PrgI. The N-terminal domain of SipD is modeled to swing away following 
assemble of the needle/tip, but that requires experimental testing. The distal end of SipD 
(mixed α/β) interacts with five copies of the N-terminal domain of SipB (red). The C-





Fig. 12-2 – Comparison of the SipD Surface Affected by Small Molecules 
The chemical structure of (A) 5-hydroxyindole and (D) 4-morpholinoaniline. The SipD 
residues affected by interaction with 5-hydroxyindole are shown on the atomic structure 
of SipD as (B) a surface representation and (C) a cartoon representation. The SipD 
residues affected by interaction with 4-morpholinoaniline are shown on the atomic 
structure of SipD as (E) a surface representation and (F) a cartoon representation. SipD 
structure is colored with the N-terminal domain in green, the coiled-coil in gray and the 
mixed α/β domain in light orange. Residues are colored as strongly affected (red), 
moderately affected (orange) or weakly affected (yellow). 
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12.1.8. Characterization of Chaperone/Translocon Complexes  
 To date, a full-length atomic structure of any of the T3SS translocon proteins has 
not yet been reported. Further, atomic resolution information on the interaction of the 
translocon proteins with other T3SS proteins is lacking. To perform biophysical and 
biochemical characterization on T3SS translocon proteins, full-length major and minor 
translocon proteins were prepared in complex with their cognate chaperone. 
Chaperone/translocon complexes were successfully expressed and purified in a single 
vector system, including hisSicA/SipC (Fig. 11-1) from Salmonella Typhimurium and 
hisPcrH/PopD (Fig. 11-4) or hisPcrH/PopB (Fig. 11-5) from Pseudomonas aeruginosa. 
CD experiments on hisSicA/SipC (Fig. 11-2) and hisPcrH/PopD (Fig. 11-7) showed that 
the chaperone/minor translocon protein complexes were contained α-helical content due 
to their θ222/208 nm ratio near 1.0, and both had a single melting point of 55°C. 
Unfortunately, all of the chaperone/translocon complexes tested gave poor NMR data in 
both 2D 1H-15N TROSY and 1H-13C HSQC experiments. HisSicA/SipC (Fig. 11-3), 
hisPcrH/PopD (Fig. 11-7) and hisPcrH/PopB (Fig. 11-8) NMR peaks were broad and 
many of the expected amide or isoleucine methyl resonances were not observed. 
Experiments comparing free HisPcrH vs. HisPcrH/PopB suggested the presence of the 
translocon, not the chaperone, dictates the poor quality of the chaperone/translocon 
complexes (Fig 11-8A, B). The chaperones bind to only a small portion of the translocon, 
leaving the rest of the translocon free to undergo dynamic motions solution. Furthermore, 
the translocon proteins are likely not in their native folded conformation because the lack 
of a membrane or membrane-like environment in our experiments. Together, these data 
suggest that chaperone/translocon complexes are not ideal for NMR experiments and 
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instead that the chaperone and translocon proteins should separated, likely by methods 
utilizing detergents or pH change. In all constructs, the chaperone contains a His tag 
while the translocon doesn't, making affinity purification following separation plausible. 
Following separation and isolation from the chaperones, the translocon proteins should 
then be put into membranes (nanodiscs) or membrane-like environments (detergents) for 
structure analysis or protein interaction experiments. 
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Addendum. Interaction of PcrV and PcrG by Fluorescence 
Spectroscopy 
A1.1. Introduction  
Pseudomonas aeruginosa is an opportunistic Gram-negative bacterial pathogen 
that is a common cause of nosocomial infections in immunocompromised patients, such 
as those with AIDS, cystic fibrosis and cancer1. P. aeruginosa harbors a protein 
nanoinjector, the type-three secretion system (T3SS), that translocates virulence factors 
into host cells to initiate and maintain infection2. The structural T3SS component, the 
needle apparatus, is comprised of a bacterial membrane spanning base, a needle-like 
structure, a tip and a host membrane embedded translocon. In P. aeruginosa, PcrV is the 
tip protein and PcrG is its chaperone3; 4. These proteins have sequence homology to LcrV 
and LcrG in Yersinia pestis. Together, PcrV and PcrG are responsible for proper 
assembly and regulation of effector secretion through the T3SS and are therefore 
essential for bacterial virulence5; 6. 
In P. aeruginosa, effector secretion is host cell contact and calcium dependent7. 
Deletion of pcrv or pcrg results in constitutive effector secretion, even in the absence of 
calcium depletion or cell contact5. In addition, PcrG is required for proper PcrV secretion 
to the needle tip, but also regulates effector secretion independent of PcrV through 
unknown mechanisms. This model of secretion is different from Yersinia model in which 
deletion of the LcrV tip inhibits effector secretion due to negative T3SS regulation by 
LcrG8. Recently, PcrV and LcrV have been examined as targets for vaccine development. 
Preliminary results from a small phase II trail showed that an anti-PcrV vaccine reduced 
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ventilator-associated pneumonia by 50% in the treated group9. These results, though 
promising, have yet to be corroborated with larger scale trails. 
A large gap in knowledge that remains to be understood is determination of the 
atomic structure of PcrV and PcrG, and the characterization of the PcrV-PcrG interaction. 
Here, fluorescence polarization (FP) and Förster resonance energy transfer (FRET) are 
utilized as protein binding assays for PcrV and PcrG. The objective of this research was 
to i) develop a method that could be combined with mutagenesis to determine essential 
interacting residues and protein binding surfaces, and ii) develop binding assays for high-
throughput screening of small molecular inhibitors of the tip-chaperone interaction.  
 
A1.2. Materials and Methods  
A1.2.1. Protein Expression and Purification 
PcrV25-294 and PcrG9-76 constructs were made as fusion proteins in pET-21a with 
His6-tagged GB1 (N-terminal for PcrV and C-terminal for PcrG) that included a tobacco 
etch virus (TEV) protease cleavage site. GB1, the β1 immunoglobulin binding domain of 
Streptococcus protein G, was used as a solubility enhancer to improve product yield. 
Truncations of PcrV and PcrG improved their NMR spectra10, and therefore PcrV25-294 
and PcrG9-76 were used here to complement NMR experiments. Proteins were expressed 
in E. coli BL21(DE3) DNAY cells in 1L of LB media containing 30 µg/mL kanamycin 
and 100 µg/mL carbenicillin. Cells were grown at 37°C until an OD600 of 0.8 then 
induced with 1 mM isopropyl-β-D-thiogalactopyrandoside (IPTG) and grown overnight 
at 15°C to a final OD600 of 2.6. Bacterial cells were harvested by centrifugation at 4000 
rpm for 10 minutes, resuspended with binding buffer (500 mM NaCl, 20 mM Tris-HCl, 5 
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mM imidazole, pH 8.0, 2 mM phenylmethanesulfonyl fluoride, PMSF) at 4°C and 
sonicated while keeping the lysate ice-cold. The cell lysate was centrifuged for 10 
minutes at 13000 rpm. Next, 700 µL of 5% polyethyleneimine (P.E.I.) was added to the 
supernatant, which was centrifuged again to remove cellular debris. The supernatant was 
loaded onto a Ni2+-affinity chromatography column (Sigma), the column was washed 
with 150 mL binding buffer (500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole, pH 8.0) 
and bound protein was eluted with 40 mL elution buffer (500 mM NaCl, 20 mM Tris-
HCl, 250 mM imidazole, pH 8.0). The column elutions were then incubated at 25°C 
overnight with 250 µL of 0.04 mM recombinant TEV protease in TEV protease buffer 
(50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, pH 8.5, 1 mM DTT, 20 mM NaCl) and 
further purified by Ni2+-affinity chromatography to separate protein from the His6-GB1 
tag. Purified proteins were dialyzed in 1✕ PBS, pH 7.4 overnight and concentrated using 
Amicon Ultra 3K (Millipore) filtration columns. Protein concentrations were determined 
by the absorbance at A280. 
 
A1.2.2. Secondary Structure Prediction 
Primary amino acid sequences were aligned using Clustal Omega11 and edited 
with ESPript 2.2 (http://espript.ibcp.fr)12. Secondary structure prediction was performed 
on PcrG with I-TASSER13, DSC, MLRC and PHD14. The 3D atomic structure of PcrV 
was predicted using I-TASSER13, based on sequence homology with the previously 
solved structure of LcrV15. The C-score of the PcrV model was 1.3, while TM-score was 
0.9 and R.M.S.D. was 3.3 ± 2.3Å. Unfortunately, I-TASSER did not produce a reliable 
model for PcrG (C-scores in the range of -3.5 and TM-score of 0.33 ± 0.11). 
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A1.2.3. Circular Dichroism (CD) 
CD spectra were acquired in triplicate using a JASCO J-815 Spectropolarimeter. 
Scans were collected from 195 nm to 260 nm at 25°C at a scan rate of 50 nm/min to 
assess the secondary structure and foldedness of PcrV and PcrG. Thermal stability was 
monitored between 25°C and 80°C at 222 nm at temperature ramp rate of 30°C/hr. All 
spectra were subtracted from a 1✕, PBS pH 7.4 blank. 
 
A1.2.4. Fluorophore Conjugation 
A single cysteine mutation was introduced into PcrV25-294 and PcrG9-76 by site-
directed mutagenesis using a Qiagen Kit (Stratagene). Maleimide conjugated 
fluorophores were used to label PcrV and PcrG constructs. First, proteins were dialyzed 
into 1✕ PBS, pH 7.4 overnight prior to labeling. A 10 fold excess of tris(2-
carboxyethyl)phosphine (TCEP) to protein was used to reduce disulfide bonds for 30 
minutes at 25°C. A 20 fold excess of dye to protein was resuspended in 100% (v/v) 
DMSO for Fluorescein-C5-maleimide (Invitrogen) or 1✕ PBS, pH 7.4 for Alexa Fluor 
647-C2-Maleimide (Invitrogen). Dye was added drop wise to the reduced protein solution 
while mixing and allowed to react for 3 hours in the dark at 25°C. Unreacted dye was 
removed by dialysis in 1✕ PBS, pH 7.4 followed by passage through an Amicon Ultra 
3K (Millipore) filtration column. The concentrations of labeled proteins were assessed 
using UV-vis spectra. Herein, dyes are denoted as FM (Fluorescein-C5-maleimide) and 
AF647 (Alexa Fluor 647-C2-Maleimide). 
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A1.2.5. Fluorescence Polarizaton (FP)  
FP experiments were performed by titrating 25 nM of PcrG9-76 E28C-FM with 
increasing concentrations of unlabeled PcrV25-294. The fluorometer was zeroed to 1✕ PBS, 
pH 7.4. The average of measured data points (n=5) was subtracted from a base 
polarization value of PcrG9-76 E28C-FM without any PcrV25-294 added. The difference in 
millipolarization (ΔmP) was plotted against increasing concentrations of PcrV25-294 to 
obtain a saturated binding curve. The FP binding curve was fitted with Origin (OriginLab, 
Northampton, MA). All FP data was collected using a Varian Cary Eclipse Fluorescence 
Spectrophotometer at 25°C. 
 
A1.2.6. Förster Resonance Energy Transfer (FRET) 
Fluorescence emission spectra were examined for 1 µM PcrG9-76 E28C-FM 
(donor only), 1 µM PcrV25-294 D133C-AF647 (acceptor only), and 1 µM PcrG9-76 E28C-
FM in the presence of 1 µM PcrV25-294 D133C-AF647 (donor + acceptor). Spectra were 
collected between 500 nm and 800 nm using an excitation wavelength of 480 nm, 
excitation and emission slit widths of 5 nm and an integration time of 0.1 seconds. All 
data was collected on a Varian Cary Eclipse Fluorescence Spectrophotometer at 25°C. 
FRET efficiency, E, can be calculated from emission spectra as follows: 
              
Once FRET efficiency is known, the distance between the FRET dye pairs, r, can be 
calculated from the following formula: 
















Here, R0 is the Förster distance between two FRET pairs at which E = 50%, which is 56Å 
for the FRET pairs used in this study (Invitrogen). 
 
A1.3. Results  
A1.3.1. CD of Fluorophore Labeled PcrG9-76 E28C and PcrV25-294 D133C 
A cysteine mutation was introduced into PcrV and PcrG for the attachment of 
fluorophore. Sites chosen were based on minimal sequence conservation (Fig. A1-1A, B), 
likelihood to be surface exposed and likelihood to be present on an α-helix. For PcrG, this 
was estimated based on secondary structure prediction from the primary amino acid 
sequence (Fig. A1-1C). For PcrV, these parameters were partially estimated from the I-
TASSER 3D structure predicted based on homology to the Yersinia homolog, LcrV (Fig. 
A1-1D). Following purification, PcrG9-76 E28C was labeled with FM and PcrV25-294 
D133C was labeled with AF647. CD spectra taken between 190 and 260 nm showed that 
fluorophore and non-fluorophore conjugated PcrV25-294 D133C is a highly α-helical (A1-
2A), while fluorophore and non-fluorophore conjugated PcrG9-76 E28C is partially α-
helical and partially random-coil (A1-2B). The secondary structure characteristics of 
PcrV25-294 D133C-AF647 resembled PcrV25-294 D133C (Fig. A1-2A). Similarly, the 
secondary structure characteristics of PcrG9-76 E28C-FM resembled PcrG9-76 E28C (Fig. 
A1-2B). PcrV25-294 D133C and PcrV25-294 D133C-AF647 showed a single melting point at 
65°C, while none of the PcrG constructs showed a distinct melting point (data not shown). 
The CD data of PcrV25-294 and PcrG9-76 presented here are in agreement with previously 
reported spectra16 and show that fluorophore conjugation did not have a drastic effect on 
overall protein fold or stability. 
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A1.3.2. FP of PcrG9-76 E28C-FM and Unlabeled PcrV25-294 
FP was used to determine the binding affinity between PcrG9-76 and PcrV25-294. FP 
of 25 nM PcrG9-76 E28C-FM titrated with increasing concentrations of unlabeled PcrV25-
294 resulted in a saturated binding curve with an estimated dissociation constant of 1.0 ± 
0.1 µM (Fig. A1-3).  
 
A1.3.3. FRET of PcrG9-76 E28C-FM and PcrV25-294 D133C-AF647 
To determine distance specific information on the PcrG9-76 and PcrV25-294 
interaction, FRET was performed on PcrG9-76 E28C-FM and PcrV25-294 D133C-AF647 to 
estimate the intermolecular distance between the FRET dye pairs. Donor only (PcrG9-76 
E28C-FM) and acceptor only (PcrV25-294 D133C-AF647) spectra were combined to 
exclude fluorophore emission due to cross talk and bleed through (Fig. A1-4, solid line). 
When PcrG9-76 E28C-FM and PcrV25-294 D133C-AF647 were added together in a 1:1 ratio, 
there was a noticeable decrease in donor emission and increase in acceptor emission 
indicating FRET had occured (Fig. A1-4, dotted line). The estimated FRET efficiency, E,  
between PcrG 9-76 E28C-FM and PcrV25-294 D133C-AF647 was 5.1%, which suggests the 
FRET pairs were 91Å apart. This suggests the possibility that the N-terminus of PcrG9-76 







Fig. A1-1 – Positions of Cysteine Mutation on PcrG and PcrV  
(A) Primary sequence alignment PcrG and LcrG. Black arrows show the position of the 
PcrG cysteine mutation. (B) Primary sequence alignment of PcrV and LcrV. Black arrow 
show the position of the PcrV cysteine mutation. (C) Secondary structure prediction of 
PcrG using I-TASSER, DSC, MLRC, and PHD. ‘c’ denotes random coil and ‘h’ denotes 
helical content. (D) I-TASSER 3D structure prediction of PcrV. The position of the 








Fig. A1-2 – CD of Fluorophore Labeled PcrG9-76 E28C and PcrV25-294 D133C 
Far UV circular dichroism spectra of protein without fluorophore (solid line) and with 










Fig. A1-3 – Fluorescence Polarization of PcrG9-76 E28C-FM with PcrV25-294  
FP of 25 nM PcrG9-76 E28C-FM titrated with increasing concentration of unlabeled 







Fig. A1-4 – FRET of PcrG9-76 E28C-FM and PcrV25-294 D133C-AF647 
The fluorescence emission spectrum of donor only (PcrG9-76 E28C-FM) plus the emission 
spectrum of the acceptor only (PcrV25-294 D133C-AF647) is shown as a solid line. The 
fluorescence emission spectra of PcrG9-76 E28C-FM in the presence of PcrV25-294 D133C-
AF647 at a 1:1 ratio is shown as a dotted line. FRET is observed as seen by the donor 
emission decrease and the acceptor emission increase. An expanded view of the acceptor 
emission is shown.  










 The protein-protein interaction data reported here are the first report of an 
interaction between PcrG and PcrV by fluorescence spectroscopy. FP experiments 
estimated the dissociation constant between FM labeled PcrG9-76 E28C and unlabeled 
PcrV25-294 to be 1 µM (Fig. A1-3). This value is similar to a recent publication by Basu 
and co-workers17 that estimated the dissociation constant by surface plasmon resonance 
experiments between PcrG13-72 and PcrV128-294 to be 0.6 µM; although the Kd between 
full-length proteins was reported to be 15.6 nM. These results suggest that PcrG and PcrV 
truncations interact weaker than wild-type proteins by around 65 fold. FRET signal was 
also observed between FM labeled PcrG9-76 E28C and AF647 labeled PcrV25-294 D133C 
(Fig. A1-4). However, the FRET efficiency was low and the distance between the 
between the FRET pairs was estimated to be 91Å. First, it is possible that the location of 
the fluorophore at D133C on PcrV25-294 inhibited the interaction with PcrG9-76 E28C 
because the PcrV coiled-coil is suspected to be an interaction site with PcrG10. This 
possibility could be tested by creating cysteine point mutations in the distal region of 
PcrV, labeling with fluorophore and then tested for interaction with PcrG. Another 
possibility is that the N-terminus of PcrG9-76 that contains E28C fluorophore is oriented 








Fig. A1-5 – Possible Model of the PcrG and PcrV Interaction 
PcrV25-294 (simulated 3D structure from I-TASSER) is shown in gray and PcrG9-76 (no 
known atomic structure) is shown in blue with two predicted α-helices. The model shows 
the N-terminus of PcrG9-76 with the label E28C (red sphere) pointing away from the 
coiled-coil of PcrV25-294 with the label D133C (red stick) based on the estimate of the two 
fluorophore labeled residues by FRET in Fig. A1-4. 
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